amodiaquine has been researched along with Malaria, Falciparum in 458 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
Malaria, Falciparum: Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
| Excerpt | Relevance | Reference |
|---|---|---|
| "IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers." | 9.69 | Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. ( Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023) |
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 9.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| " The present study aims to determine the emergence of gametocyte and gametocyte clearance after artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) treatment in children with uncomplicated Plasmodium falciparum malaria in 5 regions of Madagascar." | 9.51 | Comparative effect of artemether-lumefantrine and artesunate-amodiaquine on gametocyte clearance in children with uncomplicated Plasmodium falciparum malaria in Madagascar. ( Andrianaranjaka, VHI; Dodoson, BT; Fenomanana, J; Rakotoarisoa, MA; Ratsimbasoa, A, 2022) |
| "The purpose of this study was to update efficacy data of Artesunate-Amodiaquine (AS+AQ) and Artemether-Lumefantrine (AL) used as first-line malaria treatment in Côte d'Ivoire since 2005." | 9.34 | Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa. ( Abba, T; Angora, EK; Assi, SB; Bedia, VA; Daho, AK; Emmanuel, B; Kiki-Barro, PMC; Konate, AA; Menan, H; Tiacoh, LN; Toure, OA; Yavo, W, 2020) |
| "Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) have been widely used for the treatment of uncomplicated Plasmodium falciparum malaria since 2005 in Gabon." | 9.30 | Persistence of High In Vivo Efficacy and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine as the First- and Second-Line Treatments for Uncomplicated Plasmodium falciparum Malaria 10 Years After Their Implementation in Gabon. ( Bouyou-Akotet, MK; Fandeur, T; Koumba Lengongo, JV; Lekana-Douki, JB; M'Bondoukwé, NP; Mawili-Mboumba, DP; Moutombi Ditombi, B; Ndong Ngomo, JM; Offouga, CL; Ondzagha Megnie, GJ; Ringwald, P, 2019) |
| "Based on per protocol analysis, unadjusted cure rates in malaria infected patients treated with artemether-lumefantrine (ALU), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DHP) were 89%, 94% and 91% respectively." | 9.22 | Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. ( Baraka, V; Kamugisha, E; Kapesa, A; Kidenya, B; Konje, E; Marwa, K; Mukonzo, J; Swedberg, G, 2022) |
| "To compare the artesunate-amodiaquine and artemether-lumefantrine combinations in the treatment of acute uncomplicated falciparum malaria during pregnancy." | 9.20 | A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy. ( Aboderin, O; Badejoko, O; Fatusi, A; Loto, O; Ogunniyi, S; Ukah, M, 2015) |
| " The in vivo efficacy of artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC) was compared to that of artemether-lumefantrine (AL) among children aged six to 59 months in Nimba County, Liberia, where Plasmodium falciparum malaria is endemic and efficacy data are scarce." | 9.17 | Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority ( Ashley, EA; Baudin, E; Boum, Y; Carn, G; Comte, E; Dhorda, M; Guérin, PJ; Houzé, P; Jones, JJ; Jullien, V; Kiechel, JR; Mazinda, CS; Pinoges, L; Schramm, B; Smith, R; Sundaygar, T; Valeh, P; Zolia, YM, 2013) |
| "The treatment efficacy of artesunate-amodiaquine (AQ) coformulated or copackaged, and the plasma and saliva concentrations of desethylamodiaquine (DEAQ), the active metabolite of AQ, were evaluated in 120 and 7 children, respectively, with uncomplicated Plasmodium falciparum malaria treated with oral daily doses of the 2 formulations for 3 days." | 9.17 | Therapeutic efficacy of artesunate-amodiaquine combinations and the plasma and saliva concentrations of desethylamodiaquine in children with acute uncomplicated Plasmodium falciparum malaria. ( Adewoye, EO; Folarin, O; Gbotosho, GO; Happi, CT; Michael, OS; Okuboyejo, TM; Sijuade, AO; Sowunmi, A, 2013) |
| "A new dose regimen of artesunate and amodiaquine (NDRAA) based on age or body weight range was compared with standard dose regimen of artesunate and amodiaquine (SDRAA) calculated according to body weight and with fixed-dose artesunate-amodiaquine (FDAA) and artemether-lumefantrine (AL) in 304 children afflicted by malaria aged 15 years or younger." | 9.16 | A simple dose regimen of artesunate and amodiaquine based on age or body weight range for uncomplicated falciparum malaria in children: comparison of therapeutic efficacy with standard dose regimen of artesunate and amodiaquine and artemether-lumefantrin ( Adewoye, EO; Folarin, OO; Gbotosho, GO; Happi, CT; Okuboyejo, TM; Sowunmi, A, 2012) |
| "The therapeutic efficacy and effects of artemether-lumefantrine (AL) and artesunate-amodiaquine co-formulated (AAcf) or co-packaged (AAcp) on malaria-associated anemia (MAA) were evaluated in 285 children < 12 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive one of the three drug combinations." | 9.15 | Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. ( Adewoye, EO; Folarin, OA; Gbotosho, GO; Happi, CT; Michael, OS; Okuboyejo, TM; Sowunmi, A, 2011) |
| " The objective was to assess the efficacy and safety of repeated administrations of two fixed-dose presentations of ACT--artesunate plus amodiaquine (ASAQ) and artemether-lumefantrine (AL)--in subsequent episodes of Plasmodium falciparum malaria." | 9.15 | Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. ( Barry, A; Cissé, B; Faye, B; Gaye, O; Gueye, A; Lameyre, V; Ndiaye, D; Ndiaye, I; Ndiaye, JL; Tchania, C; Tine, R, 2011) |
| "The effects of amodiaquine, artesunate and artesunate-amodiaquine on Plasmodium falciparum malaria-associated anaemia (PfMAA) and the recovery from PfMAA were evaluated in 328 children with uncomplicated malaria randomized to the standard dose regimens of the three drug treatments." | 9.14 | Effects of amodiaquine, artesunate, and artesunate-amodiaquine on Plasmodium falciparum malaria-associated anaemia in children. ( Balogun, ST; Gbotosho, GO; Happi, CT; Sowunmi, A, 2009) |
| "Artesunate-amodiaquine (AAQ) is efficacious for the treatment of uncomplicated Plasmodium falciparum malaria in Africa, but little is known about its efficacy in Southeast Asia." | 9.14 | Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. ( Chavchich, M; Dai, B; Edstein, MD; Phong, NC; Shanks, GD; Thanh, NX; Thien, NX; Trung, TN, 2009) |
| "The use of artemisinin derivative-based combination therapy (ACT) such as artesunate plus amodiaquine is currently recommended for the treatment of uncomplicated Plasmodium falciparum malaria." | 9.14 | Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. ( Brasseur, P; Dara, N; Diallo, M; Dicko, Y; Djimde, A; Faye, B; Forlemu, D; Gaye, O; Lameyre, V; Moor, VA; Ndiaye, I; Ndiaye, JL; Randrianarivelojosia, M; Randrianasolo, L; Ratsimbasoa, A; Sagara, I; Same-Ekobo, A; Traore, A, 2009) |
| "The activities of artesunate-cotrimoxazole and artesunate-amodiaquine combinations against asexual-and sexual-stage parasites were evaluated in 182 Nigerian children with uncomplicated Plasmodium falciparum malaria." | 9.13 | Effects of artesunate-cotrimoxazole and amodiaquine-artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children. ( Adedeji, AA; Balogun, ST; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sijuade, AO; Sowunmi, A, 2008) |
| " The aim of this study was to compare effectiveness, tolerability and acceptance of artesunate plus amodiaquine (ASAQ) against that of artemether-lumefantrine (AL) in Ghanaian children with uncomplicated Plasmodium falciparum malaria." | 9.13 | A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. ( Adjei, S; Amemasor, S; Ansong, D; Bührlen, M; Heidemann, H; Hogan, B; Klein, P; Kobbe, R; Kreuels, B; Loag, W; May, J; Nielsen, MV; Thompson, WN; Vohwinkel, J, 2008) |
| "To assess the efficacy and safety of atovaquone-proguanil (alone and in combination with artemisinin drugs) versus other antimalarial drugs for treating uncomplicated Plasmodium falciparum malaria in adults and children." | 9.12 | Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. ( Blanshard, A; Hine, P, 2021) |
| "Amodiaquine+SP is not well tolerated and a substantial proportion of patients experienced pruritus and fatigue, thus decreasing their compliance and compromising the first line treatment implementation at national level." | 9.12 | Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. ( D'Alessandro, U; Fanello, CI; Karema, C; Rwagacondo, CE; van Doren, W, 2006) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 9.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| "An open randomized controlled study of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) for the treatment of uncomplicated Plasmodium falciparum malaria was carried out in 181 children." | 9.12 | The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children. ( Adedeji, AA; Amoo, AO; Fateye, BA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| "Amodiaquine alone or in combination with sulphadoxine-pyrimethamine, although associated with minor side-effects, is effective when used to treat malaria in pregnancy." | 9.12 | Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. ( Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006) |
| "The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination." | 9.12 | Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| "The efficacy of amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP) was assessed in 310 symptomatic children from western Kenya with uncomplicated Plasmodium falciparum malaria." | 9.11 | Comparison of the parasitologic efficacy of amodiaquine and sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in the Bungoma District of western Kenya. ( Cobelens, FG; Gikunda, S; Hoogstraatte, SR; Kager, PA; Scheper, FY; Smolders, M; Vreugdenhil, CJ, 2004) |
| "To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon." | 9.10 | Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. ( Basco, LK; Metoh, T; Ndounga, M; Ngane, VF; Ringwald, P; Same-Ekobo, A; Soula, G, 2002) |
| "The safety and efficacy of amodiaquine (AQ), sulfadoxine-pyrimethamine (SP), and coadministered AQ+SP was assessed in 351 Tanzanian children (age range, 6-59 months) with uncomplicated Plasmodium falciparum malaria." | 9.10 | The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. ( Alonso, PL; Aponte, JJ; Drakeley, C; Kahigwa, E; Malende, A; Menendez, C; Mshinda, H; Msokame, C; Schellenberg, D; Tanner, M; Wigayi, J, 2002) |
| "The effects of chloroquine (CQ), amodiaquine (AQ) and CQ plus chlorpheniramine (a histamine H(1) antagonist that reverses CQ resistance in vitro and in vivo) on the disposition of the enlarged liver associated with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were evaluated." | 9.10 | The effects of chloroquine, amodiaquine and chloroquine plus chlorpheniramine on the disposition kinetics of the hepatomegaly associated with acute, uncomplicated, Plasmodium falciparum malaria in children. ( Adedeji, AA; Sowunmi, A, 2002) |
| "Many African countries currently use a sulfadoxine-pyrimethamine combination (SP) or amodiaquine (AQ) to treat uncomplicated Plasmodium falciparum malaria." | 9.10 | Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. ( Aubouy, A; Bakary, M; Cot, M; Deloron, P; Keundjian, A; Le Bras, J; Makita, JR; Mbomat, B; Migot-Nabias, F, 2003) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 9.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| " Between January and July 1993, 100 patients presenting with symptomatic Plasmodium falciparum malaria were randomised to receive amodiaquine or chloroquine at the dose of 30 mg/kg for 3 days." | 9.07 | [Parasitological and clinical response to amodiaquine versus chloroquine in the treatment of Plasmodium falciparum malaria in children in an endemic area]. ( Assi-Coulibaly, L; Ehouman, A; Kaptué, B; Konan, D; Penali, LK, 1994) |
| "We did a systematic review of interventional or observational cohort studies assessing the efficacy of artemisinin-based or quinine-based treatments in pregnancy." | 9.05 | Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. ( Anvikar, AR; Ashley, EA; Chandramohan, D; Cohee, LM; D'Alessandro, U; Genton, B; Gilder, ME; Guérin, PJ; Juma, E; Kalilani-Phiri, L; Kennon, K; Kuepfer, I; Laufer, MK; Lwin, KM; Mansoor, R; McGready, R; Meshnick, SR; Mosha, D; Mwapasa, V; Mwebaza, N; Nambozi, M; Ndiaye, JA; Nosten, F; Nyunt, M; Ogutu, B; Parikh, S; Paw, MK; Phyo, AP; Pimanpanarak, M; Piola, P; Rijken, MJ; Saito, M; Sriprawat, K; Stepniewska, K; Tagbor, HK; Tarning, J; Tinto, H; Valéa, I; Valecha, N; White, NJ; Wiladphaingern, J, 2020) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 8.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 8.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia." | 8.12 | Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers. ( Asinya, M; Jeuronlon, MK; Kamara, P; Koko, VS; Kollie, A; Ma, L; Menard, D; Nyansaiye, P; Parwon, S; Pratt, OJ; Ringwald, P; Taweh, F; Tehmeh, L; Vonhm, B; Warsame, M, 2022) |
| "The Angolan government recommends three artemisinin-based combinations for the treatment of uncomplicated Plasmodium falciparum malaria: artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP)." | 7.88 | Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. ( Andrade, BN; Davlantes, E; Dimbu, PR; Dos Santos Souza, S; Félix, J; Ferreira, CM; Florinda Joao, M; Fortes, F; Halsey, ES; Martins, JF; Mbounga, E; Owens, C; Plucinski, MM; Pode, D; Sanhangala, E; Talundzic, E; Udhayakumar, V; Wiesner, L, 2018) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 7.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "A novel class of benzoheterocyclic analogues of amodiaquine designed to avoid toxic reactive metabolite formation was synthesized and evaluated for antiplasmodial activity against K1 (multidrug resistant) and NF54 (sensitive) strains of the malaria parasite Plasmodium falciparum." | 7.81 | Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies. ( Chibale, K; Egan, TJ; Jurva, U; Masimirembwa, CM; Njoroge, M; Ongarora, DS; Strydom, N; Wicht, K; Wiesner, L; Wittlin, S, 2015) |
| "Twenty-eight day in-vivo efficacy trial of amodiaquine-artesunate in 103 children aged 6-59 months in western Kenya with smear-confirmed uncomplicated Plasmodium falciparum malaria." | 7.75 | In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. ( Desai, M; Hamel, MJ; Kariuki, S; McMorrow, M; Newman, RD; Odero, CO; Odhiambo, FO; Ord, R; Otieno, KO; Roper, C; Slutsker, L; Thwing, JI; Vulule, J, 2009) |
| "The in-vivo efficacies of the artesunate malartin, alone and in combination with amodiaquine, have been assessed against uncomplicated cases of Plasmodium falciparum malaria attending two treatment centres in Cameroon (the WHO/University of Buea malaria health post in Bolifamba and the University of Buea's health centre in Molyko)." | 7.74 | The comparative efficacies of malartin, with and without amodiaquine, in the treatment of Plasmodium falciparum malaria in the Buea district of Cameroon. ( Kimbi, HK; Ndamukong, KN; Nkuo-Akenji, TK; Nkwescheu, A; Patchong, AF, 2007) |
| " We treated 81 children <5 years with uncomplicated Plasmodium falciparum malaria with AQ alone and related the treatment outcome to the possible selection of pfcrt 76T, 152T, 163S, 326S, pfmdr1 86Y and pfmrp 191H, 437S in recurrent infections (recrudescenses and re-infections) and to the blood concentration of desethylamodiaquine (DEAQ)." | 7.73 | Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. ( Björkman, A; Ferreira, PM; Gil, JP; Holmgren, G; Obonyo, CO; Veiga, MI, 2006) |
| " The efficacy of AQ was assessed at the dose of 30 mg/kg in treating Plasmodium falciparum malaria attacks in 74 children from southeast Gabon, and the in vitro activity of monodesethylamodiaquine (MdAQ), the main metabolite of AQ, was measured against P." | 7.72 | Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. ( Aubouy, A; Bakary, M; Deloron, P; Keundjian, A; Le Bras, J; Mayombo, J, 2004) |
| " Mild and moderate adverse events, including gastrointestinal and/or nervous disorders, were reported in 11." | 7.30 | Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated Plasmodium falciparum malaria in children on the rainy south-east coast of Madagascar. ( Carn, G; Harimanana, AN; Hotahiene, R; Irinantenaina, J; Ralemary, N; Randriamiarinjatovo, DNAL; Randrianarivelojosia, M; Randriarison, M; Razafinjato, C; Razanatsiorimalala, S, 2023) |
| " Safety was based on assessment of adverse events (AEs) and severe adverse events (SAEs) from day 1 to day 28." | 7.11 | Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial. ( Aboh, PM; Adzemye, LM; Akam, LF; Ali, IM; Alifrangis, M; Ambani, MCE; Ango, Z; Bigoga, JD; Chedjou, JPK; Dinza, G; Dongmo, CH; Douanla, A; Ewane, MS; Fomboh, CT; Fosah, DA; Kotcholi, GB; Ludovic, AJ; Mbacham, WF; Moyeh, MN; Nana, WD; Ndikum, VN; Ngu, JA; Niba, PTN; Nji, AM; Nna, DRA; Oben, OLA; Omgba, PAM; Selly-Ngaloumo, AA; Tatah, FM; Ticha, JT, 2022) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 7.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 7.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| " The most frequent adverse event in both groups was asthenia." | 6.90 | Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial. ( Adegbite, BR; Adegnika, AA; Agnandji, ST; Dejon-Agobe, JC; Edoa, JR; Honkpehedji, YJ; Koehne, E; Kreidenweiss, A; Kremsner, PG; Kun, J; Lalremruata, A; Lell, B; Lotola-Mougueni, F; Mbong-Ngwese, M; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Obone Atome, FA; Ramharter, M; Safiou, AR; Velavan, TP; Zinsou, FJ, 2019) |
| " No statistical significant differences were observed in the occurrence of adverse events among treatment groups." | 6.80 | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. ( Ali, IM; Chedjou, JP; Ekollo, AM; Evehe, MS; Froeschl, G; Heumann, C; Mansmann, U; Mbacham, WF; Moyeh, MN; Ndikum, VN; Ngongang, EO; Nji, AM; Ogundahunsi, O, 2015) |
| "To compare, in a phase IV trial, the efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) dosed at 300 and 600 mg of amodiaquine per tablet to artemether-lumefantrine (Coartem) for the treatment of Plasmodium falciparum uncomplicated malaria in Ivory Coast and Senegal." | 6.75 | Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. ( Djoman, K; Faye, B; Gaye, O; Ndiaye, JL; Ndiaye, PS; Offianan, AT; Penali, L; Sylla, K; Tine, RC; Touré, W, 2010) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 6.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "Atovaquone/proguanil was found to be highly effective and safe for the treatment of Plasmodium falciparum malaria in infants and young children weighing 5-10 kg in Africa." | 6.71 | Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. ( Bagaphou, T; Binder, RK; Borrmann, S; Faucher, JF; Kremsner, PG; Lell, B; Matsiegui, PB; Miller, G; Missinou, MA; Pabisch, S; Rezbach, P, 2003) |
| "falciparum malaria was compared with that of CQ, each drug being given at 10 mg/kg per day for 3 days (days 0, 1 and 2)." | 6.70 | Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Adedeji, AA; Ayede, AI; Falade, AG; Falade, CO; Happi, TC; Ndikum, VN; Oduola, AM; Sowunmi, A; Sowunmi, CO, 2001) |
| "Amodiaquine-artesunate is a potential combination for use in Africa." | 6.70 | Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. ( Adjuik, M; Agnamey, P; Babiker, A; Borrmann, S; Brasseur, P; Cisse, M; Cobelens, F; Diallo, S; Faucher, JF; Garner, P; Gikunda, S; Kremsner, PG; Krishna, S; Lell, B; Loolpapit, M; Matsiegui, PB; Missinou, MA; Mwanza, J; Ntoumi, F; Olliaro, P; Osimbo, P; Rezbach, P; Some, E; Taylor, WR, 2002) |
| "Atovaquone and proguanil was a highly effective and safe drug combination in patients with acute uncomplicated P falciparum malaria in Gabon." | 6.68 | Atovaquone and proguanil for Plasmodium falciparum malaria. ( Hutchinson, D; Kremsner, PG; Nkeyi, M; Philipps, J; Radloff, PD, 1996) |
| "Pyronaridine-artesunate is a novel ACT." | 6.61 | Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. ( Hine, P; Pryce, J, 2019) |
| "AS-MQ and AL are more effective than DP and AS-AQ FDC in preventing gametocytaemia shortly after treatment, suggesting that the non-artemisinin partner drug or the timing of artemisinin dosing are important determinants of post-treatment gametocyte dynamics." | 6.53 | Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. ( , 2016) |
| "IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers." | 5.69 | Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. ( Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023) |
| " Adverse events were documented in less than 2% of participants for both drugs." | 5.62 | In vivo efficacy and safety of artemether-lumefantrine and amodiaquine-artesunate for uncomplicated Plasmodium falciparum malaria in Mozambique, 2018. ( Aide, P; Bassat, Q; Candrinho, B; Carvalho, E; Chidimatembue, A; Enosse, S; Halsey, ES; Lucchi, N; Macete, E; Mayor, A; Moriarty, LF; Nhacolo, A; Nhama, A; Nhamússua, L; Saifodine, A; Salvador, C; Svigel, SS; Zulliger, R, 2021) |
| " Thus, the efficacy of ASAQ is maintained and appears to be increased after long-term use in contrast to what is observed for other ACTs used in Africa." | 5.56 | Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar. ( Abbas, FB; Ali, AS; Ali, AW; Barnes, R; Björkman, A; Frumento, P; Mårtensson, A; Morris, U; Msellem, M; Soe, A, 2020) |
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 5.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| "Antimalarial treatments with artesunate-pyronaridine and artemether-lumefantrine reduced the excretion of S." | 5.51 | Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study. ( Adegnika, AA; Akinosho, MA; Davi, SD; Dimessa-Mbadinga, LB; Handrich, C; Kreidenweiss, A; Kremsner, PG; Lell, B; Mombo-Ngoma, G; Ndzebe-Ndoumba, WF; Nordmann, T; Okwu, DG; Ramharter, M; Stelzl, D; Veletzky, L; Zoleko-Manego, R, 2022) |
| " The present study aims to determine the emergence of gametocyte and gametocyte clearance after artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) treatment in children with uncomplicated Plasmodium falciparum malaria in 5 regions of Madagascar." | 5.51 | Comparative effect of artemether-lumefantrine and artesunate-amodiaquine on gametocyte clearance in children with uncomplicated Plasmodium falciparum malaria in Madagascar. ( Andrianaranjaka, VHI; Dodoson, BT; Fenomanana, J; Rakotoarisoa, MA; Ratsimbasoa, A, 2022) |
| "0%) patients experienced at least one drug-related adverse event (AE)." | 5.51 | Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo. ( Fungula, B; Inocencio da Luz, R; Kalabuanga, M; Lula Ntamba, Y; Lutumba, P; Muhindo Mavoko, H; Ntamabyaliro Nsengi, PM; Tona Lutete, G; Van Geertruyden, JP, 2019) |
| "Atovaquone-proguanil (ATV-PG) plus amodiaquine (AQ) has been considered as a potential replacement for sulfadoxine-pyrimethamine plus AQ for seasonal malaria chemoprevention in African children." | 5.51 | Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine. ( Abla, N; Chalon, S; Chughlay, MF; Haouala, A; Hutter, B; Lorch, U; Macintyre, F; Marie Tchouatieu, A, 2022) |
| " Adverse events (AEs) were documented at the home visit or during any unexpected visit to the Health Centre or to the hospital and coded and adjudicated by a local pharmacovigilance committee." | 5.46 | Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire. ( Aba, YT; Assi, SB; Bissagnéné, E; Duparc, S; Lameyre, V; Nguessan, AF; San, KM; Tanoh, MA; Tchiekoi, NB; Yavo, JC, 2017) |
| "The purpose of this study was to update efficacy data of Artesunate-Amodiaquine (AS+AQ) and Artemether-Lumefantrine (AL) used as first-line malaria treatment in Côte d'Ivoire since 2005." | 5.34 | Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa. ( Abba, T; Angora, EK; Assi, SB; Bedia, VA; Daho, AK; Emmanuel, B; Kiki-Barro, PMC; Konate, AA; Menan, H; Tiacoh, LN; Toure, OA; Yavo, W, 2020) |
| "Amodiaquine has several advantages over sulfadoxine-pyrimethamine combination and may be considered to be an effective drug in an endemic zone with a moderate level of chloroquine resistance." | 5.31 | Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Came ( Basco, LK; Keundjian, A; Ringwald, P; Same Ekobo, A, 2000) |
| "Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) have been widely used for the treatment of uncomplicated Plasmodium falciparum malaria since 2005 in Gabon." | 5.30 | Persistence of High In Vivo Efficacy and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine as the First- and Second-Line Treatments for Uncomplicated Plasmodium falciparum Malaria 10 Years After Their Implementation in Gabon. ( Bouyou-Akotet, MK; Fandeur, T; Koumba Lengongo, JV; Lekana-Douki, JB; M'Bondoukwé, NP; Mawili-Mboumba, DP; Moutombi Ditombi, B; Ndong Ngomo, JM; Offouga, CL; Ondzagha Megnie, GJ; Ringwald, P, 2019) |
| "Based on per protocol analysis, unadjusted cure rates in malaria infected patients treated with artemether-lumefantrine (ALU), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DHP) were 89%, 94% and 91% respectively." | 5.22 | Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. ( Baraka, V; Kamugisha, E; Kapesa, A; Kidenya, B; Konje, E; Marwa, K; Mukonzo, J; Swedberg, G, 2022) |
| "Artemisinin-based combination therapies (ACTs) have been adopted by most African countries, including Nigeria, as first-line treatments for uncomplicated falciparum malaria." | 5.20 | Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in ( Adedeji, ON; Ademowo, OG; Bolaji, OO; Falade, CO; Osonuga, OA, 2015) |
| "To compare the artesunate-amodiaquine and artemether-lumefantrine combinations in the treatment of acute uncomplicated falciparum malaria during pregnancy." | 5.20 | A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy. ( Aboderin, O; Badejoko, O; Fatusi, A; Loto, O; Ogunniyi, S; Ukah, M, 2015) |
| "Mozambique adopted artemisinin-based combination therapy (ACT) for the treatment of uncomplicated Plasmodium falciparum malaria in the year 2006, and since 2009 artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) have been proposed as alternative first-line treatments." | 5.19 | In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. ( Alonso, P; Bassat, Q; Carvalho, E; Enosse, S; Guinovart, C; Macete, E; Matsinhe, G; Mussa, A; Mutemba, R; Naueia, E; Nhacolo, A; Nhama, A; Sanz, S; Sevene, E; Tiago, A; Warsame, M, 2014) |
| "The safety and efficacy of the two most widely used fixed-dose artemisinin-based combination therapies (ACT), artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are well established for single episodes of uncomplicated Plasmodium falciparum malaria, but the effects of repeated, long-term use are not well documented." | 5.19 | Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children. ( Afizi, K; Fredrick, M; Kamya, MR; Lameyre, V; Lukwago, R; Talisuna, AO; Yeka, A, 2014) |
| " The in vivo efficacy of artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC) was compared to that of artemether-lumefantrine (AL) among children aged six to 59 months in Nimba County, Liberia, where Plasmodium falciparum malaria is endemic and efficacy data are scarce." | 5.17 | Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority ( Ashley, EA; Baudin, E; Boum, Y; Carn, G; Comte, E; Dhorda, M; Guérin, PJ; Houzé, P; Jones, JJ; Jullien, V; Kiechel, JR; Mazinda, CS; Pinoges, L; Schramm, B; Smith, R; Sundaygar, T; Valeh, P; Zolia, YM, 2013) |
| "The treatment efficacy of artesunate-amodiaquine (AQ) coformulated or copackaged, and the plasma and saliva concentrations of desethylamodiaquine (DEAQ), the active metabolite of AQ, were evaluated in 120 and 7 children, respectively, with uncomplicated Plasmodium falciparum malaria treated with oral daily doses of the 2 formulations for 3 days." | 5.17 | Therapeutic efficacy of artesunate-amodiaquine combinations and the plasma and saliva concentrations of desethylamodiaquine in children with acute uncomplicated Plasmodium falciparum malaria. ( Adewoye, EO; Folarin, O; Gbotosho, GO; Happi, CT; Michael, OS; Okuboyejo, TM; Sijuade, AO; Sowunmi, A, 2013) |
| " Artesunate-amodiaquine (AS + AQ) and artemether-lumefantrine are the first-line and second-line anti-malarial drugs to treat uncomplicated Plasmodium falciparum malaria, respectively." | 5.17 | Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. ( Basco, LK; Brasseur, P; Casimiro, PN; Loumouamou, D; Mayengue, PI; Ndounga, M; Ntoumi, F, 2013) |
| "A new dose regimen of artesunate and amodiaquine (NDRAA) based on age or body weight range was compared with standard dose regimen of artesunate and amodiaquine (SDRAA) calculated according to body weight and with fixed-dose artesunate-amodiaquine (FDAA) and artemether-lumefantrine (AL) in 304 children afflicted by malaria aged 15 years or younger." | 5.16 | A simple dose regimen of artesunate and amodiaquine based on age or body weight range for uncomplicated falciparum malaria in children: comparison of therapeutic efficacy with standard dose regimen of artesunate and amodiaquine and artemether-lumefantrin ( Adewoye, EO; Folarin, OO; Gbotosho, GO; Happi, CT; Okuboyejo, TM; Sowunmi, A, 2012) |
| "A dose regimen of artesunate and amodiaquine based on arm span- or age range (DRAAAS), derived from a study of 1674 children, was compared with standard dose regimen of the same drugs calculated according to body weight (SDRAA) in 68 malarious children." | 5.16 | A simple dose regimen of artesunate and amodiaquine based on arm span- or age range for childhood falciparum malaria: a preliminary evaluation. ( Akinrinola, IA; Gbotosho, GO; Happi, CT; Okuboyejo, TM; Sowunmi, A, 2012) |
| "The therapeutic efficacy and effects of artemether-lumefantrine (AL) and artesunate-amodiaquine co-formulated (AAcf) or co-packaged (AAcp) on malaria-associated anemia (MAA) were evaluated in 285 children < 12 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive one of the three drug combinations." | 5.15 | Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. ( Adewoye, EO; Folarin, OA; Gbotosho, GO; Happi, CT; Michael, OS; Okuboyejo, TM; Sowunmi, A, 2011) |
| " The objective was to assess the efficacy and safety of repeated administrations of two fixed-dose presentations of ACT--artesunate plus amodiaquine (ASAQ) and artemether-lumefantrine (AL)--in subsequent episodes of Plasmodium falciparum malaria." | 5.15 | Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. ( Barry, A; Cissé, B; Faye, B; Gaye, O; Gueye, A; Lameyre, V; Ndiaye, D; Ndiaye, I; Ndiaye, JL; Tchania, C; Tine, R, 2011) |
| "The effects of amodiaquine, artesunate and artesunate-amodiaquine on Plasmodium falciparum malaria-associated anaemia (PfMAA) and the recovery from PfMAA were evaluated in 328 children with uncomplicated malaria randomized to the standard dose regimens of the three drug treatments." | 5.14 | Effects of amodiaquine, artesunate, and artesunate-amodiaquine on Plasmodium falciparum malaria-associated anaemia in children. ( Balogun, ST; Gbotosho, GO; Happi, CT; Sowunmi, A, 2009) |
| "Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria." | 5.14 | The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. ( Diarra, A; Gansané, A; Kiechel, JR; Konaté, AT; Morgan, CC; Olliaro, PL; Ouédraogo, A; Sirima, SB; Taylor, WR; Tiono, AB, 2009) |
| "Artesunate-amodiaquine (AAQ) is efficacious for the treatment of uncomplicated Plasmodium falciparum malaria in Africa, but little is known about its efficacy in Southeast Asia." | 5.14 | Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. ( Chavchich, M; Dai, B; Edstein, MD; Phong, NC; Shanks, GD; Thanh, NX; Thien, NX; Trung, TN, 2009) |
| "The use of artemisinin derivative-based combination therapy (ACT) such as artesunate plus amodiaquine is currently recommended for the treatment of uncomplicated Plasmodium falciparum malaria." | 5.14 | Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. ( Brasseur, P; Dara, N; Diallo, M; Dicko, Y; Djimde, A; Faye, B; Forlemu, D; Gaye, O; Lameyre, V; Moor, VA; Ndiaye, I; Ndiaye, JL; Randrianarivelojosia, M; Randrianasolo, L; Ratsimbasoa, A; Sagara, I; Same-Ekobo, A; Traore, A, 2009) |
| "The activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites were evaluated in 42 of 181 Nigerian children with uncomplicated Plasmodium falciparum malaria who had gametocytaemia before, during or after treatment with the two combination therapies." | 5.13 | Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children. ( Adedeji, AA; Balogun, T; Bolaji, OM; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A, 2008) |
| "The activities of artesunate-cotrimoxazole and artesunate-amodiaquine combinations against asexual-and sexual-stage parasites were evaluated in 182 Nigerian children with uncomplicated Plasmodium falciparum malaria." | 5.13 | Effects of artesunate-cotrimoxazole and amodiaquine-artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children. ( Adedeji, AA; Balogun, ST; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sijuade, AO; Sowunmi, A, 2008) |
| "The use of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy (IPTp) is threatened by the spread of resistance to SP." | 5.13 | A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. ( Affipunguh, PK; Bruce, J; Chandramohan, D; Clerk, CA; Greenwood, B; Hodgson, A; Mensah, N, 2008) |
| "Amodiaquine (AQ), an effective antimalarial drug for uncomplicated malaria, has been greatly restricted after cases of life-threatening agranulocytosis and hepatic toxicity during prophylactic use." | 5.13 | Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania. ( Akida, JA; Bygbjerg, IC; Chile, MM; Kitua, AY; Lemnge, MM; Lusingu, JP; Makunde, R; Malebo, HM; Massaga, JJ; Rønn, AM; Theander, TG, 2008) |
| " The aim of this study was to compare effectiveness, tolerability and acceptance of artesunate plus amodiaquine (ASAQ) against that of artemether-lumefantrine (AL) in Ghanaian children with uncomplicated Plasmodium falciparum malaria." | 5.13 | A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. ( Adjei, S; Amemasor, S; Ansong, D; Bührlen, M; Heidemann, H; Hogan, B; Klein, P; Kobbe, R; Kreuels, B; Loag, W; May, J; Nielsen, MV; Thompson, WN; Vohwinkel, J, 2008) |
| "To assess the efficacy and safety of atovaquone-proguanil (alone and in combination with artemisinin drugs) versus other antimalarial drugs for treating uncomplicated Plasmodium falciparum malaria in adults and children." | 5.12 | Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. ( Blanshard, A; Hine, P, 2021) |
| "Amodiaquine+SP is not well tolerated and a substantial proportion of patients experienced pruritus and fatigue, thus decreasing their compliance and compromising the first line treatment implementation at national level." | 5.12 | Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. ( D'Alessandro, U; Fanello, CI; Karema, C; Rwagacondo, CE; van Doren, W, 2006) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 5.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| "An open randomized controlled study of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) for the treatment of uncomplicated Plasmodium falciparum malaria was carried out in 181 children." | 5.12 | The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children. ( Adedeji, AA; Amoo, AO; Fateye, BA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| "Amodiaquine alone or in combination with sulphadoxine-pyrimethamine, although associated with minor side-effects, is effective when used to treat malaria in pregnancy." | 5.12 | Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. ( Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006) |
| "The artemisinin-based combination therapies artemether-lumefantrine (AL) and amodiaquine (AQ) plus artesunate have been adopted for treatment of Plasmodium falciparum malaria in many African countries." | 5.12 | Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. ( Ahmed, J; Hallett, RL; Humphreys, GS; Merinopoulos, I; Mutabingwa, TK; Sutherland, CJ; Whitty, CJ, 2007) |
| "The activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites were evaluated in 360 Nigerian children with uncomplicated Plasmodium falciparum malaria randomized to the standard dose regimens of the three drugs/combination." | 5.12 | Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children. ( Adedeji, AA; Balogun, T; Fehintola, FA; Gbotosho, GO; Happi, CT; Sowunmi, A, 2007) |
| "The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination." | 5.12 | Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| " In order to investigate the latter, we conducted a randomized clinical trial testing the AR plus amodiaquine (AQ) combination for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso." | 5.11 | A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. ( Barennes, H; Koussoubé-Balima, T; Nagot, N; Ouedraogo, A; Sanou, T; Valea, I; Yé, S, 2004) |
| "We investigated the safety and efficacy of amodiaquine alone (AQ) and combined with artesunate (AQ + AS) in 308 Rwandan children 6-59 months old with uncomplicated Plasmodium falciparum malaria attending three sentinel sites." | 5.11 | Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. ( D'Alessandro, U; Dujardin, JC; Erhart, A; Karema, C; Mugisha, V; Ringwald, P; Rwagacondo, CE; Van Overmeir, C, 2004) |
| "The efficacy of amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP) was assessed in 310 symptomatic children from western Kenya with uncomplicated Plasmodium falciparum malaria." | 5.11 | Comparison of the parasitologic efficacy of amodiaquine and sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in the Bungoma District of western Kenya. ( Cobelens, FG; Gikunda, S; Hoogstraatte, SR; Kager, PA; Scheper, FY; Smolders, M; Vreugdenhil, CJ, 2004) |
| "The study examined the efficacy of chloroquine (CQ), amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated Plasmodium falciparum malaria in Ghana." | 5.11 | A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. ( Amankwa, J; Ansah, NA; Ansah, P; Anto, F; Anyorigiya, T; Atuguba, F; Hodgson, A; Mumuni, G; Oduro, AR, 2005) |
| "Both northern and southern Sudan are deploying artemisinin-based combinations against uncomplicated Plasmodium falciparum malaria (artesunate+sulfadoxine-pyrimethamine [AS+SP] in the north, artesunate+amodiaquine [AS+AQ] in the south)." | 5.11 | Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. ( Atkin, S; Checchi, F; Ford, N; Hamour, S; Hook, C; Keus, K; Melaku, Y; Montgomery, J; Wambugu, J, 2005) |
| "The therapeutic efficacy of sulfadoxine-pyrimethamine (SP) alone, SP plus amodiaquine (AQ), and SP plus artesunate (AS) was assessed in a randomized, placebo-controlled, and double-blind trial among 438 children with uncomplicated Plasmodium falciparum malaria in northern Ghana." | 5.11 | A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. ( Anemana, SD; Bienzle, U; Cramer, JP; Dzisi, SY; Eggelte, TA; Ehrhardt, S; Mockenhaupt, FP; Otchwemah, RN; Sauerwein, RW; Schreiber, J; Teun Bousema, J; Wassilew, N, 2005) |
| " The authors recommend that the treatment to be used in Abie must be firstly amodiaquine followed by sulfadoxine-pyrimethamine in cases where there is persistent asymptomatic parasitemia." | 5.11 | [Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire]. ( Adjetey, TA; Affoumou, GB; Barro-Kiki, P; Kone, M; Loukou, DD; Menan, EI; Nebavi, NG; Yavo, W, 2005) |
| "To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon." | 5.10 | Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. ( Basco, LK; Metoh, T; Ndounga, M; Ngane, VF; Ringwald, P; Same-Ekobo, A; Soula, G, 2002) |
| "The safety and efficacy of amodiaquine (AQ), sulfadoxine-pyrimethamine (SP), and coadministered AQ+SP was assessed in 351 Tanzanian children (age range, 6-59 months) with uncomplicated Plasmodium falciparum malaria." | 5.10 | The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. ( Alonso, PL; Aponte, JJ; Drakeley, C; Kahigwa, E; Malende, A; Menendez, C; Mshinda, H; Msokame, C; Schellenberg, D; Tanner, M; Wigayi, J, 2002) |
| "The effects of chloroquine (CQ), amodiaquine (AQ) and CQ plus chlorpheniramine (a histamine H(1) antagonist that reverses CQ resistance in vitro and in vivo) on the disposition of the enlarged liver associated with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were evaluated." | 5.10 | The effects of chloroquine, amodiaquine and chloroquine plus chlorpheniramine on the disposition kinetics of the hepatomegaly associated with acute, uncomplicated, Plasmodium falciparum malaria in children. ( Adedeji, AA; Sowunmi, A, 2002) |
| "Many African countries currently use a sulfadoxine-pyrimethamine combination (SP) or amodiaquine (AQ) to treat uncomplicated Plasmodium falciparum malaria." | 5.10 | Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. ( Aubouy, A; Bakary, M; Cot, M; Deloron, P; Keundjian, A; Le Bras, J; Makita, JR; Mbomat, B; Migot-Nabias, F, 2003) |
| "The relationship between the efficacy of amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria and preexisting antibodies against merozoite surface protein (MSP)-1, a blood-stage P." | 5.10 | Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. ( Borrmann, S; Cavanagh, DR; Kremsner, PG; Matsiegui, PB; Mawili-Mboumba, DP; McBride, JS; Missinou, MA; Ntoumi, F, 2003) |
| "We evaluated gametocyte carriage and intensities of gametocytaemia in 710 children presenting with acute, symptomatic, uncomplicated Plasmodium falciparum malaria who were treated with various antimalarial drug regimens: chloroquine (CQ); chloroquine plus chlorpheniramine, a histamine H1 receptor antagonist that reverses CQ resistance in P." | 5.10 | Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. ( Fateye, BA; Sowunmi, A, 2003) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 5.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| "We conducted two randomized clinical trials to determine the in vivo efficacy of amodiaquine and sulfadoxine/pyrimethamine in treating Plasmodium falciparum malaria." | 5.09 | In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. ( Ashruf, G; Bennebroek, J; Gikunda, S; Gorissen, E; Kager, PA; Lamboo, M; Mbaruku, G, 2000) |
| "The cardiac effect of amodiaquine and sulfadoxine-pyrimethamine was studied in adult Cameroonian patients with acute uncomplicated Plasmodium falciparum malaria by electrocardiographic monitoring over the course of 7 days." | 5.09 | Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. ( Basco, LK; Blackett, KN; Keundjian, A; Ngouesse, B; Ringwald, P, 2001) |
| " Between January and July 1993, 100 patients presenting with symptomatic Plasmodium falciparum malaria were randomised to receive amodiaquine or chloroquine at the dose of 30 mg/kg for 3 days." | 5.07 | [Parasitological and clinical response to amodiaquine versus chloroquine in the treatment of Plasmodium falciparum malaria in children in an endemic area]. ( Assi-Coulibaly, L; Ehouman, A; Kaptué, B; Konan, D; Penali, LK, 1994) |
| "In October 1988, a project was implemented for assessing the malaria chemoprophylactic efficacy of weekly chloroquine (CQ) and daily proguanil (PROG) during pregnancy in Muheza-Tanzania." | 5.07 | Malaria in infants whose mothers received chemoprophylaxis: response to amodiaquine therapy. ( de Geus, A; Malle, LN; Mutabingwa, TK; Wernsdorfer, WH, 1992) |
| "In-vivo and in-vitro studies to determine the sensitivity of Plasmodium falciparum malaria to chloroquine and amodiaquine were conducted in 4 districts of Western Kenya over a 2-year-period." | 5.07 | Sensitivity of falciparum malaria to chloroquine and amodiaquine in four districts of western Kenya (1985-1987). ( Adoyo, A; Boriga, DA; Kariuki, D; Koech, DK; Magiri, C; Oloo, AJ; Were, JB, 1991) |
| "The majority of Plasmodium falciparum malaria cases in Africa are treated with the artemisinin combination therapies artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ), with amodiaquine being also widely used as part of seasonal malaria chemoprevention programs combined with sulfadoxine-pyrimethamine." | 5.05 | The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. ( Bassat, Q; Baudin, E; Bretscher, MT; D'Alessandro, U; Dahal, P; Djimde, AA; Dorsey, G; Espié, E; Fofana, B; Ghani, AC; González, R; Griffin, J; Guerin, PJ; Juma, E; Karema, C; Lasry, E; Lell, B; Lima, N; Menéndez, C; Mombo-Ngoma, G; Moreira, C; Nikiema, F; Okell, LC; Ouédraogo, JB; Staedke, SG; Stepniewska, K; Tinto, H; Valea, I; Yeka, A, 2020) |
| "We did a systematic review of interventional or observational cohort studies assessing the efficacy of artemisinin-based or quinine-based treatments in pregnancy." | 5.05 | Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. ( Anvikar, AR; Ashley, EA; Chandramohan, D; Cohee, LM; D'Alessandro, U; Genton, B; Gilder, ME; Guérin, PJ; Juma, E; Kalilani-Phiri, L; Kennon, K; Kuepfer, I; Laufer, MK; Lwin, KM; Mansoor, R; McGready, R; Meshnick, SR; Mosha, D; Mwapasa, V; Mwebaza, N; Nambozi, M; Ndiaye, JA; Nosten, F; Nyunt, M; Ogutu, B; Parikh, S; Paw, MK; Phyo, AP; Pimanpanarak, M; Piola, P; Rijken, MJ; Saito, M; Sriprawat, K; Stepniewska, K; Tagbor, HK; Tarning, J; Tinto, H; Valéa, I; Valecha, N; White, NJ; Wiladphaingern, J, 2020) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 4.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| "Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa." | 4.91 | The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. ( Adjuik, MA; Allan, R; Anvikar, AR; Ashley, EA; Ba, MS; Barennes, H; Barnes, KI; Bassat, Q; Baudin, E; Björkman, A; Bompart, F; Bonnet, M; Borrmann, S; Brasseur, P; Bukirwa, H; Checchi, F; Cot, M; D'Alessandro, U; Dahal, P; Deloron, P; Desai, M; Diap, G; Djimde, AA; Dorsey, G; Doumbo, OK; Espié, E; Etard, JF; Fanello, CI; Faucher, JF; Faye, B; Flegg, JA; Gaye, O; Gething, PW; González, R; Grandesso, F; Guerin, PJ; Guthmann, JP; Hamour, S; Hasugian, AR; Hay, SI; Humphreys, GS; Ibrahim, LM; Jullien, V; Juma, E; Kamya, MR; Karema, C; Kiechel, JR; Kremsner, PG; Krishna, S; Lameyre, V; Lee, SJ; Lell, B; Mårtensson, A; Massougbodji, A; Menan, H; Ménard, D; Menéndez, C; Meremikwu, M; Moreira, C; Nabasumba, C; Nambozi, M; Ndiaye, JL; Nikiema, F; Nsanzabana, C; Ntoumi, F; Ogutu, BR; Olliaro, P; Osorio, L; Ouédraogo, JB; Penali, LK; Pene, M; Pinoges, L; Piola, P; Price, RN; Roper, C; Rosenthal, PJ; Rwagacondo, CE; Same-Ekobo, A; Schramm, B; Seck, A; Sharma, B; Sibley, CH; Sinou, V; Sirima, SB; Smith, JJ; Smithuis, F; Somé, FA; Sow, D; Staedke, SG; Stepniewska, K; Swarthout, TD; Sylla, K; Talisuna, AO; Tarning, J; Taylor, WR; Temu, EA; Thwing, JI; Tine, RC; Tinto, H; Tjitra, E; Vaillant, MT; Valecha, N; Van den Broek, I; White, NJ; Yeka, A; Zongo, I, 2015) |
| " Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel." | 4.90 | Malaria. ( Dondorp, AM; Faiz, MA; Hien, TT; Mokuolu, OA; Pukrittayakamee, S; White, NJ, 2014) |
| "To compare sulfadoxine-pyrimethamine plus amodiaquine (SP plus AQ) with sulfadoxine-pyrimethamine plus artesunate (SP plus AS) for treating uncomplicated Plasmodium falciparum malaria." | 4.83 | Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria. ( Bukirwa, H; Critchley, J, 2006) |
| "To assess the relationship between the genetic and phenotypic factors linked to the cytochrome P-450 enzyme system and the response to the antimalarial drugs chloroquine, amodiaquine, mefloquine, and proguanil, as well as to determine how certain biological and social factors of the host influence the behavior of this enzymatic complex." | 4.83 | [Cytochrome P-450 and the response to antimalarial drugs]. ( Carmona-Fonseca, J; Guzmán, V, 2006) |
| "To compare amodiaquine with chloroquine or sulfadoxine-pyrimethamine for treating uncomplicated Plasmodium falciparum malaria." | 4.82 | Amodiaquine for treating malaria. ( Mussano, P; Olliaro, P, 2003) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 4.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "In a prospective longitudinal in vivo study, neutrophil rates were compared with malaria carriage after treatment with different ACTs: Artemether - lumefantrine (AL), Artesunate - amodiaquine (ASAQ), Dihydroartemisinin - piperaquine (DP) or Pyronaridine artesunate (PA)." | 4.31 | Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. ( Arama, C; Beavogui, AH; Dicko, A; Djimde, A; Djimde, M; Fofana, B; Kayentao, K; Mens, PF; Ouedraogo, JB; Sagara, I; Schallig, HD; Sirima, SB; Tshiongo, JK, 2023) |
| "Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia." | 4.12 | Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers. ( Asinya, M; Jeuronlon, MK; Kamara, P; Koko, VS; Kollie, A; Ma, L; Menard, D; Nyansaiye, P; Parwon, S; Pratt, OJ; Ringwald, P; Taweh, F; Tehmeh, L; Vonhm, B; Warsame, M, 2022) |
| "Artesunate-amodiaquine is a potential therapy for uncomplicated malaria in Cambodia." | 4.02 | Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia. ( Ariey, F; Chy, S; Dorina Bustos, M; Eam, R; Izac, B; Kauy, C; Ke, S; Khim, N; Kim, S; Kloeung, N; Leang, R; Mairet-Khedim, M; Marmai, C; Mey Bouth, D; Ringwald, P; Witkowski, B, 2021) |
| "The Angolan government recommends three artemisinin-based combinations for the treatment of uncomplicated Plasmodium falciparum malaria: artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP)." | 3.88 | Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. ( Andrade, BN; Davlantes, E; Dimbu, PR; Dos Santos Souza, S; Félix, J; Ferreira, CM; Florinda Joao, M; Fortes, F; Halsey, ES; Martins, JF; Mbounga, E; Owens, C; Plucinski, MM; Pode, D; Sanhangala, E; Talundzic, E; Udhayakumar, V; Wiesner, L, 2018) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 3.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "A novel class of benzoheterocyclic analogues of amodiaquine designed to avoid toxic reactive metabolite formation was synthesized and evaluated for antiplasmodial activity against K1 (multidrug resistant) and NF54 (sensitive) strains of the malaria parasite Plasmodium falciparum." | 3.81 | Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies. ( Chibale, K; Egan, TJ; Jurva, U; Masimirembwa, CM; Njoroge, M; Ongarora, DS; Strydom, N; Wicht, K; Wiesner, L; Wittlin, S, 2015) |
| " Thick smears stained with Giemsa were done for every febrile villager and malaria attacks were treated with combination of Artesunate plus Amodiaquine." | 3.81 | The implication of long-lasting insecticide-treated net use in the resurgence of malaria morbidity in a Senegal malaria endemic village in 2010-2011. ( Boyer, S; Diagne, N; Doucoure, S; Faye, N; Gaudart, J; Richard, V; Sokhna, C; Tall, A; Touré-Baldé, A; Trape, JF; Wotodjo, AN, 2015) |
| "Artemisinin combination therapies (ACTs) are used worldwide as first-line treatment against confirmed or suspected Plasmodium falciparum malaria." | 3.81 | Optimum population-level use of artemisinin combination therapies: a modelling study. ( Baird, JK; Boni, MF; Dondorp, AM; Farrar, J; Lam, HM; Nguyen, TD; Olliaro, P; Thwaites, GE; White, NJ, 2015) |
| "Artesunate-amodiaquine is among the most widely available artemisinin combination therapy used as treatment regimen for uncomplicated Plasmodium falciparum malaria." | 3.80 | Artesunate-amodiaquine combination therapy in the absence of malarial parasite infection induces oxidative damage in female rats. ( Abolaji, AO; Olusemire, O; Osedeme, F, 2014) |
| " This study reports the results of therapeutic efficacy studies conducted on artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Togo, between 2005 and 2009." | 3.78 | Surveillance of the efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum among children under five in Togo, 2005-2009. ( Agbo, YM; Barrette, A; Bogreau, H; Dorkenoo, MA; Kutoati, S; Morgah, K; Sodahlon, YK, 2012) |
| " To counter the increasing challenge of anti-malarial drug resistance and improve highly effective treatment Burundi adopted artesunate-amodiaquine (AS-AQ) as first-line treatment for uncomplicated Plasmodium falciparum malaria and oral quinine as second-line treatment in its national treatment policy in 2003." | 3.77 | Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi. ( Amuasi, JH; Blay-Nguah, S; Boakye, I; Diap, G; Dismas, B; Karenzo, J; Karikari, PE; Kiechel, JR; Louie, KS; Nsabiyumva, L, 2011) |
| " A three-arm, three-centre trial of Amodiaquine (AQ), sulfadoxine-pyrimethamine (SP) and their combination (AQ + SP), conducted by OCEAC-IRD in 2003, in 538 children with uncomplicated Plasmodium falciparum malaria, is used as an illustration." | 3.76 | Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3- arm anti- malarial drug trial in Cameroon. ( Basco, LK; Gwét, H; Thalabard, JC; Whegang, SY, 2010) |
| "Twenty-eight day in-vivo efficacy trial of amodiaquine-artesunate in 103 children aged 6-59 months in western Kenya with smear-confirmed uncomplicated Plasmodium falciparum malaria." | 3.75 | In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. ( Desai, M; Hamel, MJ; Kariuki, S; McMorrow, M; Newman, RD; Odero, CO; Odhiambo, FO; Ord, R; Otieno, KO; Roper, C; Slutsker, L; Thwing, JI; Vulule, J, 2009) |
| "In 2003, the high level of chloroquine (CQ) treatment failure for uncomplicated Plasmodium falciparum malaria cases has led Senegal to adopt a new combination therapy with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ)." | 3.74 | Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine-amodiaquine failure in Pikine, Senegal. ( Ahouidi, AD; Daily, JP; Ly, O; Mboup, S; Ndiaye, D; Ndir, O; Sarr, O; Wirth, DF, 2008) |
| "The in-vivo efficacies of the artesunate malartin, alone and in combination with amodiaquine, have been assessed against uncomplicated cases of Plasmodium falciparum malaria attending two treatment centres in Cameroon (the WHO/University of Buea malaria health post in Bolifamba and the University of Buea's health centre in Molyko)." | 3.74 | The comparative efficacies of malartin, with and without amodiaquine, in the treatment of Plasmodium falciparum malaria in the Buea district of Cameroon. ( Kimbi, HK; Ndamukong, KN; Nkuo-Akenji, TK; Nkwescheu, A; Patchong, AF, 2007) |
| "The therapeutic efficacy of three monotherapies was assessed: amodiaquine and sulfadoxine/pyrimethamine for uncomplicated Plasmodium falciparum malaria, and chloroquine for Plasmodium vivax malaria in the municipality of Tarapacá, located in the Colombian province of Amazonas." | 3.74 | [Assessment of the efficacy of antimalarial drugs in Tarapacá, in the Colombian Amazon basin]. ( González, IJ; Osorio, L; Pérez, Ldel P, 2007) |
| " We treated 81 children <5 years with uncomplicated Plasmodium falciparum malaria with AQ alone and related the treatment outcome to the possible selection of pfcrt 76T, 152T, 163S, 326S, pfmdr1 86Y and pfmrp 191H, 437S in recurrent infections (recrudescenses and re-infections) and to the blood concentration of desethylamodiaquine (DEAQ)." | 3.73 | Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. ( Björkman, A; Ferreira, PM; Gil, JP; Holmgren, G; Obonyo, CO; Veiga, MI, 2006) |
| "The safety and the efficacy of amodiaquine (AQ) alone, AQ plus sulfadoxine-pyrimethamine (SP) (AQ plus SP), and artesunate (ART) plus SP (ART plus SP), three possible alternatives to chloroquine (CQ), were investigated in 379 Rwandan children 6-59 months old with uncomplicated Plasmodium falciparum malaria who visited one urban/peri-urban health center and two rural health centers." | 3.72 | Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. ( D'Alessandro, U; Dujardin, JC; Karema, C; Mugisha, V; Niyitegeka, F; Rwagacondo, CE; Sarushi, J; van den Ende, J; Van Overmeir, C, 2003) |
| "The efficacy of amodiaquine against Plasmodium falciparum malaria was assessed in an area of confirmed chloroquine resistance in the cool, north-central plateau of Nigeria, using a 14-day protocol." | 3.72 | Amodiaquine treatment of uncomplicated malaria in children, in an area of chloroquine-resistant Plasmodium falciparum in north-central Nigeria. ( Adeniji, B; Afolabi, BM; Amajoh, CN; Ekanem, OJ; Molta, NB; Odujoko, JB; Oguche, S; Omalu, IC; Pam, SD; Wuyep, VP, 2003) |
| " The efficacy of AQ was assessed at the dose of 30 mg/kg in treating Plasmodium falciparum malaria attacks in 74 children from southeast Gabon, and the in vitro activity of monodesethylamodiaquine (MdAQ), the main metabolite of AQ, was measured against P." | 3.72 | Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. ( Aubouy, A; Bakary, M; Deloron, P; Keundjian, A; Le Bras, J; Mayombo, J, 2004) |
| " Eleven volunteers received chloroquine in usually curative doses on a three-day schedule during acute clinical malaria attacks." | 3.64 | STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND. ( ALVING, AS; BREWER, GJ; MILLAR, JW; POWELL, RD, 1964) |
| " Mild and moderate adverse events, including gastrointestinal and/or nervous disorders, were reported in 11." | 3.30 | Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated Plasmodium falciparum malaria in children on the rainy south-east coast of Madagascar. ( Carn, G; Harimanana, AN; Hotahiene, R; Irinantenaina, J; Ralemary, N; Randriamiarinjatovo, DNAL; Randrianarivelojosia, M; Randriarison, M; Razafinjato, C; Razanatsiorimalala, S, 2023) |
| " Safety was based on assessment of adverse events (AEs) and severe adverse events (SAEs) from day 1 to day 28." | 3.11 | Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial. ( Aboh, PM; Adzemye, LM; Akam, LF; Ali, IM; Alifrangis, M; Ambani, MCE; Ango, Z; Bigoga, JD; Chedjou, JPK; Dinza, G; Dongmo, CH; Douanla, A; Ewane, MS; Fomboh, CT; Fosah, DA; Kotcholi, GB; Ludovic, AJ; Mbacham, WF; Moyeh, MN; Nana, WD; Ndikum, VN; Ngu, JA; Niba, PTN; Nji, AM; Nna, DRA; Oben, OLA; Omgba, PAM; Selly-Ngaloumo, AA; Tatah, FM; Ticha, JT, 2022) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 3.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 3.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| " Occurrence of adverse events was similar in both groups, except for vomiting, which was more frequent in the MB than in the PQ arm (20/50 vs 7/50, p = 0." | 2.90 | Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial. ( Compaoré, G; Coulibaly, B; D Alessandro, U; Jahn, A; Kieser, M; Klose, C; Krisam, J; Lu, G; Meissner, P; Mendes Jorge, M; Mockenhaupt, FP; Müller, O; Nebie, E; Ouermi, L; Sié, A, 2019) |
| " The most frequent adverse event in both groups was asthenia." | 2.90 | Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial. ( Adegbite, BR; Adegnika, AA; Agnandji, ST; Dejon-Agobe, JC; Edoa, JR; Honkpehedji, YJ; Koehne, E; Kreidenweiss, A; Kremsner, PG; Kun, J; Lalremruata, A; Lell, B; Lotola-Mougueni, F; Mbong-Ngwese, M; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Obone Atome, FA; Ramharter, M; Safiou, AR; Velavan, TP; Zinsou, FJ, 2019) |
| " After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild)." | 2.87 | Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. ( Bousema, T; Bradley, J; Brown, JM; Chen, I; Diarra, K; Diawara, H; Dicko, A; Drakeley, C; Gosling, R; Hwang, J; Issiaka, D; Keita, S; Kone, DT; Lanke, K; Mahamar, A; McCulloch, C; Müller, O; Roh, ME; Sanogo, K; Soumare, HM; Srinivasan, V; Stone, WJR; Traore, SF, 2018) |
| "falciparum malaria were treated with ASAQ and followed up passively for 42 days." | 2.82 | Uncomplicated Clinical Malaria Features, the Efficacy of Artesunate-Amodiaquine and Their Relation with Multiplicity of Infection in the Democratic Republic of Congo. ( Delgado-Ratto, C; Fungula, B; Inocêncio da Luz, R; Kalabuanga, M; Lutumba, P; Maketa, V; Muhindo Mavoko, H; Mukele, R; Rosanas-Urgell, A; Van Geertruyden, JP, 2016) |
| "Methylene blue (MB) has been shown to be safe and effective against falciparum malaria in Africa and to have pronounced gametocytocidal properties." | 2.80 | Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. ( Berens-Riha, N; Bountogo, M; Bousema, T; Breitkreutz, J; Coulibaly, B; Drakeley, C; Kieser, M; Klose, C; Meissner, PE; Mockenhaupt, FP; Müller, O; Nebié, E; Pritsch, M; Schirmer, RH; Sié, A; Sirima, SB; Wieser, A, 2015) |
| " No statistical significant differences were observed in the occurrence of adverse events among treatment groups." | 2.80 | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. ( Ali, IM; Chedjou, JP; Ekollo, AM; Evehe, MS; Froeschl, G; Heumann, C; Mansmann, U; Mbacham, WF; Moyeh, MN; Ndikum, VN; Ngongang, EO; Nji, AM; Ogundahunsi, O, 2015) |
| "falciparum malaria were recruited." | 2.80 | Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali. ( Beavogui, AH; Dama, S; Dara, A; Dembele, D; Diallo, N; Djimde, AA; Doumbo, OK; Maiga, H; N'Dong, C; Niangaly, H; Sagara, I; Sangare, CP; Tekete, M; Toure, O; Traore, OB; Traore, ZI, 2015) |
| " Follow-up visits were performed on days 3, 7, 14, 21, and 28 to evaluate clinical and parasitological resolution of their malaria episode as well as adverse events." | 2.80 | Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. ( Derra, K; Diallo-Nakanabo, S; Guiguemde, TR; Kazienga, A; Ouedraogo, JB; Owusu-Dabo, E; Sondo, P; Sorgho, H; Tarnagda, Z; Tinto, H; Valea, I; Zampa, O, 2015) |
| " All the other adverse events reported were mild, and no significant difference was noted by treatment." | 2.79 | Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Re ( Djallé, D; Laganier, R; Le Faou, A; Manirakiza, A; Njuimo, SP; Rogier, C, 2014) |
| "Atovaquone-proguanil was characterized by a slow blood schizontocidal action and resulted in early treatment failure in a few patients." | 2.79 | Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children. ( Almelli, T; Basco, LK; Debue, C; Djaman Allico, J; Foumane Ngane, V; Tahar, R; Whegang Youdom, S, 2014) |
| " No serious adverse event was noted during the study period." | 2.78 | Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. ( Abiola, A; Faye, B; Folly, K; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, LA; Ndiaye, M; Sow, D; Sylla, K; Tine, RC, 2013) |
| "falciparum malaria were enrolled." | 2.75 | Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. ( Oguonu, T; Okafor, HU; Shu, EN, 2010) |
| "To compare, in a phase IV trial, the efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) dosed at 300 and 600 mg of amodiaquine per tablet to artemether-lumefantrine (Coartem) for the treatment of Plasmodium falciparum uncomplicated malaria in Ivory Coast and Senegal." | 2.75 | Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. ( Djoman, K; Faye, B; Gaye, O; Ndiaye, JL; Ndiaye, PS; Offianan, AT; Penali, L; Sylla, K; Tine, RC; Touré, W, 2010) |
| "Amodiaquine (AQ) is an antimalarial drug that was frequently combined with artesunate (AS) for the treatment of uncomplicated malaria due to Plasmodium falciparum and is now available as a fixed-dose combination." | 2.75 | Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. ( Carn, G; Jullien, V; Juma, E; Kiechel, JR; Obonyo, C; Ogutu, B, 2010) |
| "Several products of artesunate plus amodiaquine (AS + AQ) are being deployed in malaria-endemic countries for treating uncomplicated falciparum malaria but dosing accuracy and consequential effects on efficacy and tolerability have not been examined." | 2.74 | Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. ( Agnamey, P; Badiane, M; Brasseur, P; Cisse, M; Gaye, O; Olliaro, P; Taylor, WR; Vaillant, M, 2009) |
| "Amodiaquine was the most effective on fever." | 2.74 | Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. ( Beavogui, AH; Dama, S; Dembele, D; Dicko, A; Djimde, AA; Doumbo, OK; Fofana, B; Kone, A; Maiga, H; Ouologuem, D; Sagara, I; Tekete, M; Wele, M, 2009) |
| " Participants were actively monitored for adverse events for the first 14 days after each treatment, and then passively followed until their next study medication treatment, or withdrawal from study." | 2.73 | Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. ( Clark, TD; Dorsey, G; Jagannathan, P; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG; Talisuna, AO; Yau, VM, 2008) |
| " The incidence of adverse events, such as pruritus, fatigue and neutropaenia were similar in the two treatment groups." | 2.73 | Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. ( Adjei, GO; Alifrangis, M; Badoe, EV; Goka, BQ; Hoegberg, LC; Kitcher, ED; Kurtzhals, JA; Lamptey, R; Rodrigues, OP, 2008) |
| "001), and the population distribution half-life was shorter (P < 0." | 2.73 | Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. ( Adjei, GO; Alifrangis, M; Goka, BQ; Hoegberg, LC; Kristensen, K; Kurtzhals, JA; Rodrigues, OP, 2008) |
| "falciparum malaria was evaluated according to G6PD deficiency in a secondary analysis of an open-label, randomized clinical trial." | 2.73 | High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. ( Avellino, P; Bancone, G; d'Alessandro, U; Fanello, CI; Karema, C; Lee, SJ; Modiano, D; Uwimana, A, 2008) |
| " Adverse events and clinical and parasitological outcomes were recorded." | 2.73 | A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. ( D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; Van Overmeir, C, 2007) |
| "Nearly all recurrences were due to new infections." | 2.73 | Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. ( Dokomajilar, C; Dorsey, G; Guiguemde, RT; Ouedraogo, JB; Rosenthal, PJ; Rouamba, N; Tinto, H; Zongo, I, 2007) |
| "Treatment with sulfadoxine-pyrimethamine was associated with an increase of gametocyte charge." | 2.73 | Efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated falciparum malaria in the urban and suburban areas of Brazzaville (Congo). ( Basco, LK; Casimiro, PN; Mallanda, G; Malonga, DA; Matondo Maya, DW; Mayengue, PI; Miakassissa-Mpassi, V; Ndounga, M; Nsonde-Ntandou, F; Ntoumi, F; Ringwald, P; Tahar, R, 2007) |
| "vivax malaria were treated according to the new policy guidelines (i." | 2.73 | Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. ( Beck, HP; Genton, B; Goroti, M; Maku, P; Marfurt, J; Müeller, I; Reeder, JC; Sie, A, 2007) |
| " The safety was evaluated by incidence of adverse events." | 2.73 | Randomized, comparative study of the efficacy and safety of artesunate plus amodiaquine, administered as a single daily intake versus two daily intakes in the treatment of uncomplicated falciparum malaria. ( Brasseur, P; Cisse, M; Diouf, AM; Faye, B; Gaye, O; Kuété, T; Lameyre, V; Ndiaye, JL; Same-Ekobo, A; Seck, PA, 2008) |
| "Methylene blue (MB) was the first synthetic antimalarial drug ever used, and recent studies have been promising with regard to its revival in malaria therapy." | 2.73 | Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. ( Coulibaly, B; Klose, C; Kouyaté, B; Mansmann, U; Meissner, P; Mockenhaupt, FP; Müller, O; Schirmer, RH; Sié, A; Walter-Sack, I; Zoungrana, A, 2008) |
| " No significant adverse event attributable to any of the study drugs was found." | 2.73 | Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. ( Dama, S; Dembele, D; Dicko, A; Djimdé, AA; Doumbo, OK; Fofana, B; Ouologuem, D; Sagara, I; Sidibe, B; Toure, S, 2008) |
| "Amodiaquine is a common partner drug in different malaria combination therapies used or investigated in sub-Saharan Africa, but data on its efficacy as a single drug are scarce." | 2.73 | Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso. ( Coulibaly, B; Mandi, G; Meissner, P; Mockenhaupt, FP; Müller, O, 2008) |
| "Amodiaquine (AQ) is an affordable compound, chemically related to chloroquine (CQ) but often effective against CQ resistant Plasmodium falciparum." | 2.72 | Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: experience with fixed-dose formulation. ( Aguttu, C; Anokbonggo, WW; Chiria, J; Gustafsson, LL; Hellgren, U; Obua, C; Ogwal-Okeng, JW, 2006) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 2.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "Atovaquone/proguanil was found to be highly effective and safe for the treatment of Plasmodium falciparum malaria in infants and young children weighing 5-10 kg in Africa." | 2.71 | Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. ( Bagaphou, T; Binder, RK; Borrmann, S; Faucher, JF; Kremsner, PG; Lell, B; Matsiegui, PB; Miller, G; Missinou, MA; Pabisch, S; Rezbach, P, 2003) |
| " In 2002, we assessed the efficacy of SP alone and combined with amodiaquine (AQ/SP) or chloroquine (CQ/SP) in Ugandan children with uncomplicated falciparum malaria." | 2.71 | Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children. ( Bakyaita, N; D'Alessandro, U; Egwang, TG; Langi, P; Mutabingwa, TK; Nalunkuma-Kazibwe, A; Talisuna, AO; Van Marck, E; Watkins, WW, 2004) |
| "falciparum malaria was compared with that of CQ, each drug being given at 10 mg/kg per day for 3 days (days 0, 1 and 2)." | 2.70 | Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Adedeji, AA; Ayede, AI; Falade, AG; Falade, CO; Happi, TC; Ndikum, VN; Oduola, AM; Sowunmi, A; Sowunmi, CO, 2001) |
| "Amodiaquine-artesunate is a potential combination for use in Africa." | 2.70 | Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. ( Adjuik, M; Agnamey, P; Babiker, A; Borrmann, S; Brasseur, P; Cisse, M; Cobelens, F; Diallo, S; Faucher, JF; Garner, P; Gikunda, S; Kremsner, PG; Krishna, S; Lell, B; Loolpapit, M; Matsiegui, PB; Missinou, MA; Mwanza, J; Ntoumi, F; Olliaro, P; Osimbo, P; Rezbach, P; Some, E; Taylor, WR, 2002) |
| "Atovaquone and proguanil was a highly effective and safe drug combination in patients with acute uncomplicated P falciparum malaria in Gabon." | 2.68 | Atovaquone and proguanil for Plasmodium falciparum malaria. ( Hutchinson, D; Kremsner, PG; Nkeyi, M; Philipps, J; Radloff, PD, 1996) |
| "Halofantrine was the most efficacious drug with 82% of the cases cured followed by fansidar(R)(62%), amodiaquine (55%) and chloroquine (29%)." | 2.68 | A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children. ( Anabwani, GM; Esamai, FO; Menya, DA, 1996) |
| "falciparum malaria were randomly treated with either amodiaquine or chloroquine 25 mg/kg, divided over three days." | 2.67 | A comparison of amodiaquine and chloroquine in the treatment therapy of falciparum malaria in Kenya. ( Munafu, CG; Nevill, CG; ten Hove, WR; van der Kaay, HJ; Verhoeff, FH; Were, JB, 1994) |
| "Amodiaquine and FansidarR were fully effective in eliminating asexual parasitaemia from the blood in all the cases during the seven days of follow-up." | 2.67 | Falciparum malaria fully cleared by amodiaquine, pyrimethamine-sulfadoxine and pyrimethamine-sulfalene in areas of chloroquine resistance in Dodoma, Tanzania. ( Irare, SG; Lemnge, MM; Mhina, JI, 1991) |
| "Pyronaridine-artesunate is a novel ACT." | 2.61 | Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. ( Hine, P; Pryce, J, 2019) |
| " Adverse events ranged from mild to moderate severity but were not directly attributed to drug intake." | 2.61 | Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon. ( Basco, LK; Chiabi, A; Whegang Youdom, S, 2019) |
| "AS-MQ and AL are more effective than DP and AS-AQ FDC in preventing gametocytaemia shortly after treatment, suggesting that the non-artemisinin partner drug or the timing of artemisinin dosing are important determinants of post-treatment gametocyte dynamics." | 2.53 | Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. ( , 2016) |
| "Amodiaquine is a central drug in the new global strategy of combination therapies for the control of malaria." | 2.44 | Amodiaquine pharmacogenetics. ( Gil, JP, 2008) |
| " However, increasing Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine makes finding alternative antimalarials that are safe and effective in pregnancy a priority." | 2.44 | The safety of amodiaquine use in pregnant women. ( Chandramohan, D; Greenwood, B; Tagbor, HK, 2007) |
| "Amodiaquine was significantly more effective than chloroquine, with odds ratios and 99% confidence intervals (OR [99% CI]) of 4." | 2.39 | Systematic review of amodiaquine treatment in uncomplicated malaria. ( Brasseur, P; Garner, P; LeBras, J; Mussano, P; Nevill, C; Olliaro, P; Ringwald, P, 1996) |
| "Amodiaquine is a pro-drug for the active antimalarial metabolite desethylamodiaquine." | 2.39 | Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ( Krishna, S; White, NJ, 1996) |
| " Adverse events were documented in less than 2% of participants for both drugs." | 1.62 | In vivo efficacy and safety of artemether-lumefantrine and amodiaquine-artesunate for uncomplicated Plasmodium falciparum malaria in Mozambique, 2018. ( Aide, P; Bassat, Q; Candrinho, B; Carvalho, E; Chidimatembue, A; Enosse, S; Halsey, ES; Lucchi, N; Macete, E; Mayor, A; Moriarty, LF; Nhacolo, A; Nhama, A; Nhamússua, L; Saifodine, A; Salvador, C; Svigel, SS; Zulliger, R, 2021) |
| "We developed a population pharmacokinetic model of dolutegravir with data from 26 healthy volunteers in two Phase 2 studies with a total of 403 dolutegravir plasma concentrations at steady state." | 1.62 | Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. ( Denti, P; Kawuma, AN; Khoo, S; Lamorde, M; Pillai, GC; Walimbwa, SI; Wasmann, RE, 2021) |
| " Thus, the efficacy of ASAQ is maintained and appears to be increased after long-term use in contrast to what is observed for other ACTs used in Africa." | 1.56 | Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar. ( Abbas, FB; Ali, AS; Ali, AW; Barnes, R; Björkman, A; Frumento, P; Mårtensson, A; Morris, U; Msellem, M; Soe, A, 2020) |
| " The secondary criteria were the clearing time of fever, parasites, and gametocytes and then the occurrence of adverse events." | 1.56 | [Safety and Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine in Niger]. ( Adehossi, E; Boureima, S; Hadiza, J; Hamidou, HH; Harouna, HK; Ibrahima, I; Laminou, IM; Mahamadou, A; Maman, D; Tidjani, IA; Yacouba, I, 2020) |
| "0%) patients experienced at least one drug-related adverse event (AE)." | 1.51 | Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo. ( Fungula, B; Inocencio da Luz, R; Kalabuanga, M; Lula Ntamba, Y; Lutumba, P; Muhindo Mavoko, H; Ntamabyaliro Nsengi, PM; Tona Lutete, G; Van Geertruyden, JP, 2019) |
| "There was no evidence of proarrhythmia with any treatment during the study although dihydroartemisinin-piperaquine, artesunate-amodiaquine and artemether-lumefantrine significantly prolonged QTc." | 1.51 | Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. ( Beavogui, AH; Borghini-Fuhrer, I; Djimdé, AA; Duparc, S; Felices, M; Funck-Brentano, C; Khan, Y; Ouedraogo, JB; Ouologuem, N; Sagara, I; Sirima, SB; Soulama, I; Voiriot, P, 2019) |
| " Suboptimal dosing in children may lead to treatment failure and increased resistance." | 1.48 | Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. ( Allen, EN; Barnes, KI; Bell, DJ; de Kock, M; Denti, P; Djimde, AA; Tarning, J; Tekete, MM; Ward, SA; Workman, L, 2018) |
| " Adverse events (AEs) were documented at the home visit or during any unexpected visit to the Health Centre or to the hospital and coded and adjudicated by a local pharmacovigilance committee." | 1.46 | Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire. ( Aba, YT; Assi, SB; Bissagnéné, E; Duparc, S; Lameyre, V; Nguessan, AF; San, KM; Tanoh, MA; Tchiekoi, NB; Yavo, JC, 2017) |
| " Without new drugs to replace artemisinins, it is essential to define dosing strategies that maximize therapeutic efficacy, limit the spread of resistance, and preserve the clinical value of ACTs." | 1.42 | Maximizing antimalarial efficacy and the importance of dosing strategies. ( Beeson, JG; Boeuf, P; Fowkes, FJ, 2015) |
| "Artemisinin resistance, a long parasite clearance half-life in response to artemisinin, has been described in patients with Plasmodium falciparum malaria in southeast Asia." | 1.39 | Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. ( Anderson, JM; Chiang, S; Diakite, M; Diakite, SA; Doumbia, S; Doumbouya, M; Fairhurst, RM; Fay, MP; Keita, AS; Konate, DS; Long, CA; Lopera-Mesa, TM; Ndiaye, D; Sa, JM; Stepniewska, K; Traore, K; Zeituni, AE, 2013) |
| " Secondary outcomes included fever/parasite clearance, change in hemoglobin levels, and frequency of adverse events." | 1.38 | Compliance, safety, and effectiveness of fixed-dose artesunate-amodiaquine for presumptive treatment of non-severe malaria in the context of home management of malaria in Madagascar. ( Jahevitra, M; Malvy, D; Ménard, D; Millet, P; Raherinjafy, R; Rakotomanga, Jde D; Rapelanoro, R; Ratsimbasoa, A; Ravony, H; Vonimpaisomihanta, JA, 2012) |
| "Recrudescence was detected by a thick blood smear and confirmed by polymerase chain reaction." | 1.35 | Some features of primary and recrudescent amodiaquine-resistant Plasmodium falciparum infections in Nigerian children. ( Balogun, ST; Gbotosho, GO; Happi, CT; Sowunmi, A, 2008) |
| " Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included in the pharmacokinetic analysis (n = 86)." | 1.34 | Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. ( Ali, AS; Ashton, M; Bhattarai, A; Björkman, A; Hietala, SF; Hombhanje, FW; Kaneko, A; Msellem, M; Röshammar, D; Strömberg, J, 2007) |
| "9%) withdrew because of drug-related adverse events; seven had gastrointestinal complaints of whom two were hospitalized for vomiting." | 1.34 | Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal. ( Agnamey, P; Brasseur, P; Gaye, O; Olliaro, PL; Taylor, WR; Vaillant, M, 2007) |
| "Falciparum Malaria is hyperendemic in southern Nigeria and chloroquine resistance is an increasing problem." | 1.33 | Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine. ( Göbels, K; Graupner, J; Grobusch, MP; Häussinger, D; Lund, A; Richter, J, 2005) |
| "Amodiaquine use has increased in the region." | 1.33 | Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. ( Alifrangis, M; Bygbjerg, IC; Dalgaard, MB; Enevold, A; Jensen, AT; Khalil, IF; Lemnge, MM; Lusingu, JP; Rønn, AM; Staalsoe, T; Theander, TG; Vestergaard, LS; Warhurst, DC, 2006) |
| " falciparum malaria infections were treated with the standard dosage of AQ and followed-up for 28 days." | 1.33 | Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. ( Bolaji, OM; Folarin, OA; Gbotosho, GO; Happi, CT; Kyle, DE; Milhous, W; Oduola, AM; Sowunmi, A; Wirth, DF, 2006) |
| "Amodiaquine was effective at all study sites (proportion of failures, 7." | 1.33 | Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. ( Abodo, RT; Basco, LK; Ndounga, M; Ngane, VF; Same-Ekobo, A; Soula, G; Youmba, JC, 2006) |
| "To test a novel methodology to define age-based dosing regimens for the treatment of malaria with a new, user-friendly, blister-packaged fixed-dose combination of artesunate and amodiaquine." | 1.33 | Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. ( Brasseur, P; Olliaro, PL; Taylor, W; ter Kuile, FO; Terlouw, DJ; White, NJ, 2006) |
| "Vomiting was more frequent in the artesunate + amodiaquine on D1 and D2." | 1.32 | [Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi]. ( Barihuta, T; Barutwanayo, M; Bosman, A; Ciza, A; Delacollette, C; Kamana, J; Karenzo, J; Mizero, L; Moyou-Somo, R; Nahimana, A; Ndaruhutse, J; Ndayiragije, A; Niyungeko, D; Niyungeko, E; Nyarushatsi, JP; Ringwald, P, 2004) |
| "Amodiaquine was 3." | 1.31 | In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar. ( Ariey, F; Duchemin, JB; Harisoa, JL; Mauclere, P; Pietra, V; Rabarijaona, LP; Raharimalala, LA; Rakotomanana, F; Ranaivo, L; Randrianarivelojosia, M; Robert, V, 2002) |
| "Amodiaquine has several advantages over sulfadoxine-pyrimethamine combination and may be considered to be an effective drug in an endemic zone with a moderate level of chloroquine resistance." | 1.31 | Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Came ( Basco, LK; Keundjian, A; Ringwald, P; Same Ekobo, A, 2000) |
| "Amodiaquine was shown to be more effective than chloroquine in clinical response and ridding patients of parasites: adequate clinical response was significantly higher with amodiaquine than chloroquine [100% (27/27) versus 45% (9/20), p < 0." | 1.31 | [Evaluation of efficacy and tolerance of amodiaquine versus chloroquine in the treatment of uncomplicated malaria outbreak in children of Gabon]. ( Bouyou Akotet, M; Guiyedi, V; Koko, J; Kombila, M; Mabika Manfoumbi, M; Matsiégui, PB; Traoré, B, 2001) |
| "Pyronaridine was less potent against chloroquine-resistant isolates than chloroquine-susceptible isolates but more potent than chloroquine against chloroquine-resistant parasites." | 1.30 | In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. ( Doury, JC; Kombila, M; Lebeau, C; Mabika Mamfoumbi, M; Mourou Mbina, JR; Owono Medang, M; Parzy, D; Pradines, B, 1999) |
| "Chloroquine resistance was present in 58." | 1.29 | In vitro responses of P. falciparum parasites to chloroquine, amodiaquine and quinine in two ecological zones in Ghana. ( Afari, EA; Akanmori, BD; Nakano, T; Ofori-Adjei, D, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.44) | 18.7374 |
| 1990's | 42 (9.17) | 18.2507 |
| 2000's | 204 (44.54) | 29.6817 |
| 2010's | 156 (34.06) | 24.3611 |
| 2020's | 54 (11.79) | 2.80 |
| Authors | Studies |
|---|---|
| Ongarora, DS | 1 |
| Strydom, N | 1 |
| Wicht, K | 1 |
| Njoroge, M | 1 |
| Wiesner, L | 2 |
| Egan, TJ | 1 |
| Wittlin, S | 1 |
| Jurva, U | 1 |
| Masimirembwa, CM | 1 |
| Chibale, K | 1 |
| Moriarty, LF | 4 |
| Nkoli, PM | 1 |
| Likwela, JL | 2 |
| Mulopo, PM | 1 |
| Sompwe, EM | 2 |
| Rika, JM | 1 |
| Mavoko, HM | 3 |
| Svigel, SS | 3 |
| Jones, S | 1 |
| Ntamabyaliro, NY | 1 |
| Kaputu, AK | 1 |
| Lucchi, N | 2 |
| Subramaniam, G | 1 |
| Niang, M | 1 |
| Sadou, A | 1 |
| Ngoyi, DM | 1 |
| Muyembe Tamfum, JJ | 1 |
| Schmedes, SE | 1 |
| Plucinski, MM | 4 |
| Chowell-Puente, G | 1 |
| Halsey, ES | 6 |
| Kahunu, GM | 1 |
| Cairns, M | 3 |
| Ceesay, SJ | 1 |
| Sagara, I | 13 |
| Zongo, I | 12 |
| Kessely, H | 2 |
| Gamougam, K | 2 |
| Diallo, A | 3 |
| Ogboi, JS | 1 |
| Moroso, D | 2 |
| Van Hulle, S | 1 |
| Eloike, T | 2 |
| Snell, P | 2 |
| Scott, S | 2 |
| Merle, C | 1 |
| Bojang, K | 2 |
| Ouedraogo, JB | 19 |
| Dicko, A | 10 |
| Ndiaye, JL | 15 |
| Milligan, P | 3 |
| Beavogui, AH | 6 |
| Diawara, EY | 1 |
| Cherif, MS | 1 |
| Delamou, A | 2 |
| Diallo, N | 2 |
| Traore, A | 6 |
| Millimouno, P | 1 |
| Camara, D | 1 |
| Sylla, MM | 1 |
| Toure, AA | 1 |
| Diallo, MS | 2 |
| Toure, S | 2 |
| Togo, A | 1 |
| Camara, G | 1 |
| Kourouma, K | 2 |
| Djimde, A | 9 |
| Nhama, A | 2 |
| Nhamússua, L | 1 |
| Macete, E | 2 |
| Bassat, Q | 4 |
| Salvador, C | 1 |
| Enosse, S | 3 |
| Candrinho, B | 1 |
| Carvalho, E | 2 |
| Nhacolo, A | 2 |
| Chidimatembue, A | 1 |
| Saifodine, A | 1 |
| Zulliger, R | 1 |
| Mayor, A | 1 |
| Aide, P | 1 |
| Richardson, S | 1 |
| Moukenet, A | 1 |
| Diar, MSI | 1 |
| de Cola, MA | 1 |
| Rassi, C | 1 |
| Counihan, H | 1 |
| Roca-Feltrer, A | 1 |
| Dentinger, CM | 1 |
| Rakotomanga, TA | 3 |
| Rakotondrandriana, A | 1 |
| Rakotoarisoa, A | 1 |
| Rason, MA | 2 |
| Steinhardt, LC | 1 |
| Kapesa, L | 1 |
| Razafindrakoto, J | 1 |
| Lucchi, NW | 3 |
| Udhayakumar, V | 5 |
| Ratsimbasoa, CA | 1 |
| Abuaku, B | 5 |
| Duah-Quashie, NO | 2 |
| Quashie, N | 3 |
| Gyasi, A | 2 |
| Afriyie, PO | 1 |
| Owusu-Antwi, F | 2 |
| Ghansah, A | 2 |
| Malm, KL | 1 |
| Bart-Plange, C | 1 |
| Koram, KA | 4 |
| Yaro, JB | 2 |
| Tiono, AB | 5 |
| Ouedraogo, A | 4 |
| Lambert, B | 1 |
| Ouedraogo, ZA | 1 |
| Diarra, A | 4 |
| Lankouande, M | 1 |
| Soulama, I | 5 |
| Sanou, A | 1 |
| Worrall, E | 1 |
| Agboraw, E | 1 |
| Sagnon, N | 1 |
| Ranson, H | 1 |
| Churcher, TS | 1 |
| Lindsay, SW | 1 |
| Wilson, AL | 1 |
| Mahamar, A | 3 |
| Sumner, KM | 1 |
| Levitt, B | 1 |
| Freedman, B | 2 |
| Barry, A | 4 |
| Issiaka, D | 3 |
| Dembele, AB | 1 |
| Kanoute, MB | 2 |
| Attaher, O | 2 |
| Diarra, BN | 1 |
| Duffy, PE | 3 |
| Fried, M | 3 |
| Taylor, SM | 3 |
| Niba, PTN | 1 |
| Nji, AM | 3 |
| Ali, IM | 3 |
| Akam, LF | 1 |
| Dongmo, CH | 1 |
| Chedjou, JPK | 1 |
| Fomboh, CT | 1 |
| Nana, WD | 1 |
| Oben, OLA | 1 |
| Selly-Ngaloumo, AA | 1 |
| Moyeh, MN | 2 |
| Ngu, JA | 1 |
| Ludovic, AJ | 1 |
| Aboh, PM | 1 |
| Ambani, MCE | 1 |
| Omgba, PAM | 1 |
| Kotcholi, GB | 1 |
| Adzemye, LM | 1 |
| Nna, DRA | 1 |
| Douanla, A | 1 |
| Ango, Z | 1 |
| Ewane, MS | 1 |
| Ticha, JT | 1 |
| Tatah, FM | 1 |
| Dinza, G | 1 |
| Ndikum, VN | 3 |
| Fosah, DA | 1 |
| Bigoga, JD | 1 |
| Alifrangis, M | 10 |
| Mbacham, WF | 4 |
| Marwa, K | 1 |
| Kapesa, A | 1 |
| Baraka, V | 4 |
| Konje, E | 1 |
| Kidenya, B | 1 |
| Mukonzo, J | 2 |
| Kamugisha, E | 3 |
| Swedberg, G | 3 |
| Peto, TJ | 2 |
| Tripura, R | 2 |
| Callery, JJ | 2 |
| Lek, D | 2 |
| Nghia, HDT | 1 |
| Nguon, C | 1 |
| Thuong, NTH | 1 |
| van der Pluijm, RW | 2 |
| Dung, NTP | 1 |
| Sokha, M | 1 |
| Van Luong, V | 1 |
| Long, LT | 1 |
| Sovann, Y | 2 |
| Duanguppama, J | 1 |
| Waithira, N | 2 |
| Hoglund, RM | 2 |
| Chotsiri, P | 1 |
| Chau, NH | 2 |
| Ruecker, A | 1 |
| Amaratunga, C | 2 |
| Dhorda, M | 5 |
| Miotto, O | 2 |
| Maude, RJ | 2 |
| Rekol, H | 1 |
| Chotivanich, K | 2 |
| Tarning, J | 6 |
| von Seidlein, L | 2 |
| Imwong, M | 2 |
| Mukaka, M | 2 |
| Day, NPJ | 2 |
| Hien, TT | 3 |
| White, NJ | 10 |
| Dondorp, AM | 5 |
| Koko, VS | 1 |
| Warsame, M | 7 |
| Vonhm, B | 1 |
| Jeuronlon, MK | 1 |
| Menard, D | 10 |
| Ma, L | 2 |
| Taweh, F | 1 |
| Tehmeh, L | 1 |
| Nyansaiye, P | 1 |
| Pratt, OJ | 1 |
| Parwon, S | 1 |
| Kamara, P | 1 |
| Asinya, M | 1 |
| Kollie, A | 1 |
| Ringwald, P | 18 |
| Hien, D | 2 |
| Kaboré, JMT | 2 |
| Siribié, M | 2 |
| Barry, N | 2 |
| Baguiya, A | 2 |
| Tchouatieu, AM | 2 |
| Sirima, SB | 12 |
| Ravaoarisoa, É | 1 |
| Andrianaranjaka, VHI | 2 |
| Ramanantsahala, AD | 1 |
| Ralinoro, F | 2 |
| Rakotosaona, R | 1 |
| Randrianarivo, RH | 1 |
| Rakoto, DAD | 1 |
| Jeannoda, V | 1 |
| Ratsimbasoa, A | 6 |
| Maiga, H | 5 |
| Opondo, C | 1 |
| Chico, RM | 1 |
| Cohee, LM | 2 |
| Traore, OB | 2 |
| Tekete, M | 4 |
| Dara, A | 2 |
| Traore, ZI | 2 |
| Diarra, M | 1 |
| Coumare, S | 1 |
| Kodio, A | 1 |
| Bamadio, A | 1 |
| Sidibe, B | 2 |
| Doumbo, OK | 9 |
| Djimde, AA | 10 |
| Korwa, S | 1 |
| Wu, A | 1 |
| Green, CL | 1 |
| Clapp, S | 1 |
| Kirui, JK | 1 |
| O'Meara, WP | 1 |
| Njuguna, FM | 1 |
| Doumbia, S | 3 |
| Sogoba, N | 1 |
| Diakite, M | 4 |
| Toure, M | 1 |
| Keita, M | 1 |
| Konaté, D | 1 |
| Diawara, SI | 1 |
| Sanogo, D | 1 |
| Kane, F | 1 |
| Diakite, SAS | 2 |
| Traore, K | 3 |
| Thiam, SM | 1 |
| Traoré, SF | 2 |
| Cisse, I | 1 |
| Mihigo, J | 2 |
| Coulibaly, MB | 1 |
| Dabitao, D | 2 |
| Barry, AE | 1 |
| Müller, GC | 1 |
| Beier, JC | 1 |
| Shaffer, JG | 1 |
| Zoleko-Manego, R | 1 |
| Okwu, DG | 1 |
| Handrich, C | 1 |
| Dimessa-Mbadinga, LB | 1 |
| Akinosho, MA | 1 |
| Ndzebe-Ndoumba, WF | 1 |
| Davi, SD | 1 |
| Stelzl, D | 1 |
| Veletzky, L | 1 |
| Kreidenweiss, A | 2 |
| Nordmann, T | 1 |
| Adegnika, AA | 2 |
| Lell, B | 8 |
| Kremsner, PG | 10 |
| Ramharter, M | 2 |
| Mombo-Ngoma, G | 4 |
| Beshir, KB | 1 |
| Muwanguzi, J | 1 |
| Nader, J | 1 |
| Mansukhani, R | 1 |
| Ceesay, S | 3 |
| Bazie, T | 2 |
| Kolie, F | 1 |
| Lamine, MM | 2 |
| Merle, CS | 1 |
| Razafindralambo, L | 1 |
| Doumagoum, D | 1 |
| Loua, K | 1 |
| Laminou, IM | 4 |
| Ogboi, SJ | 1 |
| Sutherland, CJ | 4 |
| Rakotoarisoa, MA | 1 |
| Fenomanana, J | 1 |
| Dodoson, BT | 1 |
| Olukosi, AY | 1 |
| Musa, AZ | 1 |
| Ogbulafor, N | 1 |
| Aina, O | 2 |
| Mokuolu, O | 5 |
| Oguche, S | 9 |
| Wammanda, R | 5 |
| Okafor, H | 2 |
| Ekama, SO | 1 |
| David, AN | 1 |
| Happi, CT | 23 |
| Ozor, L | 1 |
| Babatunde, S | 1 |
| Ijezie, SN | 1 |
| Uhomoibhi, PE | 1 |
| Awolola, ST | 1 |
| Mohammed, AB | 1 |
| Salako, BL | 1 |
| Arzika, II | 1 |
| Lobo, NF | 1 |
| Tidjani, IA | 2 |
| Sandrine, H | 1 |
| Sarrasin-Hubert, V | 1 |
| Mahamadou, A | 2 |
| Adehossi, E | 2 |
| Sarr, D | 1 |
| Mahmud, O | 1 |
| Maman Laminou, I | 1 |
| Makenga, G | 1 |
| Francis, F | 3 |
| Nakato, S | 1 |
| Gesase, S | 2 |
| Mtove, G | 1 |
| Madebe, R | 1 |
| Kyaruzi, E | 1 |
| Minja, DTR | 1 |
| Lusingu, JPA | 1 |
| Geertruyden, JV | 1 |
| Issa, MS | 1 |
| Mahamat, MHT | 1 |
| Saleh, IDM | 1 |
| Boulotigam, K | 1 |
| Djimrassengar, H | 1 |
| Issa, AH | 1 |
| Abdelkader, O | 1 |
| Hassoumi, M | 1 |
| Djimadoum, M | 1 |
| Doderer-Lang, C | 2 |
| Ndihiokubwayo, JB | 1 |
| Rasmussen, C | 1 |
| Irinantenaina, J | 1 |
| Carn, G | 5 |
| Randriamiarinjatovo, DNAL | 1 |
| Harimanana, AN | 1 |
| Razanatsiorimalala, S | 1 |
| Ralemary, N | 1 |
| Randriarison, M | 1 |
| Razafinjato, C | 1 |
| Hotahiene, R | 1 |
| Randrianarivelojosia, M | 6 |
| Mihreteab, S | 1 |
| Platon, L | 1 |
| Berhane, A | 1 |
| Stokes, BH | 1 |
| Campagne, P | 1 |
| Criscuolo, A | 1 |
| Petiot, N | 1 |
| Legrand, E | 1 |
| Ward, KE | 1 |
| Zehaie Kassahun, A | 1 |
| Fidock, DA | 3 |
| Djimde, M | 2 |
| Kayentao, K | 2 |
| Tshiongo, JK | 1 |
| Fofana, B | 5 |
| Arama, C | 1 |
| Mens, PF | 3 |
| Schallig, HD | 1 |
| Ndong Ngomo, JM | 2 |
| Ondzagha Megnie, GJ | 1 |
| Moutombi Ditombi, B | 1 |
| Koumba Lengongo, JV | 1 |
| M'Bondoukwé, NP | 1 |
| Offouga, CL | 1 |
| Mawili-Mboumba, DP | 4 |
| Lekana-Douki, JB | 1 |
| Fandeur, T | 3 |
| Bouyou-Akotet, MK | 2 |
| Akano, K | 10 |
| Fatunmbi, B | 10 |
| Ntadom, G | 11 |
| Ayede, AI | 9 |
| Aderoyeje, T | 8 |
| Bakre, A | 1 |
| Alebiosu, OT | 2 |
| Akpoborie, O | 2 |
| Okafor, C | 2 |
| Gbotosho, GO | 26 |
| Folarin, OA | 13 |
| Ebenebe, JC | 3 |
| Ambe, J | 4 |
| Jiya, N | 4 |
| Finomo, F | 4 |
| Emechebe, G | 4 |
| Agomo, C | 7 |
| Happi, C | 4 |
| Sowunmi, A | 42 |
| Lula Ntamba, Y | 1 |
| Muhindo Mavoko, H | 3 |
| Kalabuanga, M | 2 |
| Fungula, B | 2 |
| Ntamabyaliro Nsengi, PM | 1 |
| Tona Lutete, G | 1 |
| Inocencio da Luz, R | 2 |
| Van Geertruyden, JP | 6 |
| Lutumba, P | 5 |
| Zaidi, I | 1 |
| Kwan, JL | 1 |
| Samassekou, MB | 1 |
| Cisse, KB | 1 |
| Coulibaly, B | 8 |
| Keita, S | 2 |
| Sissoko, S | 1 |
| Traore, T | 1 |
| Diarra, K | 2 |
| Diarra, BS | 1 |
| Dembele, A | 1 |
| André, G | 1 |
| Stéphane, J | 1 |
| Yves, H | 1 |
| Xavier, A | 1 |
| Jordi, L | 1 |
| Eric, C | 1 |
| Jean, G | 1 |
| Mendes Jorge, M | 1 |
| Ouermi, L | 1 |
| Meissner, P | 5 |
| Compaoré, G | 1 |
| Nebie, E | 2 |
| Krisam, J | 1 |
| Klose, C | 4 |
| Kieser, M | 2 |
| Jahn, A | 1 |
| Lu, G | 1 |
| D Alessandro, U | 1 |
| Sié, A | 7 |
| Mockenhaupt, FP | 10 |
| Müller, O | 10 |
| Adegbite, BR | 1 |
| Edoa, JR | 1 |
| Honkpehedji, YJ | 1 |
| Zinsou, FJ | 1 |
| Dejon-Agobe, JC | 1 |
| Mbong-Ngwese, M | 1 |
| Lotola-Mougueni, F | 1 |
| Koehne, E | 1 |
| Lalremruata, A | 1 |
| Nguyen, TT | 1 |
| Kun, J | 1 |
| Agnandji, ST | 1 |
| Safiou, AR | 1 |
| Obone Atome, FA | 1 |
| Velavan, TP | 2 |
| Mordmüller, B | 1 |
| Lingani, M | 1 |
| Bonkian, LN | 1 |
| Yerbanga, I | 1 |
| Kazienga, A | 4 |
| Valéa, I | 8 |
| Sorgho, H | 4 |
| Schallig, HDFH | 1 |
| Ravinetto, R | 2 |
| d'Alessandro, U | 23 |
| Tinto, H | 14 |
| Bretscher, MT | 1 |
| Dahal, P | 4 |
| Griffin, J | 1 |
| Stepniewska, K | 6 |
| Baudin, E | 4 |
| Dorsey, G | 23 |
| Espié, E | 3 |
| González, R | 2 |
| Juma, E | 6 |
| Karema, C | 11 |
| Lasry, E | 1 |
| Lima, N | 1 |
| Menéndez, C | 3 |
| Moreira, C | 2 |
| Nikiema, F | 3 |
| Staedke, SG | 9 |
| Yeka, A | 7 |
| Ghani, AC | 2 |
| Guerin, PJ | 11 |
| Okell, LC | 1 |
| Pyae Phyo, A | 1 |
| Ul Islam, A | 1 |
| Anvikar, AR | 4 |
| Satpathi, P | 1 |
| Satpathi, S | 1 |
| Behera, PK | 1 |
| Tripura, A | 1 |
| Baidya, S | 1 |
| Onyamboko, M | 1 |
| Suon, S | 1 |
| Sreng, S | 1 |
| Mao, S | 1 |
| Oun, S | 1 |
| Yen, S | 1 |
| Chutasmit, K | 1 |
| Saelow, C | 1 |
| Runcharern, R | 1 |
| Kaewmok, W | 1 |
| Hoa, NT | 1 |
| Thanh, NV | 1 |
| Hanboonkunupakarn, B | 1 |
| Mohanty, AK | 1 |
| Heaton, J | 1 |
| Thant, M | 1 |
| Gantait, K | 1 |
| Ghosh, T | 1 |
| Amato, R | 1 |
| Pearson, RD | 1 |
| Jacob, CG | 1 |
| Gonçalves, S | 1 |
| Woodrow, CJ | 2 |
| Grobusch, MP | 5 |
| van Vugt, M | 2 |
| Fairhurst, RM | 3 |
| Cheah, PY | 2 |
| Winterberg, M | 1 |
| Thuy-Nhien, NT | 1 |
| Kwiatkowski, DP | 1 |
| Jittamala, P | 1 |
| Lin, K | 1 |
| Hlaing, TM | 1 |
| Huy, R | 1 |
| Fanello, C | 1 |
| Ashley, E | 2 |
| Mayxay, M | 1 |
| Newton, PN | 1 |
| Valecha, N | 4 |
| Smithuis, F | 2 |
| Pukrittayakamee, S | 2 |
| Faiz, A | 1 |
| Yobi, DM | 1 |
| Kayiba, NK | 1 |
| Mvumbi, DM | 1 |
| Boreux, R | 1 |
| Kabututu, PZ | 1 |
| Situakibanza, HNT | 1 |
| De Mol, P | 1 |
| Okitolonda, EW | 1 |
| Speybroeck, N | 1 |
| Mvumbi, GL | 1 |
| Hayette, MP | 1 |
| Mairet-Khedim, M | 2 |
| Leang, R | 2 |
| Marmai, C | 1 |
| Khim, N | 1 |
| Kim, S | 1 |
| Ke, S | 2 |
| Kauy, C | 1 |
| Kloeung, N | 1 |
| Eam, R | 1 |
| Chy, S | 1 |
| Izac, B | 1 |
| Mey Bouth, D | 1 |
| Dorina Bustos, M | 1 |
| Ariey, F | 4 |
| Witkowski, B | 2 |
| Diallo, MA | 1 |
| Yade, MS | 1 |
| Ndiaye, YD | 1 |
| Diallo, I | 1 |
| Diongue, K | 1 |
| Sy, SA | 1 |
| Sy, M | 1 |
| Seck, MC | 1 |
| Ndiaye, M | 4 |
| Dieye, B | 1 |
| Gomis, JF | 2 |
| Sow, D | 5 |
| Dème, AB | 1 |
| Badiane, AS | 1 |
| Ndiaye, D | 6 |
| Saito, M | 1 |
| Mansoor, R | 1 |
| Kennon, K | 1 |
| Ashley, EA | 6 |
| Chandramohan, D | 9 |
| Genton, B | 7 |
| Gilder, ME | 1 |
| Kalilani-Phiri, L | 2 |
| Kuepfer, I | 1 |
| Laufer, MK | 1 |
| Lwin, KM | 1 |
| Meshnick, SR | 3 |
| Mosha, D | 1 |
| Mwapasa, V | 2 |
| Mwebaza, N | 1 |
| Nambozi, M | 3 |
| Ndiaye, JA | 1 |
| Nosten, F | 4 |
| Nyunt, M | 1 |
| Ogutu, B | 5 |
| Parikh, S | 3 |
| Paw, MK | 1 |
| Phyo, AP | 1 |
| Pimanpanarak, M | 1 |
| Piola, P | 5 |
| Rijken, MJ | 1 |
| Sriprawat, K | 2 |
| Tagbor, HK | 2 |
| Wiladphaingern, J | 1 |
| McGready, R | 1 |
| Bah, S | 1 |
| Konaté, DS | 2 |
| Sanogo, I | 1 |
| Sangaré, M | 1 |
| Dama, S | 5 |
| Keita, B | 1 |
| Doumbouya, M | 2 |
| Guindo, MA | 1 |
| Camara, A | 1 |
| Doumbouya, A | 1 |
| Bouedouno, P | 1 |
| Guilavogui, T | 1 |
| Dos Santos Souza, S | 2 |
| Kelley, J | 1 |
| Talundzic, E | 4 |
| Fofana, A | 1 |
| Somé, FA | 2 |
| Ehrlich, HY | 1 |
| Goodwin, J | 1 |
| Lehane, A | 1 |
| Neya, C | 1 |
| Zachari, K | 1 |
| Wade, M | 1 |
| Ouattara, JM | 1 |
| Foy, BD | 1 |
| Dabiré, RK | 1 |
| Msellem, M | 3 |
| Morris, U | 3 |
| Soe, A | 1 |
| Abbas, FB | 1 |
| Ali, AW | 1 |
| Barnes, R | 1 |
| Frumento, P | 1 |
| Ali, AS | 5 |
| Mårtensson, A | 10 |
| Björkman, A | 12 |
| Gendrot, M | 2 |
| Duflot, I | 1 |
| Boxberger, M | 1 |
| Delandre, O | 1 |
| Jardot, P | 1 |
| Le Bideau, M | 1 |
| Andreani, J | 1 |
| Fonta, I | 1 |
| Mosnier, J | 2 |
| Rolland, C | 1 |
| Hutter, S | 1 |
| La Scola, B | 1 |
| Pradines, B | 8 |
| Ibrahima, I | 1 |
| Maman, D | 1 |
| Boureima, S | 1 |
| Harouna, HK | 1 |
| Hamidou, HH | 1 |
| Yacouba, I | 1 |
| Hadiza, J | 1 |
| Myers-Hansen, JL | 1 |
| Oyebola, MK | 1 |
| Mensah, BA | 1 |
| Ahorlu, C | 1 |
| Wilson, MD | 1 |
| Awandare, G | 1 |
| Ngwa, AA | 1 |
| Mahaman Moustapha, L | 1 |
| Adamou, R | 1 |
| Ibrahim, ML | 1 |
| Abdoulaye Louis Padounou, M | 1 |
| Courtin, D | 1 |
| Testa, J | 1 |
| Ndiaye, JLA | 1 |
| Blanshard, A | 1 |
| Hine, P | 2 |
| Kawuma, AN | 1 |
| Walimbwa, SI | 1 |
| Pillai, GC | 1 |
| Khoo, S | 1 |
| Lamorde, M | 1 |
| Wasmann, RE | 1 |
| Denti, P | 2 |
| Pernaute-Lau, L | 1 |
| Gil, JP | 9 |
| Nombré, Y | 1 |
| Kiba Koumaré, A | 1 |
| Héma, A | 1 |
| Dianda, F | 1 |
| Savadogo, Y | 1 |
| Kouanda, S | 1 |
| Toure, OA | 2 |
| Assi, SB | 4 |
| Kiki-Barro, PMC | 1 |
| Yavo, W | 5 |
| Abba, T | 1 |
| Tiacoh, LN | 1 |
| Konate, AA | 1 |
| Angora, EK | 1 |
| Bedia, VA | 1 |
| Menan, H | 2 |
| Daho, AK | 1 |
| Emmanuel, B | 1 |
| Diarra, Y | 1 |
| Koné, O | 1 |
| Sangaré, L | 1 |
| Doumbia, L | 1 |
| Haidara, DBB | 1 |
| Diallo, M | 2 |
| Maiga, A | 1 |
| Sango, HA | 1 |
| Sidibé, H | 1 |
| Nace, D | 1 |
| Ljolje, D | 1 |
| Eckert, E | 1 |
| Woodfill, CJ | 1 |
| Lim, P | 2 |
| Krogstad, DJ | 1 |
| Koita, OA | 1 |
| Nardella, F | 1 |
| Roesch, C | 1 |
| Maher, SP | 1 |
| Leroy, D | 1 |
| Yaméogo, KB | 1 |
| Yerbanga, RS | 1 |
| Ouattara, SB | 1 |
| Yao, FA | 1 |
| Lefèvre, T | 1 |
| Compaoré, YD | 1 |
| Greenwood, B | 9 |
| Belem, AMG | 1 |
| Cohuet, A | 1 |
| Chalon, S | 1 |
| Chughlay, MF | 1 |
| Abla, N | 1 |
| Marie Tchouatieu, A | 1 |
| Haouala, A | 1 |
| Hutter, B | 1 |
| Lorch, U | 1 |
| Macintyre, F | 1 |
| Ayede, A | 1 |
| Watila, I | 4 |
| Meremikwu, M | 6 |
| Ogala, W | 4 |
| Agomo, P | 4 |
| Adowoye, E | 1 |
| Gbotosho, G | 1 |
| Folarin, O | 3 |
| Clark, RL | 1 |
| Supan, C | 1 |
| Kombila, M | 7 |
| Ospina Salazar, CL | 1 |
| Held, J | 1 |
| Cantalloube, C | 1 |
| Djeriou, E | 1 |
| Waitumbi, J | 1 |
| Otsula, N | 1 |
| Apollo, D | 1 |
| Polhemus, ME | 1 |
| Walsh, DS | 2 |
| Rasmussen, SA | 1 |
| Ceja, FG | 1 |
| Conrad, MD | 2 |
| Tumwebaze, PK | 1 |
| Byaruhanga, O | 1 |
| Katairo, T | 1 |
| Nsobya, SL | 7 |
| Rosenthal, PJ | 22 |
| Cooper, RA | 1 |
| Amambua-Ngwa, A | 2 |
| Okebe, J | 1 |
| Mbye, H | 1 |
| El-Fatouri, F | 1 |
| Joof, F | 1 |
| Nyang, H | 1 |
| Janha, R | 1 |
| Affara, M | 1 |
| Ahmad, A | 1 |
| Kolly, O | 1 |
| Nwakanma, D | 1 |
| Mohammed, AO | 1 |
| Tewolde, S | 1 |
| Estifanos, D | 1 |
| Tekeste, Y | 1 |
| Osman, MH | 1 |
| Wewe, OA | 2 |
| Ebenebe, J | 1 |
| Ezeigwe, N | 1 |
| Adewoye, EO | 10 |
| Oyibo, WA | 1 |
| Useh, F | 3 |
| Grandesso, F | 4 |
| Guindo, O | 1 |
| Woi Messe, L | 1 |
| Makarimi, R | 2 |
| Rigal, J | 2 |
| de Smet, M | 1 |
| Ouwe Missi Oukem-Boyer, O | 1 |
| Etard, JF | 2 |
| Nabasumba, C | 4 |
| Roh, ME | 1 |
| Diawara, H | 1 |
| Soumare, HM | 1 |
| Lanke, K | 1 |
| Bradley, J | 1 |
| Sanogo, K | 1 |
| Kone, DT | 1 |
| McCulloch, C | 1 |
| Stone, WJR | 1 |
| Hwang, J | 2 |
| Brown, JM | 1 |
| Srinivasan, V | 1 |
| Drakeley, C | 5 |
| Gosling, R | 1 |
| Chen, I | 1 |
| Bousema, T | 4 |
| de Kock, M | 1 |
| Workman, L | 1 |
| Allen, EN | 1 |
| Tekete, MM | 1 |
| Bell, DJ | 1 |
| Ward, SA | 1 |
| Barnes, KI | 2 |
| Grais, RF | 1 |
| Woi-Messe, L | 1 |
| Bouriema, SH | 1 |
| Langendorf, C | 1 |
| Sibley, CH | 5 |
| Davlantes, E | 1 |
| Dimbu, PR | 2 |
| Ferreira, CM | 2 |
| Florinda Joao, M | 1 |
| Pode, D | 1 |
| Félix, J | 1 |
| Sanhangala, E | 1 |
| Andrade, BN | 1 |
| Owens, C | 1 |
| Mbounga, E | 2 |
| Martins, JF | 1 |
| Fortes, F | 4 |
| Quang, NN | 1 |
| Chavchich, M | 2 |
| Anh, CX | 1 |
| Birrell, GW | 1 |
| van Breda, K | 1 |
| Travers, T | 1 |
| Rowcliffe, K | 1 |
| Edstein, MD | 3 |
| Oyibo, W | 2 |
| Abdulkadir, M | 1 |
| Ezeigwe, NM | 2 |
| Raobela, O | 1 |
| Andriantsoanirina, V | 1 |
| Rajaonera, DG | 1 |
| Rabearimanana, S | 1 |
| Mbanzulu, KM | 1 |
| Zanga, JK | 1 |
| Mukendi, JPK | 1 |
| Mbaya Ntita, F | 1 |
| Matangila, JR | 1 |
| Muhindo, HM | 1 |
| Mpoyi Wa Mpoyi, S | 1 |
| Aloni, MN | 1 |
| Wumba, R | 1 |
| Kakolwa, MA | 1 |
| Mahende, MK | 1 |
| Ishengoma, DS | 2 |
| Mandara, CI | 2 |
| Ngasala, B | 3 |
| Kataraihya, JB | 1 |
| Mandike, R | 4 |
| Mkude, S | 2 |
| Chacky, F | 2 |
| Njau, R | 2 |
| Premji, Z | 1 |
| Lemnge, MM | 6 |
| Kabanywanyi, AM | 2 |
| Pryce, J | 1 |
| Whegang Youdom, S | 2 |
| Chiabi, A | 1 |
| Basco, LK | 17 |
| Munyangi, J | 1 |
| Cornet-Vernet, L | 1 |
| Idumbo, M | 1 |
| Lu, C | 1 |
| Lutgen, P | 1 |
| Perronne, C | 1 |
| Ngombe, N | 1 |
| Bianga, J | 1 |
| Mupenda, B | 1 |
| Lalukala, P | 1 |
| Mergeai, G | 1 |
| Mumba, D | 1 |
| Towler, M | 1 |
| Weathers, P | 1 |
| Funck-Brentano, C | 1 |
| Ouologuem, N | 1 |
| Duparc, S | 2 |
| Felices, M | 1 |
| Borghini-Fuhrer, I | 1 |
| Khan, Y | 1 |
| Voiriot, P | 1 |
| Samouda, H | 1 |
| Jacobs, J | 1 |
| Niangaly, H | 2 |
| Sombie, SB | 1 |
| Mgina, EJ | 1 |
| Vaillant, M | 4 |
| Chiduo, MG | 1 |
| Molteni, F | 1 |
| Mohamed, A | 1 |
| Peko, SM | 1 |
| Ntoumi, F | 7 |
| Vouvoungui, C | 1 |
| Nderu, D | 1 |
| Kobawila, SC | 1 |
| Koukouikila-Koussounda, F | 2 |
| Quaye, L | 1 |
| Matrevi, SA | 1 |
| Malm, K | 1 |
| Koram, K | 3 |
| Bakhiet, AMA | 1 |
| Abdelraheem, MH | 1 |
| Kheir, A | 1 |
| Omer, S | 1 |
| Gismelseed, L | 1 |
| Abdel-Muhsin, AA | 1 |
| Naiem, A | 1 |
| Al Hosni, A | 1 |
| Al Dhuhli, A | 1 |
| Al Rubkhi, M | 1 |
| Al-Hamidhi, S | 1 |
| Gadalla, A | 1 |
| Mukhtar, M | 1 |
| Sultan, AA | 1 |
| Babiker, HA | 1 |
| Ibironke, FO | 2 |
| Okafor, HU | 4 |
| Dokunmu, TM | 1 |
| Amoo, S | 1 |
| Basorun, OK | 1 |
| Oduola, A | 1 |
| Senn, N | 1 |
| Rarau, P | 1 |
| Manong, D | 1 |
| Salib, M | 1 |
| Siba, P | 1 |
| Reeder, JC | 5 |
| Rogerson, SJ | 1 |
| Mueller, I | 3 |
| Lopera-Mesa, TM | 1 |
| Chiang, S | 1 |
| Zeituni, AE | 1 |
| Keita, AS | 1 |
| Diakite, SA | 1 |
| Sa, JM | 3 |
| Anderson, JM | 1 |
| Fay, MP | 1 |
| Long, CA | 1 |
| Charle, P | 1 |
| Berzosa, P | 2 |
| de Lucio, A | 1 |
| Raso, J | 1 |
| Nseng Nchama, G | 1 |
| Benito, A | 3 |
| Issaka, M | 1 |
| Salissou, A | 1 |
| Arzika, I | 1 |
| Guillebaud, J | 1 |
| Maazou, A | 1 |
| Specht, S | 1 |
| Zamanka, H | 1 |
| Dahlström, S | 1 |
| Cooksey, R | 1 |
| Flegg, JA | 2 |
| Le Nagard, H | 1 |
| Mentré, F | 1 |
| Murillo, C | 1 |
| Musset, L | 1 |
| Quashie, NB | 2 |
| Sinou, V | 2 |
| Noedl, H | 1 |
| Johnson, JD | 2 |
| Le Bras, J | 6 |
| Lo, AC | 2 |
| Faye, B | 10 |
| Ba, el-H | 1 |
| Cisse, B | 2 |
| Tine, R | 2 |
| Abiola, A | 2 |
| Sokhna, C | 2 |
| Dieng, Y | 2 |
| Faye, O | 3 |
| Ndir, O | 2 |
| Hallett, R | 2 |
| Sutherland, C | 2 |
| Gaye, O | 13 |
| Dworkin, J | 1 |
| Janvier, M | 1 |
| Treaba, D | 1 |
| Gardner, A | 1 |
| Eyase, FL | 1 |
| Akala, HM | 1 |
| Ingasia, L | 1 |
| Cheruiyot, A | 1 |
| Omondi, A | 1 |
| Okudo, C | 1 |
| Juma, D | 1 |
| Yeda, R | 1 |
| Andagalu, B | 1 |
| Wanja, E | 1 |
| Kamau, E | 1 |
| Schnabel, D | 1 |
| Bulimo, W | 1 |
| Waters, NC | 1 |
| Falade, CO | 5 |
| Adesina-Adewole, B | 1 |
| Dada-Adegbola, HO | 1 |
| Ajayi, IO | 1 |
| Akinyemi, JO | 1 |
| Ademowo, OG | 3 |
| Adewole, IF | 1 |
| Kanki, P | 1 |
| Schramm, B | 5 |
| Valeh, P | 2 |
| Mazinda, CS | 2 |
| Smith, R | 2 |
| Pinoges, L | 6 |
| Sundaygar, T | 2 |
| Zolia, YM | 3 |
| Jones, JJ | 3 |
| Comte, E | 2 |
| Bruneel, A | 1 |
| Branger, M | 1 |
| Jullien, V | 6 |
| Kiechel, JR | 10 |
| Boum, Y | 1 |
| Houzé, P | 3 |
| Faiz, MA | 2 |
| Mokuolu, OA | 1 |
| Henrich, PP | 1 |
| O'Brien, C | 1 |
| Sáenz, FE | 1 |
| Cremers, S | 1 |
| Kyle, DE | 3 |
| Abolaji, AO | 1 |
| Osedeme, F | 1 |
| Olusemire, O | 1 |
| Ojurongbe, O | 2 |
| Lawal, OA | 1 |
| Abiodun, OO | 1 |
| Okeniyi, JA | 1 |
| Oyeniyi, AJ | 1 |
| Oyelami, OA | 1 |
| Sylla, K | 5 |
| Tine, RC | 5 |
| Folly, K | 1 |
| Ndiaye, LA | 1 |
| Djallé, D | 1 |
| Njuimo, SP | 1 |
| Manirakiza, A | 1 |
| Laganier, R | 1 |
| Le Faou, A | 1 |
| Rogier, C | 2 |
| Diallo, S | 2 |
| Guiraud, I | 1 |
| Kpoda, H | 1 |
| Guiguemdé, TR | 3 |
| Zwang, J | 3 |
| Brasseur, P | 14 |
| Olliaro, P | 15 |
| Antonia, AL | 1 |
| Janko, M | 1 |
| Emch, M | 1 |
| Tshefu, AK | 2 |
| Hetzel, MW | 1 |
| Page-Sharp, M | 1 |
| Bala, N | 1 |
| Pulford, J | 1 |
| Betuela, I | 1 |
| Davis, TM | 1 |
| Lavu, EK | 1 |
| Tahar, R | 3 |
| Almelli, T | 1 |
| Debue, C | 1 |
| Foumane Ngane, V | 1 |
| Djaman Allico, J | 1 |
| Onyamboko, MA | 1 |
| Fanello, CI | 5 |
| Wongsaen, K | 1 |
| Tshefu, KA | 1 |
| Day, NP | 1 |
| Venkatesan, M | 1 |
| Gadalla, NB | 2 |
| Nsanzabana, C | 3 |
| Moriera, C | 1 |
| Price, RN | 4 |
| Guérin, P | 1 |
| Davis, TME | 1 |
| Adam, I | 2 |
| Ademowo, G | 1 |
| Arze, C | 1 |
| Baliraine, FN | 2 |
| Berens-Riha, N | 2 |
| Borrmann, S | 7 |
| Checchi, F | 9 |
| Desai, M | 3 |
| El-Sayed, BB | 1 |
| Eshetu, T | 1 |
| Eyase, F | 1 |
| Falade, C | 1 |
| Faucher, JF | 6 |
| Fröberg, G | 3 |
| Grivoyannis, A | 1 |
| Hamour, S | 4 |
| Houzé, S | 3 |
| Johnson, J | 1 |
| Kariuki, S | 3 |
| Kironde, F | 3 |
| Kofoed, PE | 3 |
| LeBras, J | 2 |
| Malmberg, M | 1 |
| Mwai, L | 2 |
| Nzila, A | 3 |
| Oguike, M | 1 |
| Otienoburu, SD | 2 |
| Rombo, L | 3 |
| Somé, AF | 2 |
| Thwing, J | 1 |
| Ursing, J | 3 |
| Wong, RPM | 1 |
| Zeynudin, A | 1 |
| Plowe, CV | 1 |
| Mutemba, R | 1 |
| Naueia, E | 1 |
| Sevene, E | 1 |
| Guinovart, C | 1 |
| Sanz, S | 1 |
| Mussa, A | 1 |
| Matsinhe, G | 1 |
| Alonso, P | 1 |
| Tiago, A | 1 |
| Wurtz, N | 1 |
| Fall, B | 3 |
| Pascual, A | 1 |
| Fall, M | 3 |
| Baret, E | 1 |
| Camara, C | 2 |
| Nakoulima, A | 3 |
| Diatta, B | 3 |
| Fall, KB | 1 |
| Mbaye, PS | 1 |
| Diémé, Y | 3 |
| Bercion, R | 1 |
| Wade, B | 3 |
| Adjei, GO | 3 |
| Goka, BQ | 3 |
| Enweronu-Laryea, CC | 1 |
| Rodrigues, OP | 3 |
| Renner, L | 1 |
| Sulley, AM | 1 |
| Khalil, I | 1 |
| Kurtzhals, JA | 3 |
| Banjo, O | 1 |
| Okuboyejo, T | 3 |
| Ogunrinde, G | 1 |
| Odey, F | 1 |
| Sofola, T | 1 |
| Maboko, F | 1 |
| Guiyedi, V | 3 |
| Mourou Mbina, JR | 3 |
| Bouyou Akotet, MK | 1 |
| Pritsch, M | 1 |
| Bountogo, M | 1 |
| Meissner, PE | 2 |
| Wieser, A | 1 |
| Breitkreutz, J | 1 |
| Schirmer, RH | 4 |
| Evehe, MS | 3 |
| Netongo, PM | 2 |
| Atogho-Tiedeu, B | 1 |
| Akindeh-Nji, M | 1 |
| Ngora, H | 1 |
| Domkam, IK | 1 |
| Baldip, K | 1 |
| Ranford-Cartwright, L | 2 |
| Mimche, PN | 2 |
| Lamb, T | 1 |
| N'Guessan, TL | 1 |
| Adji, GE | 1 |
| Ako, AB | 1 |
| Brou, MJ | 1 |
| Ehouman, MF | 1 |
| Gnamien, LA | 1 |
| Coulibaly, MA | 1 |
| Beourou, S | 1 |
| Bassinka, I | 1 |
| Soumahoro, A | 1 |
| Kadjo, F | 1 |
| Tano, MA | 1 |
| Lameyre, V | 6 |
| Afizi, K | 1 |
| Fredrick, M | 1 |
| Lukwago, R | 1 |
| Kamya, MR | 11 |
| Talisuna, AO | 5 |
| Ouldabdallahi, M | 1 |
| Alew, I | 1 |
| Salem, MS | 1 |
| Dit Dialaw Ba, M | 1 |
| Boukhary, AO | 1 |
| Khairy, ML | 1 |
| Aziz, MB | 1 |
| Niang, SD | 1 |
| Lebatt, SM | 1 |
| Obonyo, C | 2 |
| Taylor, WR | 10 |
| Ngongang, EO | 1 |
| Ekollo, AM | 1 |
| Chedjou, JP | 1 |
| Froeschl, G | 1 |
| Heumann, C | 1 |
| Mansmann, U | 3 |
| Ogundahunsi, O | 1 |
| Adjuik, MA | 1 |
| Allan, R | 1 |
| Ba, MS | 1 |
| Barennes, H | 3 |
| Bompart, F | 1 |
| Bonnet, M | 4 |
| Bukirwa, H | 4 |
| Cot, M | 5 |
| Deloron, P | 8 |
| Diap, G | 2 |
| Gething, PW | 1 |
| Guthmann, JP | 13 |
| Hasugian, AR | 2 |
| Hay, SI | 1 |
| Humphreys, GS | 2 |
| Krishna, S | 3 |
| Ibrahim, LM | 1 |
| Lee, SJ | 2 |
| Massougbodji, A | 2 |
| Ogutu, BR | 2 |
| Osorio, L | 3 |
| Penali, LK | 2 |
| Pene, M | 1 |
| Roper, C | 5 |
| Rwagacondo, CE | 4 |
| Same-Ekobo, A | 7 |
| Seck, A | 1 |
| Sharma, B | 2 |
| Smith, JJ | 1 |
| Swarthout, TD | 2 |
| Temu, EA | 1 |
| Thwing, JI | 2 |
| Tjitra, E | 2 |
| Vaillant, MT | 2 |
| Van den Broek, I | 5 |
| Toure, O | 1 |
| Sangare, CP | 1 |
| N'Dong, C | 1 |
| Dembele, D | 3 |
| Tavera, G | 1 |
| Mu, J | 1 |
| Kabyemela, ER | 1 |
| Wellems, TE | 1 |
| Adedeji, ON | 1 |
| Bolaji, OO | 1 |
| Osonuga, OA | 1 |
| Beeson, JG | 1 |
| Boeuf, P | 1 |
| Fowkes, FJ | 1 |
| Wotodjo, AN | 1 |
| Richard, V | 1 |
| Boyer, S | 1 |
| Doucoure, S | 1 |
| Diagne, N | 1 |
| Touré-Baldé, A | 1 |
| Tall, A | 3 |
| Faye, N | 1 |
| Gaudart, J | 1 |
| Trape, JF | 3 |
| Samad, R | 1 |
| Rahman, MR | 1 |
| Yunus, EB | 1 |
| Hussain, MA | 1 |
| Arif, SM | 1 |
| Islam, MN | 1 |
| Hafiz, SA | 1 |
| Hossain, MM | 1 |
| Ukah, M | 1 |
| Badejoko, O | 1 |
| Ogunniyi, S | 1 |
| Loto, O | 1 |
| Aboderin, O | 1 |
| Fatusi, A | 1 |
| Sondo, P | 2 |
| Derra, K | 2 |
| Diallo-Nakanabo, S | 1 |
| Tarnagda, Z | 2 |
| Zampa, O | 2 |
| Owusu-Dabo, E | 2 |
| Komino, F | 1 |
| Okoth, SA | 1 |
| Goldman, I | 1 |
| Onyona, P | 1 |
| Wiegand, RE | 1 |
| Shi, YP | 1 |
| Barnwell, JW | 1 |
| Ndounga, M | 7 |
| Casimiro, PN | 3 |
| Bitemo, M | 1 |
| Diassivy Matondo, B | 1 |
| Ndounga Diakou, LA | 1 |
| Nguyen, TD | 1 |
| Baird, JK | 2 |
| Lam, HM | 1 |
| Farrar, J | 1 |
| Thwaites, GE | 1 |
| Boni, MF | 1 |
| Kigozi, R | 1 |
| Lugemwa, M | 1 |
| Okui, P | 1 |
| Katureebe, C | 1 |
| Belay, K | 1 |
| Kapella, BK | 1 |
| Chang, MA | 1 |
| Schwartz, E | 1 |
| Lachish, T | 1 |
| Pekyi, D | 1 |
| Ampromfi, AA | 1 |
| Traoré-Coulibaly, M | 1 |
| Tahita, MC | 1 |
| Kalanda, G | 1 |
| Madanitsa, M | 1 |
| Mutabingwa, T | 1 |
| Gbekor, P | 1 |
| Tagbor, H | 2 |
| Antwi, G | 1 |
| Menten, J | 1 |
| De Crop, M | 1 |
| Claeys, Y | 1 |
| Schurmans, C | 1 |
| Van Overmeir, C | 7 |
| Thriemer, K | 1 |
| Mulenga, M | 1 |
| Hachizovu, S | 1 |
| Kabuya, JB | 1 |
| Mulenga, J | 1 |
| Diallo Nakanabo, S | 1 |
| Madamet, M | 2 |
| Amalvict, R | 2 |
| Paczkowski, M | 1 |
| Mwandama, D | 1 |
| Marthey, D | 1 |
| Luka, M | 1 |
| Makuta, G | 1 |
| Sande, J | 1 |
| Ali, D | 1 |
| Troell, P | 1 |
| Mathanga, DP | 1 |
| Gutman, J | 1 |
| Delgado-Ratto, C | 1 |
| Maketa, V | 1 |
| Mukele, R | 1 |
| Rosanas-Urgell, A | 2 |
| Dorkenoo, AM | 1 |
| Yehadji, D | 1 |
| Agbo, YM | 2 |
| Layibo, Y | 1 |
| Agbeko, F | 1 |
| Adjeloh, P | 1 |
| Yakpa, K | 1 |
| Sossou, E | 1 |
| Awokou, F | 1 |
| Maïga-Ascofaré, O | 1 |
| de Wit, M | 1 |
| Funk, AL | 1 |
| Moussally, K | 1 |
| Nkuba, DA | 1 |
| Siddiqui, R | 1 |
| Bil, K | 1 |
| Piriou, E | 1 |
| Bart, A | 1 |
| Bahizi Bizoza, P | 1 |
| Kateera, F | 1 |
| Tukwasibwe, S | 1 |
| Hakizimana, E | 1 |
| Mutesa, L | 1 |
| Kumar, N | 1 |
| Guerra, M | 1 |
| Neres, R | 1 |
| Salgueiro, P | 1 |
| Mendes, C | 1 |
| Ndong-Mabale, N | 1 |
| de Sousa, B | 1 |
| Arez, AP | 1 |
| da Luz, RI | 1 |
| Kambugu, A | 1 |
| Zhou, LJ | 1 |
| Xia, J | 1 |
| Wei, HX | 1 |
| Liu, XJ | 1 |
| Peng, HJ | 1 |
| Aba, YT | 1 |
| Yavo, JC | 1 |
| Nguessan, AF | 1 |
| Tchiekoi, NB | 1 |
| San, KM | 1 |
| Bissagnéné, E | 1 |
| Tanoh, MA | 1 |
| Diawara, S | 1 |
| Kounta, MB | 1 |
| Briolant, S | 1 |
| Wade, KA | 1 |
| Benoit, N | 1 |
| Macaia, AP | 1 |
| Samutondo, C | 1 |
| Quivinja, J | 1 |
| Afonso, M | 1 |
| Kiniffo, R | 1 |
| Kelley, JS | 1 |
| Patel, DS | 1 |
| He, Y | 1 |
| Garrett, DO | 1 |
| Dippmann, AK | 1 |
| Bienzle, U | 4 |
| Harms, G | 1 |
| Sarr, O | 1 |
| Ahouidi, AD | 1 |
| Ly, O | 1 |
| Daily, JP | 1 |
| Mboup, S | 1 |
| Wirth, DF | 2 |
| Maiteki-Sebuguzi, C | 2 |
| Jagannathan, P | 1 |
| Yau, VM | 1 |
| Clark, TD | 2 |
| Njama-Meya, D | 2 |
| Nzarubara, B | 3 |
| Balogun, T | 3 |
| Adedeji, AA | 13 |
| Bolaji, OM | 3 |
| Fehintola, FA | 8 |
| Balogun, ST | 4 |
| Sijuade, AO | 2 |
| Souares, A | 2 |
| Lalou, R | 2 |
| Sene, I | 2 |
| Le Hesran, JY | 3 |
| Hoegberg, LC | 2 |
| Kitcher, ED | 1 |
| Badoe, EV | 1 |
| Lamptey, R | 1 |
| Clarke, SE | 1 |
| Jukes, MC | 1 |
| Njagi, JK | 1 |
| Khasakhala, L | 1 |
| Cundill, B | 1 |
| Otido, J | 1 |
| Crudder, C | 1 |
| Estambale, BB | 1 |
| Brooker, S | 1 |
| Turyakira, E | 1 |
| Urruta, PP | 1 |
| van Herp, M | 3 |
| Balkan, S | 6 |
| Carmona-Fonseca, J | 3 |
| Arango, E | 2 |
| Blair, S | 4 |
| Clerk, CA | 1 |
| Bruce, J | 2 |
| Affipunguh, PK | 1 |
| Mensah, N | 1 |
| Hodgson, A | 4 |
| Kristensen, K | 1 |
| Oduro, AR | 3 |
| Anyorigiya, T | 3 |
| Anto, F | 3 |
| Amenga-Etego, L | 1 |
| Ansah, NA | 2 |
| Atobrah, P | 2 |
| Ansah, P | 2 |
| Yang, H | 1 |
| Yang, Y | 1 |
| Yang, P | 1 |
| Li, X | 1 |
| Gao, B | 1 |
| Zhang, Z | 1 |
| Yang, Z | 1 |
| Cui, L | 1 |
| Agnamey, P | 5 |
| Cisse, M | 4 |
| Badiane, M | 1 |
| Massaga, JJ | 3 |
| Lusingu, JP | 2 |
| Makunde, R | 1 |
| Malebo, HM | 1 |
| Chile, MM | 1 |
| Akida, JA | 2 |
| Rønn, AM | 5 |
| Theander, TG | 4 |
| Bygbjerg, IC | 6 |
| Kitua, AY | 2 |
| Alker, AP | 1 |
| Kazadi, WM | 1 |
| Kutelemeni, AK | 1 |
| Bloland, PB | 2 |
| Prugger, C | 1 |
| Engl, M | 1 |
| Ogwang, M | 1 |
| Ploner, F | 1 |
| Ploner, M | 1 |
| Gluderer, D | 1 |
| Wernsdorfer, G | 2 |
| Wernsdorfer, WH | 3 |
| Kobbe, R | 2 |
| Klein, P | 1 |
| Adjei, S | 1 |
| Amemasor, S | 1 |
| Thompson, WN | 1 |
| Heidemann, H | 1 |
| Nielsen, MV | 1 |
| Vohwinkel, J | 1 |
| Hogan, B | 1 |
| Kreuels, B | 1 |
| Bührlen, M | 1 |
| Loag, W | 1 |
| Ansong, D | 1 |
| May, J | 2 |
| Avellino, P | 1 |
| Bancone, G | 1 |
| Uwimana, A | 1 |
| Modiano, D | 1 |
| Newman, RD | 2 |
| McMorrow, ML | 1 |
| Hoppe, A | 1 |
| Yattara, O | 1 |
| Traore, H | 1 |
| Kone, Y | 1 |
| Guirou, EA | 1 |
| Saye, R | 1 |
| Traore, B | 2 |
| Odero, CO | 1 |
| Odhiambo, FO | 1 |
| Otieno, KO | 1 |
| Ord, R | 1 |
| McMorrow, M | 1 |
| Vulule, J | 1 |
| Slutsker, L | 1 |
| Hamel, MJ | 1 |
| Ouologuem, D | 2 |
| Kone, A | 1 |
| Wele, M | 1 |
| Gansané, A | 3 |
| Konaté, AT | 2 |
| Morgan, CC | 1 |
| Olliaro, PL | 3 |
| Thanh, NX | 1 |
| Trung, TN | 1 |
| Phong, NC | 1 |
| Thien, NX | 1 |
| Dai, B | 1 |
| Shanks, GD | 1 |
| Ntale, M | 1 |
| Obua, C | 2 |
| Mahindi, M | 1 |
| Gustafsson, LL | 3 |
| Beck, O | 1 |
| Ogwal-Okeng, JW | 2 |
| Zoungrana, A | 2 |
| Aubouy, A | 4 |
| Adeothy, A | 1 |
| Cottrell, G | 1 |
| Doritchamou, J | 1 |
| Gourmel, B | 1 |
| Kossou, H | 1 |
| Amedome, H | 1 |
| Asih, PB | 1 |
| Dewi, RM | 1 |
| Tuti, S | 1 |
| Sadikin, M | 1 |
| Sumarto, W | 1 |
| Sinaga, B | 1 |
| van der Ven, AJ | 1 |
| Sauerwein, RW | 2 |
| Syafruddin, D | 1 |
| Ndiaye, I | 2 |
| Randrianasolo, L | 1 |
| Forlemu, D | 1 |
| Moor, VA | 1 |
| Dicko, Y | 2 |
| Dara, N | 2 |
| Obaldia, N | 1 |
| Kotecka, BM | 1 |
| Haynes, RK | 1 |
| Fugmann, B | 1 |
| Rieckmann, KH | 1 |
| Beer, N | 1 |
| Rotllant, G | 1 |
| Abass, AK | 1 |
| Omari, RS | 1 |
| Al-mafazy, AW | 1 |
| Källander, K | 1 |
| Broek, Iv | 1 |
| Urrutia, PP | 1 |
| Kyomuhendo, J | 2 |
| Ndosimao, CN | 1 |
| Cohuet, S | 2 |
| Rwagacondo, C | 2 |
| Boly, MD | 1 |
| Kweku, M | 2 |
| Webster, J | 1 |
| Adjuik, M | 2 |
| Abudey, S | 1 |
| Kouyaté, B | 2 |
| Nawaz, F | 1 |
| Kiggundu, M | 2 |
| Joloba, M | 2 |
| Marfurt, J | 3 |
| Smith, TA | 2 |
| Hastings, IM | 1 |
| Müller, I | 2 |
| Oa, O | 2 |
| Baisor, M | 1 |
| Beck, HP | 3 |
| Danquah, I | 1 |
| Petruschke, I | 1 |
| Ateh, IA | 1 |
| Ajua, A | 1 |
| Irenee, D | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Tawe, B | 1 |
| Targett, G | 1 |
| Shu, EN | 1 |
| Oguonu, T | 1 |
| Whegang, SY | 2 |
| Foumane, VN | 1 |
| Soula, G | 3 |
| Gwét, H | 2 |
| Thalabard, JC | 2 |
| Offianan, AT | 1 |
| Touré, W | 1 |
| Djoman, K | 1 |
| Ndiaye, PS | 1 |
| Penali, L | 1 |
| Séré, YY | 1 |
| Dokomajilar, C | 8 |
| Rouamba, N | 4 |
| Greenhouse, B | 1 |
| Okell, L | 1 |
| Shekalaghe, S | 1 |
| Griffin, JT | 1 |
| Omar, S | 1 |
| Sawa, P | 1 |
| Sauerwein, R | 1 |
| Beshir, K | 1 |
| Merinopoulos, I | 2 |
| Durrani, N | 2 |
| Leslie, T | 2 |
| Rowland, M | 2 |
| Hallett, RL | 2 |
| Kauss, T | 1 |
| Fawaz, F | 1 |
| Guyot, M | 1 |
| Lagueny, AM | 1 |
| Dos Santos, I | 1 |
| Bonini, F | 1 |
| Caminiti, A | 1 |
| Millet, P | 3 |
| Michael, O | 1 |
| Alumasa, JN | 1 |
| Gorka, AP | 1 |
| Casabianca, LB | 1 |
| Comstock, E | 1 |
| de Dios, AC | 1 |
| Roepe, PD | 1 |
| Liljander, A | 1 |
| Olsson, D | 1 |
| Montgomery, SM | 2 |
| Färnert, A | 1 |
| Michael, OS | 3 |
| Oduola, AM | 7 |
| Twu, O | 1 |
| Okuboyejo, TM | 6 |
| Ayede, IA | 1 |
| Falade, AG | 2 |
| Jansen, FH | 1 |
| Amuasi, JH | 1 |
| Blay-Nguah, S | 1 |
| Boakye, I | 1 |
| Karikari, PE | 1 |
| Dismas, B | 1 |
| Karenzo, J | 2 |
| Nsabiyumva, L | 1 |
| Louie, KS | 1 |
| Bla, KB | 1 |
| Djaman, AJ | 1 |
| Mazabraud, A | 1 |
| Koné, M | 5 |
| Folarin, OO | 1 |
| Gueye, A | 1 |
| Tchania, C | 1 |
| Ouédraogo, AZ | 1 |
| Kangoyé, DT | 1 |
| Kaboré, Y | 1 |
| Ouédraogo, E | 1 |
| Ouédraogo, IN | 1 |
| Cousens, S | 2 |
| Milligan, PJ | 2 |
| Greenwood, BM | 3 |
| Diallo, DA | 2 |
| Dicko, M | 1 |
| Diallo, AI | 1 |
| Tembine, I | 1 |
| Sidibe, Y | 1 |
| Santara, G | 1 |
| Conaré, T | 1 |
| Akinrinola, IA | 1 |
| Ndour, CT | 1 |
| Bassene, C | 1 |
| Magnussen, P | 2 |
| Ndour, JD | 1 |
| Arango, EM | 1 |
| Upegui, YA | 1 |
| Ravony, H | 1 |
| Vonimpaisomihanta, JA | 1 |
| Raherinjafy, R | 1 |
| Jahevitra, M | 2 |
| Rapelanoro, R | 1 |
| Rakotomanga, Jde D | 1 |
| Malvy, D | 1 |
| Bustamante, C | 1 |
| da Silva, LH | 1 |
| Mesquita, E | 1 |
| Zalis, MG | 1 |
| Shahi, BH | 1 |
| Tyagi, PK | 1 |
| Bose, TK | 1 |
| Sharma, SK | 1 |
| Srivastava, P | 1 |
| Srivastava, B | 1 |
| Dash, AP | 1 |
| Mesia, K | 1 |
| Tona, L | 1 |
| Mampunza, MM | 1 |
| Ntamabyaliro, N | 1 |
| Muanda, T | 1 |
| Muyembe, T | 1 |
| Musuamba, T | 1 |
| Mets, T | 1 |
| Cimanga, K | 1 |
| Totté, J | 1 |
| Pieters, L | 1 |
| Vlietinck, AJ | 1 |
| Lima, A | 1 |
| Atua, B | 1 |
| Flévaud, L | 1 |
| Palma Urrutia, PP | 1 |
| Jörnhagen, L | 1 |
| Shakely, D | 1 |
| Msellem, MI | 3 |
| Sutanto, I | 1 |
| Suprianto, S | 1 |
| Widiaty, A | 1 |
| Ruckert, P | 1 |
| von Bethmann, A | 1 |
| de Monbrison, F | 1 |
| Picot, S | 1 |
| Laihad, F | 2 |
| Dorkenoo, MA | 1 |
| Barrette, A | 1 |
| Bogreau, H | 1 |
| Kutoati, S | 1 |
| Sodahlon, YK | 1 |
| Morgah, K | 1 |
| Okombo, J | 1 |
| Kiara, SM | 1 |
| Abdirahman, A | 1 |
| Ohuma, E | 1 |
| Ward, S | 1 |
| Ferreira, PE | 1 |
| Ali, A | 1 |
| Kuété, T | 2 |
| Kiki-Barro, CP | 1 |
| Nkoa, T | 1 |
| Kakpo, CA | 1 |
| El Menan, H | 1 |
| Moussa, K | 1 |
| De la Hoz Restrepo, F | 1 |
| Porras Ramírez, A | 1 |
| Rico Mendoza, A | 1 |
| Córdoba, F | 1 |
| Rojas, DP | 1 |
| Mayengue, PI | 2 |
| Loumouamou, D | 1 |
| Keundjian, A | 5 |
| Ngane, VF | 2 |
| Metoh, T | 1 |
| Moyou, SR | 1 |
| Galega, PF | 1 |
| Schellenberg, D | 1 |
| Kahigwa, E | 1 |
| Malende, A | 1 |
| Wigayi, J | 1 |
| Msokame, C | 1 |
| Aponte, JJ | 2 |
| Tanner, M | 1 |
| Mshinda, H | 1 |
| Alonso, PL | 2 |
| Rieckmann, K | 1 |
| Cheng, Q | 1 |
| Bakary, M | 2 |
| Mbomat, B | 1 |
| Makita, JR | 1 |
| Migot-Nabias, F | 3 |
| Gasasira, AF | 1 |
| Nassali, A | 1 |
| Cattamanchi, A | 1 |
| Kyabayinze, D | 1 |
| Hubbard, A | 1 |
| Cavanagh, DR | 1 |
| McBride, JS | 1 |
| Matsiegui, PB | 5 |
| Missinou, MA | 4 |
| Harisoa, JL | 1 |
| Rabarijaona, LP | 2 |
| Raharimalala, LA | 1 |
| Ranaivo, L | 1 |
| Pietra, V | 2 |
| Duchemin, JB | 1 |
| Rakotomanana, F | 1 |
| Robert, V | 4 |
| Mauclere, P | 1 |
| Malle, LN | 2 |
| Mussano, P | 2 |
| Niyitegeka, F | 1 |
| Sarushi, J | 1 |
| Mugisha, V | 2 |
| Dujardin, JC | 3 |
| van den Ende, J | 1 |
| Fateye, BA | 8 |
| Ochong, EO | 1 |
| van den Broek, IV | 2 |
| Keus, K | 2 |
| POWELL, RD | 2 |
| BREWER, GJ | 2 |
| ALVING, AS | 2 |
| MILLAR, JW | 1 |
| DEGOWIN, RL | 1 |
| Vlahos, J | 1 |
| Molta, NB | 1 |
| Pam, SD | 1 |
| Omalu, IC | 1 |
| Afolabi, BM | 1 |
| Odujoko, JB | 1 |
| Amajoh, CN | 1 |
| Adeniji, B | 1 |
| Wuyep, VP | 1 |
| Ekanem, OJ | 1 |
| Bagaphou, T | 1 |
| Binder, RK | 1 |
| Pabisch, S | 1 |
| Rezbach, P | 2 |
| Miller, G | 1 |
| Adonis-Koffy, L | 1 |
| Daubrey, T | 1 |
| Kouadio, A | 1 |
| Timité-Konan, AM | 1 |
| Kabran, J | 1 |
| Casey, GJ | 1 |
| Ginny, M | 1 |
| Uranoli, M | 1 |
| Cowman, AF | 2 |
| Abacassamo, F | 1 |
| Gómez-Olivé, FX | 1 |
| Quintó, L | 1 |
| Mabunda, S | 1 |
| Barreto, A | 1 |
| Thompson, R | 1 |
| Nalunkuma-Kazibwe, A | 1 |
| Bakyaita, N | 3 |
| Langi, P | 1 |
| Mutabingwa, TK | 3 |
| Watkins, WW | 1 |
| Van Marck, E | 2 |
| Egwang, TG | 1 |
| Nagot, N | 1 |
| Koussoubé-Balima, T | 1 |
| Sanou, T | 1 |
| Yé, S | 1 |
| Kosack, C | 1 |
| Ardizzoni, E | 1 |
| Klarkowski, D | 1 |
| Kwezi, E | 1 |
| Priotto, G | 1 |
| Brockman, A | 1 |
| Ndayiragije, A | 1 |
| Niyungeko, D | 1 |
| Niyungeko, E | 1 |
| Barutwanayo, M | 1 |
| Ciza, A | 1 |
| Bosman, A | 1 |
| Moyou-Somo, R | 1 |
| Nahimana, A | 1 |
| Nyarushatsi, JP | 1 |
| Barihuta, T | 1 |
| Mizero, L | 1 |
| Ndaruhutse, J | 1 |
| Delacollette, C | 1 |
| Kamana, J | 1 |
| Stivanello, E | 1 |
| Cavailler, P | 1 |
| Cassano, F | 1 |
| Omar, SA | 1 |
| Kariuki, D | 3 |
| Mwangi, J | 1 |
| Mayombo, J | 2 |
| Happi, TC | 4 |
| Erhart, A | 2 |
| Babalola, CP | 1 |
| Gerstner, U | 1 |
| Prajakwong, S | 1 |
| Wiedermann, G | 1 |
| Sirichaisinthop, J | 1 |
| Vreugdenhil, CJ | 1 |
| Scheper, FY | 1 |
| Hoogstraatte, SR | 1 |
| Smolders, M | 1 |
| Gikunda, S | 3 |
| Cobelens, FG | 1 |
| Kager, PA | 2 |
| Roddy, P | 1 |
| Kamara, S | 2 |
| Williams, A | 1 |
| Morineau, G | 1 |
| Wurie, AR | 1 |
| Hora, B | 1 |
| Lamotte, Nd | 1 |
| Baerwaldt, T | 1 |
| Heinzelmann, A | 1 |
| Danks, A | 1 |
| Oloo, A | 1 |
| Durand, R | 3 |
| Smet, M | 1 |
| Atuguba, F | 1 |
| Mumuni, G | 1 |
| Amankwa, J | 1 |
| Amsalu, R | 1 |
| Balasegaram, M | 2 |
| Hepple, P | 1 |
| Alemu, E | 1 |
| Hussein, el B | 1 |
| Al-Faith, M | 1 |
| Montgomery, J | 3 |
| Hombhanje, FW | 2 |
| Hwaihwanje, I | 1 |
| Tsukahara, T | 1 |
| Saruwatari, J | 1 |
| Nakagawa, M | 1 |
| Osawa, H | 1 |
| Paniu, MM | 1 |
| Takahashi, N | 1 |
| Lum, JK | 1 |
| Aumora, B | 1 |
| Masta, A | 1 |
| Sapuri, M | 1 |
| Kobayakawa, T | 1 |
| Kaneko, A | 3 |
| Ishizaki, T | 1 |
| Cavaco, I | 1 |
| Strömberg-Nörklit, J | 1 |
| Dahoma, M | 1 |
| Ribeiro, VL | 1 |
| Graupner, J | 1 |
| Göbels, K | 1 |
| Lund, A | 1 |
| Richter, J | 1 |
| Häussinger, D | 1 |
| Melaku, Y | 1 |
| Wambugu, J | 1 |
| Atkin, S | 1 |
| Ford, N | 1 |
| Hook, C | 1 |
| Ampuero, J | 1 |
| Gaboulaud, V | 1 |
| Tobback, S | 1 |
| Dunand, J | 1 |
| Saraiva, N | 2 |
| Gillet, P | 1 |
| Franco, J | 1 |
| Denoncin, A | 1 |
| Legros, D | 1 |
| Das, P | 1 |
| Banek, K | 1 |
| Talisuna, A | 2 |
| Nsobya, S | 1 |
| Kilian, A | 1 |
| Reingold, A | 2 |
| Wabwire-Mangen, F | 1 |
| Ehrhardt, S | 2 |
| Dzisi, SY | 1 |
| Teun Bousema, J | 1 |
| Wassilew, N | 1 |
| Schreiber, J | 1 |
| Anemana, SD | 2 |
| Cramer, JP | 1 |
| Otchwemah, RN | 2 |
| Eggelte, TA | 2 |
| Rahim, S | 1 |
| Graham, K | 1 |
| Ahmad, F | 1 |
| Sendagire, H | 1 |
| Kaddumukasa, M | 1 |
| Ndagire, D | 1 |
| Aguttu, C | 2 |
| Nassejje, M | 1 |
| Pettersson, M | 1 |
| Duah, N | 1 |
| Dumoulin, J | 1 |
| Taylor-Robinson, D | 1 |
| Jones, K | 1 |
| Garner, P | 4 |
| Strömberg, J | 2 |
| Sisowath, C | 1 |
| Malecela, EK | 1 |
| Sambu, E | 1 |
| Abdulla, R | 1 |
| Juma, MS | 1 |
| Fakih, K | 1 |
| Abdulla, KH | 1 |
| Njau, RJ | 1 |
| McIntosh, HM | 4 |
| Jones, KL | 1 |
| Tambo, E | 3 |
| Adjetey, TA | 2 |
| Affoumou, GB | 1 |
| Loukou, DD | 1 |
| Nebavi, NG | 2 |
| Barro-Kiki, P | 1 |
| Menan, EI | 3 |
| Holmgren, G | 2 |
| Ferreira, PM | 1 |
| Veiga, MI | 2 |
| Obonyo, CO | 2 |
| Lankoande, M | 1 |
| Bachy, C | 1 |
| Donam, I | 1 |
| Ntambi, J | 1 |
| Habimana, J | 1 |
| Maikere, J | 1 |
| Vanlerberghe, V | 1 |
| Kerah, CH | 1 |
| Mupfasoni, D | 1 |
| Vandoren, W | 1 |
| Rusanganwa, E | 1 |
| Röwer, S | 1 |
| Weise, A | 1 |
| Lambertz, U | 1 |
| Forst, T | 1 |
| Pfützner, A | 1 |
| Critchley, J | 1 |
| Francis, D | 1 |
| Machekano, R | 1 |
| Guzmán, V | 1 |
| Rolland, E | 1 |
| Patrick Kachur, S | 1 |
| Schulden, J | 1 |
| Goodman, CA | 1 |
| Kassala, H | 1 |
| Elling, BF | 1 |
| Khatib, RA | 1 |
| Causer, LM | 1 |
| Mkikima, S | 1 |
| Abdulla, S | 3 |
| Mulligan, JA | 1 |
| Palmer, N | 1 |
| Williams, H | 1 |
| Bloland, P | 1 |
| Mills, A | 1 |
| Zurovac, D | 1 |
| Midia, B | 1 |
| Ochola, SA | 1 |
| English, M | 1 |
| Snow, RW | 1 |
| van Doren, W | 2 |
| Dalgaard, MB | 1 |
| Vestergaard, LS | 2 |
| Staalsoe, T | 2 |
| Jensen, AT | 2 |
| Enevold, A | 2 |
| Khalil, IF | 2 |
| Warhurst, DC | 2 |
| Alaribe, A | 1 |
| Ejemot, R | 1 |
| Oyo-Ita, A | 1 |
| Ekenjoku, J | 1 |
| Nwachukwu, C | 1 |
| Ordu, D | 1 |
| Ezedinachi, E | 1 |
| Bitarakwate, E | 1 |
| Pai, M | 1 |
| Hagerman, A | 1 |
| Lam, E | 1 |
| Scollo, G | 1 |
| Rigutto, C | 1 |
| Kiguli, J | 1 |
| Francis, M | 1 |
| Noël, F | 1 |
| Mulemba, M | 1 |
| Milhous, W | 1 |
| Lemnge, M | 2 |
| Kafuye, MY | 1 |
| Segeja, MD | 1 |
| Minja, D | 1 |
| Poulsen, A | 1 |
| Rodrigues, A | 2 |
| Bergquist, Y | 1 |
| Aaby, P | 1 |
| Youmba, JC | 1 |
| Abodo, RT | 1 |
| Juma, EA | 1 |
| Vulule, JM | 1 |
| Lau, J | 1 |
| Kayembe, G | 1 |
| Pota, H | 1 |
| Ngamije, D | 1 |
| Amoo, AO | 1 |
| Browne, E | 1 |
| Randal, A | 1 |
| Sidhu, AB | 1 |
| Sun, Q | 1 |
| Nkrumah, LJ | 1 |
| Dunne, MW | 1 |
| Sacchettini, JC | 1 |
| Anokbonggo, WW | 1 |
| Chiria, J | 1 |
| Hellgren, U | 1 |
| Kitz, C | 1 |
| Al Attas, S | 1 |
| Libama, F | 1 |
| Ahmed, J | 1 |
| Whitty, CJ | 1 |
| Taylor, W | 1 |
| Terlouw, DJ | 1 |
| ter Kuile, FO | 1 |
| Ibrahium, AM | 1 |
| Kheir, MM | 1 |
| Osman, ME | 1 |
| Elmardi, KA | 1 |
| Malik, EM | 1 |
| Morrow, RH | 1 |
| Guiguemde, RT | 2 |
| Ferreira, ID | 1 |
| Lopes, D | 1 |
| Martinelli, A | 1 |
| Ferreira, C | 1 |
| do Rosário, VE | 2 |
| Cravo, P | 2 |
| Meyer, CG | 1 |
| Kimbi, HK | 1 |
| Nkuo-Akenji, TK | 1 |
| Patchong, AF | 1 |
| Ndamukong, KN | 1 |
| Nkwescheu, A | 1 |
| Gonzalez, I | 1 |
| Oyakhirome, S | 1 |
| Pötschke, M | 1 |
| Schwarz, NG | 1 |
| Dörnemann, J | 1 |
| Laengin, M | 1 |
| Salazar, CO | 1 |
| Kun, JF | 1 |
| Goldstein, JA | 1 |
| Kroetz, DL | 1 |
| Purba, HL | 1 |
| Kenangalem, E | 1 |
| Wuwung, RM | 1 |
| Ebsworth, EP | 1 |
| Maristela, R | 1 |
| Penttinen, PM | 1 |
| Anstey, NM | 1 |
| Zuluaga, L | 1 |
| Pabón, A | 1 |
| López, C | 1 |
| Ochoa, A | 1 |
| Félix, M | 1 |
| Coulibaly, L | 1 |
| Kankolongo, GM | 1 |
| Andrianina, NN | 1 |
| Ramiandrasoa, Z | 1 |
| Randriamanantena, A | 1 |
| Rasoarilalao, N | 1 |
| Tuseo, L | 1 |
| Raveloson, A | 2 |
| Staedke, S | 1 |
| Pérez, Ldel P | 1 |
| González, IJ | 1 |
| Duah, NO | 1 |
| Andrianantenaina, HB | 1 |
| Domarle, O | 2 |
| Kaiser, S | 1 |
| Adjei, L | 1 |
| Burchard, GD | 1 |
| Bedja, SA | 1 |
| Hietala, SF | 1 |
| Bhattarai, A | 1 |
| Röshammar, D | 1 |
| Ashton, M | 1 |
| Matondo Maya, DW | 1 |
| Miakassissa-Mpassi, V | 1 |
| Malonga, DA | 1 |
| Nsonde-Ntandou, F | 1 |
| Mallanda, G | 1 |
| Montoya, P | 1 |
| Tobón, A | 2 |
| Carmona, J | 1 |
| Maestre, A | 2 |
| Oga, SS | 1 |
| Evi, JB | 1 |
| Kiki-Barro, PC | 1 |
| Kassi, RR | 1 |
| Atissou, JF | 1 |
| Maku, P | 1 |
| Goroti, M | 1 |
| Séré, Y | 1 |
| Mwita, A | 1 |
| Sumari, D | 1 |
| Mugittu, K | 1 |
| Nkya, WM | 1 |
| Theisen, M | 1 |
| Eriksen, J | 1 |
| Mwankusye, S | 1 |
| Mduma, S | 1 |
| Kitua, A | 1 |
| Tomson, G | 1 |
| Petzold, MG | 1 |
| Diouf, AM | 1 |
| Seck, PA | 1 |
| Olasupo, NO | 1 |
| Nsimba, B | 1 |
| Mabika-Mamfoumbi, M | 1 |
| Mourou-Mbina, JR | 1 |
| Ngoungou, E | 1 |
| Bouyou-Akotet, M | 1 |
| Loembet, R | 1 |
| Walter-Sack, I | 1 |
| Guekoun, L | 1 |
| Ogundele, AO | 1 |
| Yusuf, BO | 1 |
| Ladipo, SM | 1 |
| Ogungbamigbe, TO | 1 |
| Ogunro, PS | 1 |
| Okanlawon, BM | 1 |
| Kolawole, SO | 1 |
| Michael, SO | 1 |
| Mandi, G | 1 |
| Restrepo-Pineda, E | 1 |
| Roche, J | 2 |
| Molina, R | 2 |
| Amela, C | 2 |
| Alvar, J | 2 |
| Nevill, CG | 2 |
| Ochen, K | 1 |
| Munafu, CG | 2 |
| Bekobita, D | 1 |
| Sezi, CL | 1 |
| Del Nero, L | 1 |
| Lamizana, L | 1 |
| Nebié, I | 1 |
| Assi-Coulibaly, L | 1 |
| Kaptué, B | 1 |
| Konan, D | 1 |
| Ehouman, A | 1 |
| Kamugisha, J | 1 |
| Kipp, W | 1 |
| Burnham, G | 1 |
| Verhoeff, FH | 1 |
| ten Hove, WR | 1 |
| van der Kaay, HJ | 1 |
| Were, JB | 2 |
| Pandya, AP | 1 |
| Barkakaty, BN | 1 |
| Narasimham, MV | 1 |
| Nicolas, P | 1 |
| Hovette, P | 1 |
| Merouze, F | 1 |
| Touze, JE | 1 |
| Martet, G | 1 |
| Tchuinkam, T | 1 |
| Mulder, B | 1 |
| Dechering, K | 1 |
| Stoffels, H | 1 |
| Verhave, JP | 2 |
| Carnevale, P | 1 |
| Meuwissen, JH | 1 |
| Hagos, B | 1 |
| Khan, B | 1 |
| Ofulla, AV | 1 |
| Martin, SK | 1 |
| Afari, EA | 1 |
| Akanmori, BD | 1 |
| Nakano, T | 1 |
| Ofori-Adjei, D | 1 |
| Fowler, VG | 1 |
| Irare, SG | 2 |
| Malecela, E | 1 |
| Mhina, J | 1 |
| Mtui, S | 1 |
| Mashaka, M | 1 |
| Mtoi, R | 1 |
| Ayecaba, S | 1 |
| Edrissian, GH | 1 |
| Afshar, A | 1 |
| Sayedzadeh, A | 1 |
| Mohsseni, G | 1 |
| Satvat, MT | 1 |
| Misra, SP | 1 |
| Nandi, J | 1 |
| Lal, S | 1 |
| Agnamey, PP | 1 |
| Leroy, G | 1 |
| Kouamouo, J | 1 |
| van Hensbroek, MB | 1 |
| Jaffar, S | 1 |
| Okorie, C | 1 |
| Joof, D | 1 |
| Pinder, M | 1 |
| Radloff, PD | 1 |
| Philipps, J | 1 |
| Nkeyi, M | 1 |
| Hutchinson, D | 1 |
| Anabwani, GM | 1 |
| Esamai, FO | 1 |
| Menya, DA | 1 |
| Nevill, C | 1 |
| Duraisingh, MT | 1 |
| Drakeley, CJ | 1 |
| Bailey, R | 1 |
| Snounou, G | 1 |
| Targett, GA | 1 |
| Boudin, C | 2 |
| Personne, P | 1 |
| Chambon, R | 2 |
| Foumane, V | 1 |
| de Vries, C | 1 |
| al-Yaman, F | 1 |
| Mokela, D | 1 |
| Narara, A | 2 |
| Raiko, A | 1 |
| Alpers, MP | 1 |
| Lemardeley, P | 1 |
| Chandenier, J | 1 |
| Breckenridge, AM | 1 |
| Winstanley, PA | 1 |
| Mabika Mamfoumbi, M | 2 |
| Parzy, D | 3 |
| Owono Medang, M | 2 |
| Lebeau, C | 2 |
| Doury, JC | 2 |
| Luty, AJ | 1 |
| Renaut, A | 1 |
| Minh, TN | 1 |
| Mbessy, JR | 1 |
| Chaiyaroj, SC | 1 |
| Buranakiti, A | 1 |
| Angkasekwinai, P | 1 |
| Looressuwan, S | 1 |
| Mvoukani, JL | 1 |
| Lu, CY | 1 |
| Nabias, R | 1 |
| Tiga, H | 1 |
| Spiegel, A | 1 |
| Fusai, T | 1 |
| Adou-Bryn, KD | 1 |
| Kouassi, D | 1 |
| Ouhon, J | 1 |
| Assoumou, A | 1 |
| Gorissen, E | 1 |
| Ashruf, G | 1 |
| Lamboo, M | 1 |
| Bennebroek, J | 1 |
| Mbaruku, G | 1 |
| Same Ekobo, A | 1 |
| Lacharme, LL | 1 |
| Fonseca, JC | 1 |
| Gasasira, A | 1 |
| Ndeezi, G | 1 |
| Charlebois, ED | 1 |
| Sokhna, CS | 1 |
| Sowunmi, CO | 1 |
| Koko, J | 1 |
| Bouyou Akotet, M | 1 |
| Mabika Manfoumbi, M | 1 |
| Ngouesse, B | 1 |
| Blackett, KN | 1 |
| Babiker, A | 1 |
| Cobelens, F | 1 |
| Loolpapit, M | 1 |
| Mwanza, J | 1 |
| Osimbo, P | 1 |
| Some, E | 1 |
| Barro-Kiki, PC | 1 |
| Nigué, L | 1 |
| Konan, YJ | 1 |
| Talani, P | 1 |
| Samba, G | 1 |
| Moyen, G | 1 |
| Ghosh, SK | 1 |
| Yadav, RS | 1 |
| Sharma, VP | 1 |
| de Geus, A | 1 |
| Keuter, M | 1 |
| Sanders, J | 1 |
| Ronday, M | 1 |
| Veltkamp, S | 1 |
| Kamsteeg, H | 1 |
| Schouten, E | 1 |
| Khalumi, G | 1 |
| Ngwawe, W | 1 |
| Wetsteyn, JC | 1 |
| Brandling-Bennett, AD | 1 |
| Louis, JP | 1 |
| Hengy, C | 1 |
| Louis, FJ | 1 |
| Gazin, P | 1 |
| Jambou, R | 1 |
| Gardon, J | 1 |
| Fadat, G | 1 |
| Trebucq, A | 1 |
| Sudre, P | 1 |
| Breman, JG | 1 |
| McFarland, D | 1 |
| Koplan, JP | 1 |
| Salako, LA | 1 |
| Oloo, AJ | 1 |
| Adoyo, A | 1 |
| Boriga, DA | 1 |
| Magiri, C | 1 |
| Koech, DK | 1 |
| Mhina, JI | 1 |
| Sapak, P | 1 |
| Baea, M | 1 |
| Heywood, P | 1 |
| Alpers, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite Open Label, Two-cohort Clinical Trial in Mozambique[NCT04370977] | Phase 4 | 630 participants (Actual) | Interventional | 2018-03-21 | Completed | ||
| Monitoring the Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine During the Treatment of Uncomplicated Plasmodium Falciparum Malaria Among Children in Yaounde, Cameroon[NCT04565184] | Phase 4 | 242 participants (Actual) | Interventional | 2019-05-09 | Completed | ||
| A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and [NCT03355664] | Phase 3 | 310 participants (Actual) | Interventional | 2018-03-19 | Completed | ||
| Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)[NCT03178643] | Phase 4 | 246 participants (Actual) | Interventional | 2018-01-23 | Completed | ||
| Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection[NCT04264130] | Phase 2 | 54 participants (Actual) | Interventional | 2018-07-31 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206] | Phase 3 | 900 participants (Anticipated) | Interventional | 2024-03-15 | Not yet recruiting | ||
| Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment[NCT02504918] | 200 participants (Actual) | Observational | 2015-07-21 | Completed | |||
| Safety of Artesunate-amodiaquine Combined With Methylene Blue or Primaquine for Falciparum Malaria Treatment in African Children: A Randomised Controlled Trial[NCT02851108] | Phase 2 | 100 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso[NCT00808951] | Phase 4 | 440 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies (TACTs) Com-pared to Artemisinin-based Combination Therapies (ACTs) in Uncomplicated Falciparum Malaria and to Ma[NCT02453308] | Phase 2/Phase 3 | 1,110 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Feasibility, Acceptability and Costs of a Strategy Deploying Multiple First-lines Artemisinin-based Combination Therapies for Uncomplicated Malaria: a Pilot Programme in the Health District of Kaya, Burkina Faso[NCT04265573] | 150,000 participants (Actual) | Observational | 2018-11-10 | Completed | |||
| An Open Label, 4 Escalating Dose, Randomized Multicentre Study Evaluating the Safety and Activity of Ferroquine Associated With Artesunate Versus a Positive Calibrator (Amodiaquine Associated With Artesunate) in African Adult Patients With Uncomplicated M[NCT00563914] | Phase 1/Phase 2 | 72 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13[NCT01755559] | Phase 4 | 663 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali[NCT02831023] | Phase 2 | 80 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients[NCT04530617] | Phase 2 | 246 participants (Actual) | Interventional | 2020-10-05 | Terminated (stopped due to Results from the interim analysis) | ||
| Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania[NCT03431714] | Phase 4 | 333 participants (Actual) | Interventional | 2017-07-14 | Completed | ||
| Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants[NCT00285662] | 1,100 participants (Anticipated) | Interventional | 2006-06-30 | Completed | |||
| Artemether-Lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali[NCT02645604] | 154 participants (Actual) | Observational | 2016-01-01 | Completed | |||
| Studies of Innate and Acquired Resistance to P. Falciparum Malaria in Mali[NCT00669084] | 1,718 participants (Actual) | Observational | 2008-04-21 | Completed | |||
| Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care[NCT01976325] | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Infections in Migrants in Sweden - the Importance of Malaria and Other Parasitic Infections[NCT05086887] | 715 participants (Anticipated) | Observational [Patient Registry] | 2019-04-15 | Recruiting | |||
| Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes[NCT02325180] | Phase 4 | 338 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains[NCT01374581] | Phase 3 | 2,117 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children[NCT01407887] | Phase 2 | 180 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Oc[NCT00699920] | Phase 4 | 413 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon[NCT01845701] | Phase 3 | 720 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Pharmacovigilance for Artemisinin-based Combination Treatments in Africa[NCT01232530] | 3,176 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria[NCT00852423] | Phase 3 | 3,428 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo[NCT02741024] | Phase 4 | 288 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy[NCT00123552] | Phase 3 | 601 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| [NCT00406146] | Phase 3 | 0 participants | Interventional | 2004-10-31 | Active, not recruiting | ||
| Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya[NCT00142246] | Phase 3 | 6,758 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial[NCT00146783] | Phase 2/Phase 3 | 3,642 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children[NCT00461578] | 800 participants | Interventional | 2005-04-30 | Completed | |||
| [NCT00354380] | Phase 2 | 0 participants | Interventional | 2006-09-30 | Completed | ||
| Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study[NCT00460369] | 240 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Multinational, Randomized, Comparative Study of the Efficacy and Safety of Three Therapeutic Regimens: Coarsucam™ (Artesunate + Amodiaquine Fixed-Dose Combination) Administered in 1 or 2 Intakes Per Day Versus Coartem® (Artemether + Lumefantrine) in the T[NCT00316329] | Phase 3 | 1,032 participants | Interventional | 2006-03-31 | Completed | ||
| Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04301531] | 5,861 participants (Actual) | Interventional | 2020-03-01 | Completed | |||
| A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana[NCT00119132] | Phase 2/Phase 3 | 2,602 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Exploring the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04167566] | 5,000 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa[NCT02974348] | Phase 3 | 300 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598] | Phase 3 | 468 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal[NCT00540410] | Phase 4 | 366 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children[NCT00738946] | 6,000 participants (Anticipated) | Interventional | 2008-08-31 | Completed | |||
| Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children[NCT00393679] | Phase 3 | 4,112 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam[NCT02604966] | Phase 4 | 120 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008[NCT01567423] | 301 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| "Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools"[NCT03241901] | Phase 4 | 280 participants (Actual) | Interventional | 2017-07-27 | Completed | ||
| Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya[NCT00111163] | 1,516 participants | Interventional | 2004-03-31 | Completed | |||
| Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia[NCT00399074] | Phase 3 | 220 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial[NCT00168948] | Phase 4 | 1,200 participants | Interventional | 2003-03-31 | Active, not recruiting | ||
| Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial[NCT00206739] | Phase 4 | 1,070 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850] | Phase 3 | 2,793 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria[NCT00374205] | Phase 4 | 245 participants (Actual) | Interventional | 2006-09-30 | Terminated (stopped due to Interim analysis showed more LCFs in one of the treatment arms) | ||
| Randomized Study of the Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate Plus Amodiaquine Coadministered for the Treatment of Uncomplicated Falciparum Malaria in Zanzibar[NCT03764527] | Phase 4 | 408 participants (Actual) | Interventional | 2002-11-01 | Completed | ||
| A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy[NCT00131703] | Phase 3 | 900 participants | Interventional | 2003-03-31 | Completed | ||
| The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance in an Area of Seasonal Transmission[NCT00440752] | 100 participants (Actual) | Observational | 2006-10-31 | Completed | |||
| Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria[NCT02110784] | Phase 2 | 27 participants (Actual) | Interventional | 2014-06-18 | Terminated (stopped due to Low recruitment) | ||
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours (NCT03355664)
Timeframe: 42 day
| Intervention | Hours to fever clearance (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 18.3 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 14.9 |
Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured (NCT03355664)
Timeframe: 42 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 53 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 63 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. (NCT03355664)
Timeframe: 28 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
"All numerators in AE tables mean that the AE was reported as present according to the definitions defined in the US government DAIDS 2017 grading tables for reporting of adverse events. The AEs are reported without grading in this table, but are graded in the paper reporting this clinical trial.~All Primary analyses are reported (also in the accepted manuscript) along with the secondary outcomes needed to support the primary analysis. Secondary outcomes not involving the randomised comparison will be updated when the analyses are available. Please note that analyses of these Secondary outcomes will take time." (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 2 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5 |
Parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance (NCT03355664)
Timeframe: 42 day
| Intervention | Hours (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 5 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5.5 |
Efficacy is defined as participants, following initial parasite and fever clearance, not having a recrudescence of the original plasmodium infection and fever, up to 42 days of follow up. (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 146 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 151 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. There were zero events of this at any time point in either study arm. So no further analyses are possible. (NCT03355664)
Timeframe: Hour 4, Hour 24, Hour 28, Hour 48, Hour 52, Hour 60, Hour 64, Day 7 and Day 28 and between these time points
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
42-day polymerase chain reaction corrected efficacy defined as adequate clinical and parasitological response (ACPR) according to site/geographic region. (NCT03355664)
Timeframe: 42 day
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| West Cambodia | East Cambodia | Vietnam | |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 35 | 90 | 26 |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 32 | 91 | 23 |
Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden) (NCT02851108)
Timeframe: 7 days
| Intervention | g/dl (Mean) |
|---|---|
| AS-AQ-MB | 0.18 |
| AS-AQ-PQ | 0.54 |
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
31 reviews available for amodiaquine and Malaria, Falciparum
| Article | Year |
|---|---|
Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case-control studies in 5 countries.
Topics: Africa, Western; Age Factors; Amodiaquine; Antimalarials; Case-Control Studies; Child, Preschool; Co | 2021 |
Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Co | 2022 |
The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2020 |
Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Artemisinins; Artesunate; Atovaquone; Clindamycin | 2020 |
Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.
Topics: Adult; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Atovaquo | 2021 |
Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Malaria; Malar | 2017 |
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, | 2019 |
Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon.
Topics: Amodiaquine; Artemether, Lumefantrine Drug Combination; Artemisinins; Cameroon; Drug Combinations; H | 2019 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemisinins; Drug Combinations; Humans; Kin | 2014 |
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.
Topics: Africa; Amodiaquine; Antimalarials; Artemisinins; Dose-Response Relationship, Drug; Drug Combination | 2015 |
Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data.
Topics: Africa; Africa South of the Sahara; Amodiaquine; Antimalarials; Artemisinins; Drug Combinations; Dru | 2015 |
Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Drug Therapy, Combina | 2016 |
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Resistance; Drug Ther | 2017 |
Amodiaquine pharmacogenetics.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Cytochrome P-450 Enzyme System; Endemic Diseases; Fore | 2008 |
Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa.
Topics: Adolescent; Adult; Africa South of the Sahara; Amodiaquine; Animals; Antimalarials; Artemisinins; Ch | 2012 |
Amodiaquine for treating malaria.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Pyrimethami | 2003 |
Malaria: uncomplicated, caused by Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Combina | 2005 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2005 |
Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria.
Topics: Amodiaquine; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Humans; Malaria | 2006 |
[Cytochrome P-450 and the response to antimalarial drugs].
Topics: Administration, Oral; Adult; Amodiaquine; Animals; Antimalarials; Biotransformation; Child; Chloroqu | 2006 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malar | 2006 |
Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis.
Topics: Africa; Amodiaquine; Artemisinins; Drug Combinations; Humans; Malaria, Falciparum; Multicenter Studi | 2007 |
Artesunate-amodiaquine for the treatment of uncomplicated malaria.
Topics: Amodiaquine; Animals; Artemisinins; Artesunate; Dose-Response Relationship, Drug; Drug Administratio | 2007 |
The safety of amodiaquine use in pregnant women.
Topics: Amodiaquine; Animals; Antimalarials; Female; Humans; Malaria, Falciparum; Pregnancy; Pregnancy Compl | 2007 |
Systematic review of amodiaquine treatment in uncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria, Falciparum; Randomized Controlled Trials a | 1996 |
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Interactions; Drug Therapy, Combination; Malaria, Falc | 1996 |
Clinical pharmacology and malaria.
Topics: Amodiaquine; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Falciparum; Proguanil; Quinine; | 1997 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria--a systematic review.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Malaria, Falciparum; Pyr | 1998 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2000 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2001 |
217 trials available for amodiaquine and Malaria, Falciparum
| Article | Year |
|---|---|
Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2021 |
SELECTION OF PFCRT 76T AND PFMDR1 86Y MUTANT PLASMODIUM FALCIPARUM AFTER TREATMENT OF UNCOMPLICATED MALARIA WITH ARTESUNATE-AMODIAQUINE IN REPUBLIC OF GUINEA.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinati | 2021 |
Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2021 |
Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2022 |
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Dru | 2022 |
Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy | 2022 |
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Presch | 2022 |
Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Drug | 2022 |
Comparative effect of artemether-lumefantrine and artesunate-amodiaquine on gametocyte clearance in children with uncomplicated Plasmodium falciparum malaria in Madagascar.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artes | 2022 |
Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.
Topics: Amodiaquine; Antimalarials; Artesunate; Child; COVID-19; Drug Combinations; Hemoglobins; Humans; Inc | 2023 |
Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated Plasmodium falciparum malaria in children on the rainy south-east coast of Madagascar.
Topics: Amodiaquine; Artemether, Lumefantrine Drug Combination; Artesunate; Child; Humans; Madagascar; Malar | 2023 |
Persistence of High In Vivo Efficacy and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine as the First- and Second-Line Treatments for Uncomplicated Plasmodium falciparum Malaria 10 Years After Their Implementation in Gabon.
Topics: Amodiaquine; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Drug | 2019 |
Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Burkina Faso; Child, Preschool; Drug Therapy, | 2019 |
Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, P | 2019 |
In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2020 |
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
Topics: Adolescent; Adult; Amodiaquine; Anthraquinones; Antimalarials; Artemether, Lumefantrine Drug Combina | 2020 |
Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2020 |
Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2020 |
Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Cot | 2020 |
Effect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness.
Topics: Amodiaquine; Animals; Antimalarials; Azithromycin; Chemoprevention; Child, Preschool; Culicidae; Dru | 2021 |
Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.
Topics: Amodiaquine; Antimalarials; Atovaquone; Drug Combinations; Drug Therapy, Combination; Female; Humans | 2022 |
Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated
Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Amodiaquine; Antimalarials; Artemisinins; Artesunat | 2017 |
Changing Antimalarial Drug Sensitivities in Uganda.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Aspartic Acid Endopeptidases; Child; Child, Pr | 2017 |
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Female; Humans; Infan | 2018 |
Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Democratic Republic of the C | 2018 |
Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial.
Topics: Adolescent; Adult; Amodiaquine; Artemisinins; Child; Child, Preschool; Drug Combinations; Humans; Ma | 2018 |
Efficacy of artesunate-amodiaquine in the treatment of falciparum uncomplicated malaria in Madagascar.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinati | 2018 |
Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisia; Artemisia annua; Artemisinins; Child; Doub | 2019 |
Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Child, Preschool; Ethanolamines; Fluorenes; Hu | 2013 |
Artesunate/amodiaquine malaria treatment for Equatorial Guinea (Central Africa).
Topics: Amodiaquine; Artemisinins; Child, Preschool; DNA, Protozoan; Drug Combinations; Equatorial Guinea; F | 2013 |
Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisini | 2013 |
Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2013 |
Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2013 |
Efficacy of artemisinin combination therapy for the treatment of uncomplicated falciparum malaria in Nigerian children.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, P | 2013 |
Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinati | 2013 |
Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Re
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Central African | 2014 |
Effectiveness of artesunate-amodiaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C | 2014 |
Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Atovaquone; Cameroon; Child, Preschool; Cytochromes b; Dru | 2014 |
Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2014 |
In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2014 |
A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemether; Artemisinins; Blood Cell Count; Child; | 2014 |
Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children.
Topics: Amodiaquine; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, | 2014 |
Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Burkina Faso; Child, Preschool; Drug Therapy, | 2015 |
Host candidate gene polymorphisms and associated clearance of P. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in Cameroon.
Topics: Amodiaquine; Antimalarials; Cameroon; Child, Preschool; Drug Combinations; Drug Resistance; Female; | 2014 |
Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemether, Lumefantrine Dru | 2014 |
Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Child, Preschool; Data Collection; Drug Combin | 2014 |
Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Drug Therapy, Combination; | 2014 |
Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Cameroon; Child | 2015 |
Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Female; Humans; Infan | 2015 |
Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in
Topics: Administration, Oral; Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Chromatography, H | 2015 |
An open randomized controlled trial to compare the efficacy of two fixed dose combinations of artemesinin based combinations for uncomplicated falciparum malaria in Bangladesh.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisini | 2013 |
A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisini | 2015 |
Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C | 2015 |
Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.
Topics: Administration, Intravenous; Adolescent; Amodiaquine; Anemia; Antimalarials; Artemether, Lumefantrin | 2015 |
Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisi | 2015 |
Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial.
Topics: Amodiaquine; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Drug Combina | 2016 |
Four Artemisinin-Based Treatments in African Pregnant Women with Malaria.
Topics: Adult; Africa; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; | 2016 |
Four Artemisinin-Based Treatments in African Pregnant Women with Malaria.
Topics: Adult; Africa; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; | 2016 |
Four Artemisinin-Based Treatments in African Pregnant Women with Malaria.
Topics: Adult; Africa; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; | 2016 |
Four Artemisinin-Based Treatments in African Pregnant Women with Malaria.
Topics: Adult; Africa; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; | 2016 |
In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2016 |
Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria.
Topics: Adolescent; Amodiaquine; Anemia; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinat | 2016 |
Uncomplicated Clinical Malaria Features, the Efficacy of Artesunate-Amodiaquine and Their Relation with Multiplicity of Infection in the Democratic Republic of Congo.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Democratic Republic of the Congo; Drug C | 2016 |
Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2016 |
In vivo efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2016 |
Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomise
Topics: Amodiaquine; Anorexia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child | 2017 |
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.
Topics: Amodiaquine; Anorexia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artes | 2008 |
Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Therapy | 2008 |
Effects of artesunate-cotrimoxazole and amodiaquine-artesunate against asexual and sexual stages of Plasmodium falciparum malaria in Nigerian children.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combina | 2008 |
Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisi | 2008 |
Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Amodiaquine; Anemia; Animals; Antimalarials; Child; Child, Preschool; Cluster Analysis; | 2008 |
[Gametocytemia in falciparum malaria treated with amodiaquine or artesunate].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; | 2008 |
A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana.
Topics: Amodiaquine; Anemia; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Comb | 2008 |
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Aryl Hydrocarbon Hydroxylases; Child; Child, P | 2008 |
A randomized, comparative study of supervised and unsupervised artesunate-amodiaquine, for the treatment of uncomplicated malaria in Ghana.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Therapy | 2008 |
Effects of amodiaquine, artesunate, and artesunate-amodiaquine on Plasmodium falciparum malaria-associated anaemia in children.
Topics: Amodiaquine; Anemia; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug | 2009 |
Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Body Weight; Child; Child, | 2009 |
Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania.
Topics: Adolescent; Adult; Agranulocytosis; Amodiaquine; Analysis of Variance; Animals; Antimalarials; Chemi | 2008 |
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Democratic Republic of the C | 2008 |
A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children.
Topics: Amodiaquine; Animals; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Dru | 2008 |
High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug Combina | 2008 |
Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Drug Therapy | 2009 |
Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali.
Topics: Amodiaquine; Animals; Antigens, Protozoan; Antimalarials; Child; Child, Preschool; Chloroquine; Drug | 2009 |
The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Burkina Faso; Child, Preschool; Drug Combinations | 2009 |
Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinati | 2009 |
Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chromatography, Liquid; | 2009 |
Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Burkina Faso; Child; Drug Therapy, Co | 2009 |
Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Benin; Child, Preschool; Drug Combina | 2009 |
Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Africa; Aged; Aged, 80 and over; Amodiaquine; Animals; Antimalarials; Artemisinin | 2009 |
Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Democratic Republic o | 2009 |
Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis.
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Aged, 80 and over; Amodiaquine; Animals; Antima | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Community Health Services; Drug Combinations; Female; | 2009 |
Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda.
Topics: Amino Acid Sequence; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisi | 2009 |
Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Cameroon; Child, Preschool; Double-Blind Method; D | 2010 |
Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2010 |
Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Artemisinins; Cameroon; Child, Preschool; Drug Adm | 2010 |
Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisini | 2010 |
Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Drug Combinations; Female; Half-Life; H | 2010 |
Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anemia after treatment.
Topics: Amodiaquine; Anemia; Antimalarials; Area Under Curve; Artemether, Lumefantrine Drug Combination; Art | 2011 |
Influences of intermittent preventive treatment and persistent multiclonal Plasmodium falciparum infections on clinical malaria risk.
Topics: Amodiaquine; Antigens, Protozoan; Antimalarials; Child, Preschool; Cross-Sectional Studies; Drug Com | 2010 |
Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Child; C | 2010 |
Therapeutic efficacy of artesunate-amodiaquine combinations and the plasma and saliva concentrations of desethylamodiaquine in children with acute uncomplicated Plasmodium falciparum malaria.
Topics: Acute Disease; Administration, Oral; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Prescho | 2013 |
An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixe
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Ther | 2010 |
A simple dose regimen of artesunate and amodiaquine based on age or body weight range for uncomplicated falciparum malaria in children: comparison of therapeutic efficacy with standard dose regimen of artesunate and amodiaquine and artemether-lumefantrin
Topics: Administration, Oral; Adolescent; Age Factors; Amodiaquine; Antimalarials; Artemether, Lumefantrine | 2012 |
Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria.
Topics: Amodiaquine; Anemia; Antimalarials; Area Under Curve; Artemether, Lumefantrine Drug Combination; Art | 2011 |
Oral artesunate-amodiaquine and artemether-lumefantrine in the treatment of uncomplicated hyperparasitaemic Plasmodium falciparum malaria in children.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, P | 2012 |
Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Arte | 2011 |
Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Burkina Faso; Child, Preschool; Double-Blind Method | 2011 |
Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trial.
Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Child, Preschool; Drug Administration Schedule; Dru | 2011 |
A simple dose regimen of artesunate and amodiaquine based on arm span- or age range for childhood falciparum malaria: a preliminary evaluation.
Topics: Adolescent; Age Distribution; Amodiaquine; Antimalarials; Area Under Curve; Arm; Artemisinins; Artes | 2012 |
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.
Topics: Adult; Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combina | 2011 |
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.
Topics: Adult; Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combina | 2011 |
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.
Topics: Adult; Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combina | 2011 |
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.
Topics: Adult; Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combina | 2011 |
Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial.
Topics: Amodiaquine; Anemia; Animals; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; C | 2011 |
Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2012 |
Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; DNA, Protozoan | 2012 |
Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 2: a clinical phase IIB trial.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Mala | 2012 |
Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2012 |
Good efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in eastern Sumba, East Nusatenggara, Indonesia.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinatio | 2012 |
Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Cameroon; Chemi | 2012 |
Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial.
Topics: Adult; Amodiaquine; Antimalarials; Artemether; Artemisinins; Colombia; Drug Combinations; Drug Thera | 2012 |
Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville.
Topics: Adolescent; Adult; Amodiaquine; Artemisinins; Child; Child, Preschool; Congo; Drug Combinations; Fem | 2013 |
Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Cameroon; Child; Child, Preschool; Drug Administra | 2002 |
The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Combination; | 2002 |
The effects of chloroquine, amodiaquine and chloroquine plus chlorpheniramine on the disposition kinetics of the hepatomegaly associated with acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Adolescent; Amodiaquine; Antimalarials; Area Under Curve; Child; Child, Preschool; Ch | 2002 |
Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children.
Topics: Amodiaquine; Animals; Child; Child, Preschool; Drug Combinations; Female; Gabon; Genotype; Humans; I | 2003 |
Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinatio | 2003 |
Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria.
Topics: Amodiaquine; Animals; Antibodies, Protozoan; Antimalarials; Child; Child, Preschool; Female; Gabon; | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial.
Topics: Amodiaquine; Anemia, Iron-Deficiency; Antimalarials; Double-Blind Method; Drug Administration Schedu | 2003 |
A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Administration, Oral; Amodiaquine; Analysis of Variance; Antimalarials; Child; Child, | 2003 |
Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2003 |
Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children.
Topics: Amodiaquine; Animals; Antimalarials; Atovaquone; Child; Drug Combinations; Drug Tolerance; Female; H | 2003 |
Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, | 2004 |
Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Huma | 2004 |
A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Double-Bl | 2004 |
Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Developing Countries; Drug Combinations; | 2004 |
Efficacy of chloroquine, sulphadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in Kajo Keji county, Sudan.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, C | 2004 |
Risk factors for gametocyte carriage in uncomplicated falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Chloroquine; Chlorpheni | 2004 |
Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Resistance; Drug Therap | 2004 |
Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2004 |
Comparison of the in-vitro activity of amodiaquine and its main metabolite, monodesethyl-amodiaquine, in Plasmodium falciparum.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Cell Proliferation; Chloroquine; Dose-Respon | 2003 |
Comparison of the parasitologic efficacy of amodiaquine and sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in the Bungoma District of western Kenya.
Topics: Amodiaquine; Animals; Antimalarials; Drug Administration Schedule; Drug Combinations; Drug Resistanc | 2004 |
Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Developing Countries; Drug Combi | 2005 |
A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Fever; Ghana; | 2005 |
Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; Drug Ther | 2005 |
CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.
Topics: Alleles; Amodiaquine; Antimalarials; Aryl Hydrocarbon Hydroxylases; Child, Preschool; Cytochrome P-4 | 2005 |
Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Combinatio | 2005 |
Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola.
Topics: Amodiaquine; Angola; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Chloroquine | 2005 |
Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, C | 2005 |
A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Double-Blind Method | 2005 |
Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan.
Topics: Adolescent; Adult; Afghanistan; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; C | 2005 |
Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Combinatio | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2005 |
Therapeutic efficacy of sulfadoxine-pyrimethamine and amodiaquine among children with uncomplicated Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Anemia; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; H | 2005 |
Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Com | 2005 |
[Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire].
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Cote d'Ivoire; Drug Combinations | 2005 |
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Drug | 2005 |
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Comb | 2006 |
Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults.
Topics: Adult; Amodiaquine; Antimalarials; Blood Cell Count; Double-Blind Method; Drug Combinations; Drug Th | 2006 |
Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Drug Co | 2006 |
High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola.
Topics: Amodiaquine; Angola; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; | 2006 |
Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations.
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Dose-Response Relation | 2007 |
Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Democratic Republic | 2006 |
A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2007 |
The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2007 |
Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial.
Topics: Adult; Amodiaquine; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Combinations; Fem | 2006 |
Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: experience with fixed-dose formulation.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Administration Schedule; Dr | 2006 |
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Democra | 2006 |
Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya.
Topics: Amodiaquine; Animals; Antimalarials; Child; Drug Resistance, Multiple; Follow-Up Studies; Gene Ampli | 2006 |
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transpo | 2007 |
Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Comb | 2007 |
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C | 2007 |
Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; | 2007 |
Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Bone Marrow Diseas | 2007 |
Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combi | 2007 |
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Drug Resistance, Multiple; Drug Toler | 2007 |
Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Dihydropteroate Syn | 2007 |
Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistan | 2007 |
Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroqui | 2007 |
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesu | 2007 |
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Pr | 2007 |
Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child | 2007 |
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; | 2007 |
Efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated falciparum malaria in the urban and suburban areas of Brazzaville (Congo).
Topics: Amodiaquine; Antimalarials; Carrier State; Child, Preschool; Congo; DNA, Protozoan; Drug Combination | 2007 |
Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2007 |
Amodiaquine in future combination treatment of malaria in Ghana.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combi | 2007 |
[Open radomized study comparing chloroquine and amodiaquine for treatment of uncomplicated plasmodium falciparum malaria in children in Aboisso, Cote d' Ivoire].
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Cote d'Ivoire; Female; Humans; Infant; Ma | 2007 |
Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug R | 2007 |
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkin | 2007 |
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Child, Preschool; Drug Therapy, Combination; E | 2007 |
Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; | 2008 |
Randomized, comparative study of the efficacy and safety of artesunate plus amodiaquine, administered as a single daily intake versus two daily intakes in the treatment of uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Cameroon; Child; C | 2008 |
Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Dihydropteroate Syn | 2008 |
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Topics: Amodiaquine; Artemisinins; Artesunate; Burkina Faso; Drug Therapy, Combination; Drug-Related Side Ef | 2008 |
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Biomarkers; Drug Combinations; Drug R | 2008 |
High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; | 2008 |
Enhanced efficacy of amodiaquine and chlorpheniramine combination over amodiaquine alone in the treatment of acute uncomplicated Plasmodium falciparum malaria in children.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chlorpheniramine; Drug | 2008 |
Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso.
Topics: Amino Acid Substitution; Amodiaquine; Animals; Antimalarials; Burkina Faso; Child, Preschool; DNA, P | 2008 |
Response of Plasmodium falciparum to chloroquine and Fansidar in vivo and chloroquine and amodiaquine in vitro in Uganda.
Topics: Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Evaluation, Preclin | 1995 |
[Parasitological and clinical response to amodiaquine versus chloroquine in the treatment of Plasmodium falciparum malaria in children in an endemic area].
Topics: Adolescent; Amodiaquine; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; Infa | 1994 |
In vivo sensitivity of Plasmodium falciparum to chloroquine, amodiaquine and sulfadoxine-pyrimethamine in western Uganda.
Topics: Adult; Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; | 1994 |
A comparison of amodiaquine and chloroquine in the treatment therapy of falciparum malaria in Kenya.
Topics: Adolescent; Adult; Amodiaquine; Child; Child, Preschool; Chloroquine; Drug Costs; Humans; Kenya; Mal | 1994 |
Response of falciparum malaria to chloroquine and three second line antimalarial drugs in a Kenyan coastal school age population.
Topics: Adolescent; Amodiaquine; Child; Chloroquine; Drug Combinations; Drug Resistance; Humans; Kenya; Mala | 1993 |
Resistance of Plasmodium falciparum to antimalarial drugs in Equatorial Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug R | 1993 |
Chloroquine versus amodiaquine in the treatment of Plasmodium falciparum malaria in northeast India.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Female; H | 1995 |
A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance | 1996 |
Atovaquone and proguanil for Plasmodium falciparum malaria.
Topics: Acute Disease; Adult; Amodiaquine; Antimalarials; Atovaquone; Drug Administration Schedule; Drug The | 1996 |
A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance | 1996 |
Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; ATP-Binding Cassette Transporters; Child; Child, Presc | 1997 |
[Clinical trial of amodiaquine in the community of Attécoubé (Abidjan, Côte d'Ivoire)(May-December 1955)].
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Cote d'Ivoire; Female; Humans; Malaria, Falciparum; M | 2000 |
In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial; Female; Fe | 2000 |
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial.
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Therapy, Combination; Female; | 2001 |
Gametocytaemia in Senegalese children with uncomplicated falciparum malaria treated with chloroquine, amodiaquine or sulfadoxine + pyrimethamine.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistan | 2001 |
Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Age Factors; Amodiaquine; Analysis of Variance; Antimalarials; Child; Child, Preschool; Chloroquine; | 2001 |
Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients.
Topics: Administration, Oral; Adolescent; Adult; Amodiaquine; Antimalarials; Bradycardia; Cameroon; Drug Adm | 2001 |
Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Adminis | 2002 |
A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combi | 2002 |
Malaria in infants whose mothers received chemoprophylaxis: response to amodiaquine therapy.
Topics: Administration, Oral; Amodiaquine; Chloroquine; Drug Resistance; Female; Humans; Immunity, Maternall | 1992 |
Parasitological, clinical and haematological response of children with Plasmodium falciparum to 4-aminoquinolines and to pyrimethamine-sulfadoxine with quinine in western Kenya.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combinati | 1992 |
Evaluation of the relative efficacy of various antimalarial drugs in Nigerian children under five years of age suffering from acute uncomplicated falciparum malaria.
Topics: Acute Disease; Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Administration Schedu | 1992 |
Sensitivity of falciparum malaria to chloroquine and amodiaquine in four districts of western Kenya (1985-1987).
Topics: Adolescent; Adult; Amodiaquine; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; Kenya | 1991 |
Falciparum malaria fully cleared by amodiaquine, pyrimethamine-sulfadoxine and pyrimethamine-sulfalene in areas of chloroquine resistance in Dodoma, Tanzania.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance | 1991 |
210 other studies available for amodiaquine and Malaria, Falciparum
| Article | Year |
|---|---|
Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies.
Topics: Aminoquinolines; Animals; Antimalarials; Benzene Derivatives; Humans; Malaria; Malaria, Falciparum; | 2015 |
In vivo efficacy and safety of artemether-lumefantrine and amodiaquine-artesunate for uncomplicated Plasmodium falciparum malaria in Mozambique, 2018.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2021 |
Modeled Impact of Seasonal Malaria Chemoprevention on District-Level Suspected and Confirmed Malaria Cases in Chad Based on Routine Clinical Data (2013-2018).
Topics: Amodiaquine; Antimalarials; Chad; Chemoprevention; Child, Preschool; Disability-Adjusted Life Years; | 2021 |
Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005-2018.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2021 |
Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention.
Topics: Adolescent; Adult; Amodiaquine; Antigens, Protozoan; Antimalarials; Burkina Faso; Child; Child, Pres | 2022 |
Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Cross-Sectional Studies; Drug | 2022 |
Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Child | 2022 |
Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2022 |
[Pcr-rflp genotyping of
Topics: Amodiaquine; Artesunate; Child; Chloroquine; Drug Resistance; Genotype; Humans; Madagascar; Malaria, | 2022 |
A Decade of Progress Accelerating Malaria Control in Mali: Evidence from the West Africa International Center of Excellence for Malaria Research.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Humans; Malari | 2022 |
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Drug Combinations; Drug Resistance; Genomics; Ha | 2023 |
Design, Implementation, and Coordination of Malaria Therapeutic Efficacy Studies in Nigeria in 2018.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Drug Combi | 2023 |
Plasmodium falciparum kelch13 polymorphisms identified after treatment failure with artemisinin-based combination therapy in Niger.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Dru | 2023 |
Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Chad: clinical and genetic surveillance.
Topics: Adult; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisini | 2023 |
Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Resistance | 2023 |
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Topics: Africa; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesun | 2023 |
Clinical illness and outcomes in Nigerian children with persistent early-appearing anaemia following initiation of artemisinin-based combination treatments of uncomplicated falciparum malaria.
Topics: Amodiaquine; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, | 2019 |
Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combina | 2019 |
Effect of Seasonal Malaria Chemoprevention on Immune Markers of Exhaustion and Regulation.
Topics: Amodiaquine; Antigens, CD; Antimalarials; Biomarkers; CD4-Positive T-Lymphocytes; Child, Preschool; | 2020 |
Comment on "A. annua and A. afra infusions vs. Artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial" Munyangi et al., 2019.
Topics: Amodiaquine; Artemisinins; Artesunate; Double-Blind Method; Humans; Malaria, Falciparum | 2022 |
Molecular surveillance of anti-malarial drug resistance in Democratic Republic of Congo: high variability of chloroquinoresistance and lack of amodiaquinoresistance.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Democrati | 2020 |
Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Asia; Cambodia; Child; Humans; Malaria; | 2021 |
Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Res | 2020 |
Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Chemoprevention; Child, Preschool; Cross-Sectional Studies | 2020 |
Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar.
Topics: Amodiaquine; Antimalarials; Artesunate; Asia; Drug Combinations; Drug Resistance; Humans; Malaria; M | 2020 |
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Betaco | 2020 |
[Safety and Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine in Niger].
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2020 |
Assessment of antimalarial drug resistant markers in asymptomatic Plasmodium falciparum infections after 4 years of indoor residual spraying in Northern Ghana.
Topics: Amodiaquine; Antimalarials; Biomarkers, Pharmacological; Carrier State; Child, Preschool; Chloroquin | 2020 |
Evidence that seasonal malaria chemoprevention with SPAQ influences blood and pre-erythrocytic stage antibody responses of Plasmodium falciparum infections in Niger.
Topics: Amodiaquine; Antibodies, Protozoan; Antibody Formation; Antimalarials; Chemoprevention; Child, Presc | 2021 |
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.
Topics: Africa; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunat | 2021 |
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Cytochrome P-450 CYP2C8; Drug Combinatio | 2021 |
Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Bur | 2021 |
Therapeutic efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015-2016.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2021 |
Cross-resistance of the chloroquine-derivative AQ-13 with amodiaquine in Cambodian Plasmodium falciparum isolates.
Topics: Amodiaquine; Antimalarials; Asian People; Chloroquine; Drug Combinations; Drug Resistance; Humans; M | 2021 |
Anaemia following Artemisinin-Based Combination Treatments of Uncomplicated Plasmodium falciparum Malaria in Children: Temporal Patterns of Haematocrit and the Use of Uncomplicated Hyperparasitaemia as a Model for Evaluating Late-Appearing Anaemia.
Topics: Amodiaquine; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2017 |
Sustained
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Drug Therapy, Combination; E | 2017 |
Therapeutic efficacy of artesunate - amiodaquine for treating uncomplicated falciparum malaria at Ghindae Zonal Referral Hospital, Eritrea.
Topics: Amodiaquine; Antimalarials; Artemisinins; Drug Combinations; Eritrea; Female; Humans; Malaria, Falci | 2018 |
Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.
Topics: Amodiaquine; Anemia; Antimalarials; Area Under Curve; Artemisinins; Child, Preschool; Drug Combinati | 2017 |
Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria.
Topics: Africa; Age Factors; Amodiaquine; Antimalarials; Biomarkers, Pharmacological; Body Weight; Chemoprev | 2018 |
Molecular markers of resistance to amodiaquine plus sulfadoxine-pyrimethamine in an area with seasonal malaria chemoprevention in south central Niger.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Dihydropteroate Synthase; Drug Combin | 2018 |
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017.
Topics: Adolescent; Amodiaquine; Angola; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisin | 2018 |
Comparison of the Pharmacokinetics and Ex Vivo Antimalarial Activities of Artesunate-Amodiaquine and Artemisinin-Piperaquine in Healthy Volunteers for Preselection Malaria Therapy.
Topics: Amodiaquine; Antimalarials; Area Under Curve; Artemisinins; Biotransformation; Drug Administration S | 2018 |
Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children Ten Years Following Adoption as First-Line Antimalarials.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2018 |
The Impact of Artesunate-Amodiaquine on Schistosoma mansoni Infection among Children Infected by Plasmodium in Rural Area of Lemfu, Kongo Central, Democratic Republic of the Congo.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Artesunate; Child; Child, Preschool; Democratic Rep | 2018 |
Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2018 |
Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method.
Topics: Adolescent; Amodiaquine; Antimalarials; Arrhythmias, Cardiac; Artemether; Artemether, Lumefantrine D | 2019 |
Relationship between weight status and anti-malarial drug efficacy and safety in children in Mali.
Topics: Adolescent; Amodiaquine; Antimalarials; Artesunate; Body Weight; Child; Child, Preschool; Clinical T | 2019 |
High cure rates and tolerability of artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Female; Humans | 2019 |
Distribution of the cytochrome P450 CYP2C8*2 allele in Brazzaville, Republic of Congo.
Topics: Alleles; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Congo; Cytochrome P-450 | 2019 |
Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine combinations for uncomplicated malaria in 10 sentinel sites across Ghana: 2015-2017.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, P | 2019 |
Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; DNA, Protozoan; Drug | 2019 |
Declining responsiveness of childhood Plasmodium falciparum infections to artemisinin-based combination treatments ten years following deployment as first-line antimalarials in Nigeria.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2019 |
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity.
Topics: Adaptive Immunity; Adolescent; Amodiaquine; Antibodies, Protozoan; Antimalarials; Artemisinins; Arte | 2013 |
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity.
Topics: Adaptive Immunity; Adolescent; Amodiaquine; Antibodies, Protozoan; Antimalarials; Artemisinins; Arte | 2013 |
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity.
Topics: Adaptive Immunity; Adolescent; Amodiaquine; Antibodies, Protozoan; Antimalarials; Artemisinins; Arte | 2013 |
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity.
Topics: Adaptive Immunity; Adolescent; Amodiaquine; Antibodies, Protozoan; Antimalarials; Artemisinins; Arte | 2013 |
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Ethanolamines; Fluorenes; Hu | 2013 |
High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool.
Topics: Amodiaquine; Antimalarials; Artemisinins; Automation, Laboratory; Chloroquine; Drug Resistance; Drug | 2013 |
Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Resist | 2013 |
Trouble from the tropics: challenges in managing malaria in Rhode Island.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Diagnosis, Diff | 2013 |
The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.
Topics: Amodiaquine; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Ethanolamines; Fluorenes; | 2013 |
Evaluation of Paracheck-Pf(TM) rapid malaria diagnostic test for the diagnosis of malaria among HIV-positive patients in Ibadan, south-western Nigeria.
Topics: AIDS-Related Opportunistic Infections; Amodiaquine; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte C | 2013 |
Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Resistance; F | 2014 |
Artesunate-amodiaquine combination therapy in the absence of malarial parasite infection induces oxidative damage in female rats.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Combinations; Erythrocytes; Female; Kidney; | 2014 |
Submicroscopic infections among children with adequate clinical and parasitological response (ACPR).
Topics: Amodiaquine; Antimalarials; Artemisinins; Blood; Child; Child, Preschool; DNA, Protozoan; Drug Combi | 2014 |
A cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Cross-Sectional Studies; Democratic | 2014 |
Quality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chain.
Topics: Amodiaquine; Amoxicillin; Antimalarials; Artemether; Artemisinins; Biosimilar Pharmaceuticals; Chlor | 2014 |
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
Topics: Amino Acid Substitution; Amodiaquine; Antimalarials; Artemether; Artemisinins; Child; Child, Prescho | 2014 |
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Biological Transport; Child; Chloroquine; Drug Resi | 2014 |
Pfcrt 76T and pfmdr1 86Y allele frequency in Plasmodium falciparum isolates and use of self-medication in a rural area of Gabon.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Gabon; Ge | 2014 |
Efficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern Mauritania.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinati | 2014 |
Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Combinations; Drug | 2015 |
Maximizing antimalarial efficacy and the importance of dosing strategies.
Topics: Amodiaquine; Antimalarials; Artemisinins; Female; Humans; Malaria, Falciparum; Male | 2015 |
The implication of long-lasting insecticide-treated net use in the resurgence of malaria morbidity in a Senegal malaria endemic village in 2010-2011.
Topics: Adolescent; Adult; Amodiaquine; Animals; Artemisinins; Child; Child, Preschool; Cross-Sectional Stud | 2015 |
In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Dr | 2015 |
Optimum population-level use of artemisinin combination therapies: a modelling study.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Administra | 2015 |
Artemisinin-based combination therapy (ACT) versus atovaquone-proguanil: do not choose between but, rather, combine them.
Topics: Amodiaquine; Antimalarials; Artemisinins; Atovaquone; Female; Humans; Malaria, Falciparum; Male; Pro | 2016 |
Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso.
Topics: Adult; Aged; Alleles; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemis | 2016 |
Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014.
Topics: Amodiaquine; Antimalarials; Drug Resistance; Female; Humans; Inhibitory Concentration 50; Malaria, F | 2016 |
Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo, 2012-2013.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2016 |
Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under.
Topics: Amodiaquine; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, | 2016 |
Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Dru | 2016 |
Plasmodium falciparum Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapy.
Topics: Amodiaquine; Antigens, Protozoan; Antimalarials; Artemisinins; Artesunate; Chloroquine; DNA Copy Num | 2017 |
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemisinins; Child; Child, | 2017 |
Association between Polymorphisms in the Pf
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Asparagine; ATP-Binding Cassette Transporters; | 2017 |
Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria.
Topics: Administration, Oral; Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child Health Serv | 2017 |
Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015.
Topics: Amodiaquine; Angola; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2017 |
Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian children during seven years of adoption as first-line treatments.
Topics: Adolescent; Amodiaquine; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisin | 2017 |
pfmdr1 mutations in imported African Plasmodium falciparum isolates.
Topics: Africa; Alleles; Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Art | 2008 |
Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine-amodiaquine failure in Pikine, Senegal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Amodiaquine; Animals; Antimalar | 2008 |
Adherence and effectiveness of drug combination in curative treatment among children suffering uncomplicated malaria in rural Senegal.
Topics: Amodiaquine; Animals; Antimalarials; Attitude to Health; Caregivers; Child; Child, Preschool; Drug C | 2008 |
Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children.
Topics: Africa; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; | 2008 |
Plasmodium falciparum gametocyte sex ratios in children with acute, symptomatic, uncomplicated infections treated with amodiaquine.
Topics: Africa; Amodiaquine; Anemia; Animals; Child; Child, Preschool; Female; Humans; Infant; Kaplan-Meier | 2008 |
Monitoring Plasmodium falciparum chloroquine resistance in Yunnan Province, China, 1981-2006.
Topics: Amodiaquine; Animals; Antimalarials; China; Chloroquine; Drug Resistance; Humans; Inhibitory Concent | 2008 |
Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chlor | 2008 |
Some features of primary and recrudescent amodiaquine-resistant Plasmodium falciparum infections in Nigerian children.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Case-Control Studies; Child; Child, Preschool; D | 2008 |
In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Drug Resista | 2009 |
Efficacy of artemisinin-based combination therapy for treatment of persons with uncomplicated Plasmodium falciparum malaria in West Sumba District, East Nusa Tenggara Province, Indonesia, and genotypic profiles of the parasite.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Drug | 2009 |
Evaluation of artemisone combinations in Aotus monkeys infected with Plasmodium falciparum.
Topics: Amodiaquine; Animals; Antimalarials; Aotus trivirgatus; Artemisinins; Drug Therapy, Combination; Mal | 2009 |
Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Cross-Sectional Studies; Drug Combinatio | 2009 |
PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria.
Topics: Amodiaquine; Antigens, Protozoan; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisi | 2009 |
Artemisinin resistance on the Thai-Cambodian border.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Cambodia; Drug Combinations; Drug Resistance | 2009 |
Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.
Topics: Adolescent; Aged; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; DNA, Pr | 2010 |
Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso.
Topics: Alleles; Amino Acid Substitution; Amodiaquine; Animals; Antimalarials; Burkina Faso; Child, Preschoo | 2010 |
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Burkina Faso; Drug Combinations; Drug Resistan | 2010 |
Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2010 |
Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76.
Topics: Afghanistan; Alleles; Amodiaquine; Animals; Antimalarials; Codon; Drug Resistance; Haplotypes; Malar | 2010 |
Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3- arm anti- malarial drug trial in Cameroon.
Topics: Amodiaquine; Antimalarials; Cameroon; Child, Preschool; Drug Combinations; Drug Therapy, Combination | 2010 |
Fixed artesunate-amodiaquine combined pre-formulation study for the treatment of malaria.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chemistry, Pharmaceutical; Drug Combinations; Drug Compoun | 2010 |
The hydroxyl functionality and a rigid proximal N are required for forming a novel non-covalent quinine-heme complex.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dimerization; Dose-Response Relationship, Drug; Hemeprotein | 2011 |
Alternative visual displays of metaanalysis of malaria treatment trials to facilitate translation of research into policy.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Computer Graphics; Drug Therapy, Combination; | 2010 |
Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the PfCRT SVMNT type.
Topics: Amodiaquine; Angola; Antimalarials; Chloroquine; Codon; Drug Resistance; Haplotypes; Humans; Malaria | 2010 |
Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burundi; Cross-Sectional Studies; Drug Combinations; Drug | 2011 |
In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d'Ivoire).
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Cote d'Ivoire; Drug Resistan | 2010 |
Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments.
Topics: Amodiaquine; Analysis of Variance; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemis | 2011 |
Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda.
Topics: Alleles; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2011 |
Compliance, safety, and effectiveness of fixed-dose artesunate-amodiaquine for presumptive treatment of non-severe malaria in the context of home management of malaria in Madagascar.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Dose-Response Relationship, Drug; Drug C | 2012 |
Different patterns of pfcrt and pfmdr1 polymorphisms in P. falciparum isolates from Nigeria and Brazil: the potential role of antimalarial drug selection pressure.
Topics: Alleles; Amodiaquine; Antimalarials; Artemisinins; Brazil; DNA Copy Number Variations; Drug Combinat | 2012 |
Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar.
Topics: Amodiaquine; Antimalarials; Artemisinins; Clinical Trials as Topic; Drug Resistance; Gene Frequency; | 2012 |
Surveillance of the efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum among children under five in Togo, 2005-2009.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2012 |
Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in pfcrt and pfmdr1 genes.
Topics: Amodiaquine; Antimalarials; Humans; Inhibitory Concentration 50; Kenya; Malaria, Falciparum; Membran | 2013 |
Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.
Topics: Amodiaquine; Antimalarials; Biological Transport; Chloroquine; Drug Resistance; Genetic Fitness; Gen | 2013 |
Molecular epidemiology of malaria in cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children.
Topics: Amodiaquine; Animals; Antimalarials; Cameroon; Child, Preschool; Chloroquine; Chromatography, High P | 2002 |
[Center of multidrug-resistant malaria in a forest zone of Cameroon revisited after 14 years].
Topics: Amodiaquine; Animals; Cameroon; Chloroquine; Drug Resistance, Multiple; Humans; Malaria, Falciparum; | 2002 |
Molecular epidemiology of malaria in Cameroon. X. Evaluation of PFMDR1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Base Sequence; Cameroon; Child; Child, Presc | 2002 |
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum must be delayed in Africa.
Topics: Africa; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Resis | 2002 |
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp.
Topics: Amodiaquine; Animals; Antigens, Protozoan; Antimalarials; Artemisinins; Artesunate; Child, Preschool | 2003 |
In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Resistance, Multiple; Humans | 2002 |
Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; | 2003 |
Rapid clearance of Plasmodium falciparum hyperparasitaemia after oral amodiaquine treatment in patients with uncomplicated malaria.
Topics: Administration, Oral; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Female; Humans; | 2003 |
Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; ATP-Binding Cassette Transporters; Chloroquine; Drug R | 2003 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND.
Topics: Amodiaquine; Antimalarials; Asia, Southeastern; Biomedical Research; Chloroquine; Drug Resistance; D | 1964 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM VIET-NAM.
Topics: Amodiaquine; Antimalarials; Biomedical Research; Chloroquine; Drug Therapy; Humans; Malaria; Malaria | 1964 |
Molecular epidemiology of malaria in Cameroon. XV. Experimental studies on serum substitutes and supplements and alternative culture media for in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum.
Topics: Amodiaquine; Animals; Antimalarials; Cameroon; Chloroquine; Culture Media; Humans; Malaria, Falcipar | 2003 |
Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Dihydropteroate Syn | 2003 |
Amodiaquine treatment of uncomplicated malaria in children, in an area of chloroquine-resistant Plasmodium falciparum in north-central Nigeria.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; Infant; | 2003 |
[Misunderstood neurological side effects of amodiaquine: apropos of 35 cases in children at Central University Hospital of Yopougon at Abidjan, Côte d' Ivoire].
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Cote d'Ivoire; Drug Re | 2003 |
Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea.
Topics: Aminoquinolines; Amodiaquine; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chlo | 2004 |
[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi].
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Burundi; Child, Preschool; Drug Re | 2004 |
Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Resistance; Gabon; Humans; In Vitro Techni | 2004 |
Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Dihydropteroate | 2004 |
The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Aryl Hydrocarbon Hydroxylases; Child; Child, Presc | 2005 |
Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistan | 2005 |
New combination drug to treat malaria.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Humans; Malar | 2005 |
Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Clinical Trials as Topic; Drug C | 2005 |
Economic evaluation of a policy change from single-agent treatment for suspected malaria to artesunate-amodiaquine for microscopically confirmed uncomplicated falciparum malaria in the Oussouye District of south-western Senegal.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Ch | 2005 |
Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y.
Topics: Amino Acid Substitution; Amodiaquine; Animals; Antigens, Protozoan; Antimalarials; ATP-Binding Casse | 2006 |
Efficacy of chloroquine, sulfadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria among children under five in Bongor and Koumra, Chad.
Topics: Amodiaquine; Animals; Chad; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Drug | 2006 |
In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chlor | 2006 |
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Aryl Hydrocarbon Hydroxylases; Child; Child, P | 2005 |
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Cost-Benefit An | 2006 |
Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004.
Topics: Adult; Amodiaquine; Analgesics, Non-Narcotic; Anemia; Antimalarials; Child, Preschool; Drug Combinat | 2006 |
The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania.
Topics: Amodiaquine; Antimalarials; Chloroquine; Clinical Protocols; Drug Combinations; Health Care Costs; H | 2006 |
Microscopy and outpatient malaria case management among older children and adults in Kenya.
Topics: Adolescent; Adult; Ambulatory Care; Amodiaquine; Antimalarials; Case Management; Child; Cross-Sectio | 2006 |
Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistan | 2006 |
Low efficacy of the combination artesunate plus amodiaquine for uncomplicated falciparum malaria among children under 5 years in Kailahun, Sierra Leone.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combination; F | 2006 |
Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria.
Topics: Age Factors; Amodiaquine; Animals; Antigens, Protozoan; Antimalarials; Child; Child, Preschool; Drug | 2006 |
[Knowledge and practice among health workers from the Thiès region with regard to new malaria treatment policies].
Topics: Amodiaquine; Antimalarials; Chloroquine; Clinical Competence; Community Health Services; Drug Combin | 2006 |
Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria.
Topics: Amodiaquine; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Child; Child, Presc | 2007 |
High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Cohort Studies; Haplotypes; Hematocrit; Human | 2006 |
Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change.
Topics: Amodiaquine; Antimalarials; Cameroon; Child; Chloroquine; Drug Combinations; Health Policy; Humans; | 2006 |
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
Topics: Amodiaquine; Animals; Antimalarials; Azithromycin; DNA, Protozoan; Drug Resistance; Erythrocytes; Hu | 2007 |
Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria.
Topics: Adolescent; Age Distribution; Amodiaquine; Antimalarials; Artemisinins; Body Weight; Child; Child, P | 2006 |
Antimalarial drug combinations in vastly different settings.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkin | 2007 |
Effects of pyrimethamine-sulphadoxine, chloroquine plus chlorpheniramine, and amodiaquine plus pyrimethamine-sulphadoxine on gametocytes during and after treatment of acute, uncomplicated malaria in children.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Chlorpheni | 2006 |
In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from São Tomé and Príncipe.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Atlantic Islands; Child; | 2007 |
Chloroquine-resistant malaria in Malawi.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malari | 2007 |
The comparative efficacies of malartin, with and without amodiaquine, in the treatment of Plasmodium falciparum malaria in the Buea district of Cameroon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Ca | 2007 |
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.
Topics: Alkynes; Amodiaquine; Antimalarials; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Burkina Faso; Chro | 2007 |
Amodiaquine failure associated with erythrocytic glutathione in Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Amodiaquine; Animals; Child; Erythrocytes; Female; Glutamate-Cysteine Ligase; Glu | 2007 |
[Assessment of the efficacy of antimalarial drugs in Tarapacá, in the Colombian Amazon basin].
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Colombia; Female; Humans; In | 2007 |
The in-vitro susceptibilities of Ghanaian Plasmodium falciparum to antimalarial drugs.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug R | 2007 |
Prevalent pfmdr1 n86y mutant Plasmodium falciparum in Madagascar despite absence of pfcrt mutant strains.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Humans; Inhibitor | 2007 |
Large-scale surveillance of Plasmodium falciparum crt(K76T) in northern Ghana.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Chloroquine; Drug | 2007 |
Enhancement of the antimalarial efficacy of amodiaquine by chlorpheniramine in vivo.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Chlorpheniram | 2007 |
Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Humans; Infant; Malaria, Falciparum; Models, Bi | 2007 |
[Polymorphisms of the pfmdr1 gene in field samples of Plasmodium falciparum and their association with therapeutic response to antimalarial drugs and severe malaria in Colombia].
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Colombia; Drug Resistance, Multiple; Humans; Malar | 2007 |
Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Humans; Malaria, F | 2007 |
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum.
Topics: Amodiaquine; Animals; Antibodies, Protozoan; Child, Preschool; Drug Combinations; Drug Resistance; F | 2007 |
Activities of artesunate and amodiaquine against intestinal helminth in children with Plasmodium falciparum malaria in endemic areas.
Topics: Adolescent; Africa South of the Sahara; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunat | 2008 |
Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Humans; Infant; Malaria, | 2008 |
Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chlor | 2008 |
Chloroquine resistant Plasmodium falciparum malaria in Osogbo Nigeria: efficacy of amodiaquine + sulfadoxine-pyrimethamine and chloroquine + chlorpheniramine for treatment.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Chlorpheniramine; Clinica | 2008 |
The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Biomarkers; Drug Combinations; Malaria, Falciparum; Papua New G | 2008 |
Studies on antimalarial drug susceptibility in Colombia, in relation to Pfmdr1 and Pfcrt.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Colombia; Drug Resistance; Humans; Malaria, Falcip | 2008 |
In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea.
Topics: Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Equatorial Guinea; Human | 1995 |
Sensitivity to antimalarial drugs by Plasmodium falciparum in Goundry, Oubritenga province, Burkina Faso.
Topics: Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Resist | 1994 |
Comparative efficacy of chloroquine and amodiaquine in Plasmodium falciparum strain of north-eastern India.
Topics: Amodiaquine; Animals; Chloroquine; Drug Resistance; Humans; India; Malaria, Falciparum; Plasmodium f | 1994 |
[Cytokines and malaria. A study of TNF-alpha, IL1-beta, IL6 and IL2R in 28 patients].
Topics: Adolescent; Adult; Amodiaquine; C-Reactive Protein; Chloroquine; Humans; Interleukin-1; Interleukin- | 1994 |
Experimental infections of Anopheles gambiae with Plasmodium falciparum of naturally infected gametocyte carriers in Cameroon: factors influencing the infectivity to mosquitoes.
Topics: ABO Blood-Group System; Adolescent; Adult; Age Factors; Amodiaquine; Animals; Anopheles; Aspirin; Bo | 1993 |
In vitro responses of P. falciparum parasites to chloroquine, amodiaquine and quinine in two ecological zones in Ghana.
Topics: Amodiaquine; Animals; Child; Chloroquine; Drug Resistance; Ghana; Humans; Malaria, Falciparum; Plasm | 1993 |
Efficacy of chloroquine on Plasmodium falciparum transmitted at Amani, eastern Usambara Mountains, north-east Tanzania: an area where malaria has recently become endemic.
Topics: Adolescent; Adult; Amodiaquine; Animals; Child; Child, Preschool; Chloroquine; Dose-Response Relatio | 1993 |
Assessment of the response in vivo and in vitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Animals; Child; Child, Preschool; Chloroqui | 1993 |
[Sensitivity in vivo and in vitro of Plasmodium falciparum to chloroquine and amodiaquine in Bangangte (west Cameroon)].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Child, Preschool; Chloroqui | 1995 |
Can amodiaquine be resurrected?
Topics: Amodiaquine; Antimalarials; Drug Resistance; Humans; Malaria, Falciparum | 1996 |
In-vivo resistance of Plasmodium falciparum to chloroquine and amodiaquine in south Cameroon and age-related efficacy of the drugs.
Topics: Adolescent; Age Factors; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Child, Preschool; Chl | 1997 |
Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990-1993.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Case-Control Studies; Child; Child, Preschool; C | 1996 |
[Surveillance of the in vivo sensitivity of Plasmodium falciparum to antimalarial agents: the results of initial tests of the OCEAC Malaria Network].
Topics: Africa, Central; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Child, Preschool; Chloroquine | 1997 |
In vitro susceptibility of Gabonese wild isolates of Plasmodium falciparum to artemether, and comparison with chloroquine, quinine, halofantrine and amodiaquine.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; | 1998 |
In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Gabon; Humans | 1999 |
Relationships between malaria prevalence and malaria-related morbidity in school children from two villages in central Africa.
Topics: Adolescent; Amodiaquine; Animals; Anti-Bacterial Agents; Antibodies, Protozoan; Antimalarials; Blood | 1999 |
Analysis of mefloquine resistance and amplification of pfmdr1 in multidrug-resistant Plasmodium falciparum isolates from Thailand.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Chromosome Mapping; DNA Primers; DNA, Protozoan; D | 1999 |
Factors influencing resistance to reinfection with Plasmodium falciparum.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antibodies, Protozoan; Antimalarials; Child; Child, Prescho | 1999 |
Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates.
Topics: Amodiaquine; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antimalarials; Artemether; Arte | 2000 |
Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Came
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Drug Combinations; Fe | 2000 |
[Resistance of Plasmodium falciparum to 3 antimalarials in Turbo (Antioquia, Colombia), 1998].
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; | 2001 |
[Evaluation of efficacy and tolerance of amodiaquine versus chloroquine in the treatment of uncomplicated malaria outbreak in children of Gabon].
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Femal | 2001 |
[In vivo sensitivity of Plasmodium falciparum to amino-4-quinolines and sulfadoxine pyrimethamine in Agou (Ivory Coast)].
Topics: Adolescent; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Cote d'Iv | 2002 |
[Management of child fever in the battle against malaria in Brazzaville].
Topics: Amodiaquine; Antimalarials; Asthenia; Child, Preschool; Chills; Chloroquine; Congo; Diarrhea; Fever; | 2002 |
Sensitivity status of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine and sulfadoxine/pyrimethamine in a tribal population of District Sundargarh, Orissa.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, | 1992 |
Proposals for a new therapeutic strategy for simple Plasmodium falciparum malaria attacks in Cameroon.
Topics: Administration, Oral; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Child, | 1992 |
Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis.
Topics: Africa; Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Cost-Benefit Analysis; D | 1992 |
Ineffectiveness of amodiaquine against Plasmodium falciparum malaria in symptomatic young children living in an endemic malarious area of Papua New Guinea.
Topics: Age Factors; Amodiaquine; Child; Child, Preschool; Drug Resistance; Female; Humans; Infant; Malaria, | 1991 |